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Catheters, extracorporeal systems, stents, and artificial heart valves are all common blood-
contacting medical devices. Due to the differences in the chemical and physical properties of the 
polymeric materials used to construct medical devices and biological tissues in the cardiovascular 
system, complications such as thrombus formation arise from the resulting incompatibilities. 
Introduction of foreign materials that lack critical biological cues can result in disruption of the 
delicate balance maintained within the circulatory system. This disruption of homeostasis initiates 
a complex cascade of events such as platelet adhesion and protein deposition that ultimately result 
in thrombus formation. As such, the propensity of blood to clot upon contact with a foreign surface 
represents a challenge unique to devices intended for vascular applications. The current clinical 
use of devices such as vascular catheters includes the administration of anticoagulants, however 
their associated complications such as internal hemorrhaging renders this practice undesirable as 
a long-lasting solution. A general limitation of existing devices made from synthetic polymers is 
their inability to integrate with their environment through biological cues (natural regulators). 
Materials that lack this behavior are often described as passive towards their environment. In 
comparison, active materials that can simulate natural molecules used to maintain biological 
responses may result in enhanced integration of medical devices. In the natural, healthy 
endothelium, the prevention of thrombus formation occurs through the release of anticoagulants 
and platelet inhibitors such as gaseous nitric oxide (NO). While the use of NO for medicinal 
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purposes began indirectly in the late 1800s, the significance of its endogenous production was not 
known until the 1970s. In particular, NO is a key factor in the prevention of thrombus formation. 
While its remedial potential has led to its use as an exogenous therapeutic agent, its high reactivity 
limits its applicability as a localized therapeutic. This limitation is addressed by mimicking the 
natural endothelium and using small molecules in the bloodstream known as S-nitrosothiols 
(RSNOs) to produce NO directly from this physiological source. Biological RSNOs are theorized 
to aid in the stabilization and transport of NO and undergo an NO-forming decomposition in the 
presence of heat, light, and certain metals such as copper. Prior strategies have evaluated exploiting 
the physiological supply of RSNOs through the incorporation of copper complexes into polymeric 
materials. While these copper-based materials demonstrate the production of NO from RSNO 
decomposition, limitations arise due to the gradual loss of the catalytic material and toxicity from 
copper leaching. In order for this type of approach to be feasible, the active metal species must 
remain immobilized within the structural framework. 
Metal–organic frameworks (MOFs) are a class of crystalline materials that consist of organic 
ligands coordinated to metal centers. Certain copper-based MOFs have demonstrated the ability to 
enhance the generation of NO from RSNOs without the gradual loss of the active species. Through 
integration of certain copper-based MOFs with medically relevant polymers, materials can be 
prepared that promote the localized generation of NO at their surfaces. However, the feasibility of 
utilizing copper-based MOFs for such applications depends on effective incorporation within a 
supporting polymeric matrix and the retention of useful activity thereafter. As such, it is necessary 
to assess different MOF/polymer composites for their ability to promote NO generation from 
RSNOs prior to use in medical applications. This dissertation investigates the incorporation of two 
distinct copper-based MOFs into a selection of medically-relevant polymeric materials including 
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cotton, poly(vinyl chloride), chitosan, and poly(vinyl alcohol). These MOF/polymer materials 
were subsequently tested for their ability to promote NO generation from RSNOs in an effort to 
assess the impact of incorporation within a polymer matrix. Overall, this work demonstrates the 
potential for blood-contacting MOF-containing materials in biomedical settings by identifying 
ideal characteristics that MOF/polymer composites should exhibit for optimization and translation 
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1.1 Blood-Contacting Devices: Adverse Interactions at the Biointerface and a Unique 
Solution  
A medical device can be broadly defined as an instrument, implant, or apparatus used in 
humans for therapeutic, diagnostic or cosmetic applications. Medical devices are an inextricable 
element of modern healthcare and come in the form of syringes, sutures, and prostheses, as well 
as complicated instruments such as heart-lung or dialysis machines. Blood-contacting devices 
represent a specific niche, with millions used annually worldwide. These devices include catheters, 
guidewires, pacemakers, heart valves, stents, and extracorporeal systems. In clinical practice, these 
devices come into direct contact with circulating blood, but are distinctly unlike the biological 
tissues that make up the cardiovascular system in both their physical and chemical properties. 
Because blood is composed of a complex mixture of cells and proteins that exist in a delicate 
homeostasis with the environment of the circulatory system, these physical and chemical 
differences create challenges that are unique to instruments intended to interface with the 
vasculature. Consequently, a chief concern is the propensity of blood to clot upon contact with a 
foreign surface, which confounded pre-modern efforts to perform life-saving blood transfusions. 
Because of this, the earliest successes and failures in vascular access often avoided the use of 
devices altogether. 
The concept of medical vascular access originates in the Middle Ages, as illustrated by the 
apocryphal tale surrounding the death of Pope Innocent VIII in 1429.1,2 Following a stroke, the 
Pope fell into a coma and certain sources assert that the attending physician attempted a blood 
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transfusion by directly joining the veins from three young boys. Unfortunately, both the Pope and 
his ill-fated donors died.1,2 While the veracity of this particular account is uncertain, the principle 
of linking the veins of a donor directly to those of the recipient was not abandoned. A surgical 
technique developed by Alexis Carr in 1902 involving direct suturing of the blood vessels became 
the predominant technique for blood transfer.3 In general, these methods are difficult, invasive, 
time-consuming, and lack a reliable method for gauging blood transfer. This remained the 
predominant method until the development of instrumentation meant to channel or interact with 
blood. Although the common use of blood-contacting medical devices is a relatively recent 
development, their recorded history began much earlier.  
At the University of Oxford in the seventeenth century, Christopher Wren developed the 
first working infusion device by using quills and a pig’s bladder to administer a solution of beer, 
opium, antimony, and wine directly into a dog's veins.1,2,4 One of the first documented reports of 
a blood-contacting device for blood transfer was in the seminal work performed by Richard Lower 
in 1665. In this account, Lower performed an animal to animal blood transfusion using silver tubes 
and animal arteries for the cannulation and transfer of blood.4 Shortly thereafter, Lower and others 
went on to conduct blood transfusions from animals to humans. However, less than favorable 
outcomes led to the banning of blood transfusions across Europe, hindering their evolution for 
over a century.1 In 1818, the topic was revisited when surgeon James Blundell performed the first 
human to human blood transfusion using a syringe to extract the blood from the donor and transfer 
it to the recepient.1,2,4 While innovative, these earlier efforts to transfuse blood were constrained 
to the materials available at the time, which were primarily glass, metals, or animal products such 
as quills. Additionally, the rapid and inevitable propensity of blood to clot limited the quantity that 
could be safely administered.  
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The onset of World War I prompted the advancement of new strategies for transfusing blood. 
The first practical method of overcoming clotting came with the development of the Kimpton-
Brown transfusion apparatus in 1913.1,5 This device consisted of a glass tube coated in paraffin 
wax, which delayed the onset of blood clotting when used properly. The mid-twentieth century 
highlights the era of disposable medical devices spurred by the plastic revolution. In the years 
following World War II, the manufacturing of polymers such as poly(vinyl chloride) (PVC), 
Teflon, and polyurethanes revolutionized the healthcare industry.1 Today, catheters can be used 
for days to years, that allow direct injection of medications into the bloodstream to optimize 
efficiency. However, the use of anticoagulants remains standard practice when utilizing many of 
these blood-contacting devices.6  
Taken together, development of medical devices has influence on all aspects of healthcare. 
For many of these blood-material interactions, the absence of natural regulators is still a major 
factor in the onset of device-related complications. A central limitation of traditional synthetic 
materials is that they lack the ability to integrate with the biological system through molecular 
signals to regulate immune responses. This results in biomaterials having a passive or unresponsive 
role in regards to their surrounding environment and can lead to complications such as infection, 
improper healing, excessive tissue growth, and thrombosis.7-10 The degree to which a material in 
contact with blood produces adverse side effects such as thrombus, is typically defined as 
thrombogenicity. One method of addressing these concerns entails the development of materials 
that generate certain endogenous therapeutic molecules used to maintain homeostasis or regulate 
immune responses biologically.7,8 Such materials can be considered active with respect to the 
biological environment, and may integrate more completely with tissues through the production 
of natural biochemical signaling agents. For instance, in mammalian biology, a naturally occurring 
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radical species known as nitric oxide (NO) demonstrates substantial therapeutic potential towards 
these adverse outcomes.11 In the bloodstream, it has been theorized that NO is stored and 
transported by small molecules called S-nitrosothiols (RSNOs).12 These RSNOs display enhanced 
rates of decomposition in the presence of copper ions, resulting in the formation of the 
corresponding disulfide and NO.13 Thus, significant research has explored capitalizing on these 
endogenous sources by integrating copper-based species (copper nanoparticles, copper complexes) 
into medically relevant polymers for localized generation of NO from RSNOs.14 However, upon 
interaction with the RSNOs, the copper species leach into the surrounding environment, rendering 
them unsuitable for many medical applications. Alternatively, crystalline substances known as 
metal–organic frameworks (MOFs) are an attractive approach due to the immobilization of the 
active metal species (copper) within the framework. In an effort to circumvent the limitations 
associated with copper complexes, research by Harding et al. identified two copper-based MOFs 
capable of promoting NO release from several RSNOs for integration into medical polymers.15,16 
This research explores the unique approach of combining MOFs with medical polymers to create 
materials capable of generating a localized supply of NO at the blood-material interface.  
1.2 Preventing thrombogenicity 
The exposure of blood to medical devices will initiate a complex cascade of events that 
ultimately result in thrombus formation (Figure 1.1).17,18 The adverse clinical manifestations of 
thrombus formation are numerous and can include thrombotic occlusion in grafts, obstruction of 
stents, embolic complications, and may necessitate the life-long use of anticoagulants.6,19 
Thrombus associated complications are among the most prevalent challenges in patient care.20 For 
example, in a systematic review of reports on extracorporeal life support (ECLS) from 1994-2015, 
the overall survival to discharge ranged from 50-79%.21 Of these reports, bleeding-related death 
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accounted for up to 38%. Another report assessed all adult patients who had ECLS from 2010-
2013. Of the 132 patients admitted for ECLS, 56.1% had a serious bleeding–related event with 
13.6% being thrombosis related.22 While blood-contacting devices are essential to modern patient 
care, the clinical concerns arising from incompatibility with blood illustrate a lingering problem. 
To date, hospitals administer anticoagulants such as intravenous heparin for the management of 
thrombus formation in procedures involving blood-contacting devices.23 While anticoagulants can 
provide symptomatic relief, their associated complications make them undesirable as a permanent 
solution. As an example, the use of heparin can lead to low platelet count (thrombocytopenia) and 
produce internal hemorrhaging that requires platelet transfusions to maintain patient vitality.22-25 
Alternatively, a localized approach that prevents clotting on synthetic surfaces without systemic 
effects is ideal for future iterations of blood-contacting devices. In order to identify strategies and 
 
Figure 1.1 (a) Generalized representation of events leading to clot (thrombus) formation 
including protein adsorption as well as platelet adhesion and activation. (b) Thrombus 
formation on the outside of an implanted catheter and indicated by the arrow. (c) Scanning 
electron microscope imaging of platelet adhesion on a material surface.  
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develop rational designs for materials with enhanced blood compatibility, it is essential to 
understand why these outcomes occur when materials are in contact with blood and why they do 
not occur in healthy vasculature.  
In the early 1800s, Freund and Haycraft independently discovered that a surface coated with 
paraffin wax lengthens blood coagulation time compared to glass.26-28 During experimentation 
with blood, they discovered that blood failed to clot upon removal and placement in a tube coated 
with paraffin wax, or when directly added to a solution of paraffin oil.26-28 However, if the blood 
came into contact with a surface that lacked the oily coating, it resulted in the induction of 
coagulation. While our understanding of blood’s behavior upon contact with a material has 
significantly advanced since Freund and Haycraft’s initial observations, it marks the foundation of 
our understanding of the clinical manifestations of blood-material incompatibility. These 
rudimentary observations of blood-material incompatibility by Freund and Haycraft were caused 
by the same factors which result in blood-device incompatibilities dealt with in current clinical 
practice. The typical sequence of events that result in thrombus formation upon device 
implantation proceeds as follows: (1) protein adsorption, (2) platelet adhesion and activation, (3) 
coagulation cascade activation, and (4) thrombus formation.29 Upon implantation of a blood-
contacting biomaterial, two distinct pathways can act in parallel or separately to trigger clot 
formation.29-31 These include platelet adhesion and activation, and activation of the coagulation 
cascade which together forms the overall thrombus.  
1.2.1 Platelet adhesion, activation, and aggregation on a material surface 
Initially, plasma proteins such as albumin, fibrinogen, and von Willebrand factor (vWF) are 
deposited onto the surface of the biomaterial. This adsorption of proteins at the surface is 
considered a reversible process with the composition of the proteins changing over time.32,33 The 
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second phase of the sequence begins when adsorbed proteins interact with platelets through 
GPIIb/IIIa and GPIb receptors to promote platelet adhesion and activation. Additional receptors 
that stimulate platelet activation include thromboxane A2 (TXA2), thrombin, and platelet 
activating factor.31 The interaction between the GP receptors and blood proteins induces activation 
through the release of phospholipase C, leading to an increase in platelet cytoplasmic Ca2+ 
concentration. An increase in the cytoplasmic Ca2+ concentration leads to secretions of the granular 
contents (dense, alpha, and lysosomal granules) and subsequent shape change of the platelet.29-31,34 
Platelet activation is characterized by a morphological change from discoidal (inactivated) to 
spherical with the appearance of appendages known as pseudopods, which promote platelet contact 
and adhesion.34 Additionally, the secreted granules then release their contents (ADP, Ca2+, platelet 
factor, fibrinogen, vWF) which further activate and induce platelet aggregation.31 The process of 
platelet aggregation involves the binding of platelets to fibrinogen. Several factors such as collagen 
and thrombin can induce platelet aggregation through release or stimulation of pathways to form 
ADP and TXA2, both major agonists in the aggregation pathway. 
1.2.2 The blood coagulation cascade 
The second factor responsible for thrombus formation involves the blood coagulation 
cascade, which leads to the formation of a fibrin clot.29-31,35  The coagulation cascade consists of a 
series of proenzyme activations where one activated factor then activates another inactive 
precursor factor. The final enzyme activated is thrombin, a potent initiator of platelet aggregation 
and catalyst for conversion of fibrinogen to fibrin, which forms a stabilized cross-linked clot. 
Initiation of the blood coagulation cascade occurs through either an intrinsic or an extrinsic 
pathway. Intrinsic pathway activation initiates through the conversion of Factor XII to Factor XIIa 
upon contacting a foreign surface.29-31,35,36 Factor XIIa then activates Factor XI to Factor XIa, 
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which then activates Factor X to Factor Xa. Alternatively, extrinsic activation arises from tissue 
trauma resulting in the expression of Tissue Factor (TF), which causes activation of Factor VII to 
Factor VIIa. Factor VIIa then proceeds to cleave Factor X to Factor Xa in the presence of TF.29-
31,35,36 Both the intrinsic and extrinsic pathways converge into the common pathway upon 
formation of Factor Xa. Factor Xa then activates thrombin, which activates fibrin, resulting in 
fibrin clot formation.29-31,35,36 Collectively, the thrombus formed on the material surface is 
composed of aggregated platelets and the fibrin clot, as shown in Figure 1.2. 
Under normal conditions, the endothelium prevents thrombus formation and maintains 
homeostasis through a variety of factors.29-31 These include anticoagulants such as 
thrombomodulin and glycosaminoglycans and platelet inhibitors such as prostacyclin, ADPase, 
matrix metalloproteinases, and the gaseous molecule NO.36 Currently, the use of blood-contacting 
devices introduces a foreign surface into the bloodstream without the properties of the 
endothelium. However, the ability to use these platelet inhibitors at a material surface is an 
 
Figure 1.2 Schematic illustration of the pathways involved in thrombus formation. Platelet 
adhesion and activation (pink), the coagulation cascade through the intrinsic (green) and 
extrinsic (orange) pathways which merge into the common pathway (blue). The resulting 
thrombi is a combination of activated platelets and fibrin. 
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attractive approach as their effect on platelets is not permanent and normal function will resume 
when no longer exposed to the inhibitor.36 Of these different inhibitors, NO has been the most 
widely studied as an approach towards mimicking the biological functions of the endothelium. 
Rather than using passive materials such as a hydrophobic coating of paraffin wax, this approach 
permits improved blood compatibility through imitation of natural vascular tissue. As such, the 
next section will focus on the discovery of NO and its role in the cardiovascular system.  
1.3 Nitric oxide 
The medicinal history of the small, diatomic radical NO began indirectly with Italian chemist 
Ascanio Sobrero and his discovery of nitroglycerin in 1846.37 Sobrero achieved nitration of 
glycerol using a mixture of sulfuric and nitric acid and demonstrated the explosive nature of the 
new substance by detonating a small quantity during a lecture to the Accademia delle Scienze di 
Torino.1  Notably, Sobrero was said to have tasted a small amount of the compound to which he 
remarked “great caution should be used for a very minute quantity put on the tongue produces a 
violent headache for several hours”.38 In 1859, English chemist Frederick Guthrie noted that 
inhalation of amyl nitrite produced arterial throbbing in the neck and an increase in heart rate.39 
These observations led to interest in the medical potential of amyl nitrite, which was later 
determined to cause dilation of capillaries and lowered blood pressure. Later in the nineteenth 
century, physician T. Lauder Brunton first demonstrated the medical use of nitrites by providing 
relief for a patient suffering from angina.40,41 Brunton believed that angina could be treated by 
inducing dilation of the blood vessels (vasodilation), a hypothesis which was confirmed when the 
patient’s symptoms were eased following administration of the compound by inhalation.40,41 
Following this innovative work, researchers focused on exploiting the physiological effects of 
organic nitrates. These efforts included the first use of nitroglycerin for angina relief by English 
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physician, Dr. William Murrell.42 This eventually led to nitroglycerine becoming the preferred 
remedy for lowering arterial blood pressure.43 While the nineteenth century witnessed the 
discovery of the vasodilatory properties of nitrites and their growing popularity for symptomatic 
relief of cardiovascular ailments, their biochemical mechanism of action would remain 
unexplained for decades. 
In the 1970s, pharmacologist Ferid Murad and his colleagues were investigating the 
mechanism of action of various vasodilator molecules such as nitroglycerin and their impact on 
the enzyme guanylate cyclase (GC).44 GC is an enzyme which synthesizes cyclic guanosine 
monophosphate (cGMP) from guanosine-5’-triphosphate (GTP), which is known to be a key 
regulator of the cardiovascular system. In their work, they discovered that nitrite-containing 
compounds stimulated GC, resulting in an increase in cGMP blood levels, which in turn induced 
vasodilation. Following their seminal report, Murad then observed that exposure of GC to NO also 
results in increased GC activity.45 Based on these findings, Murad proposed that the vasodilatory 
effect of nitrite-containing compounds occurred through the formation of NO and subsequent 
activation of GC.44,45 Independently, Robert Furchgott and colleagues were investigating the role 
of acetylcholine on vasodilation when they observed that blood vessel relaxation only occurred in 
the presence of endothelial cells.46 Furchgott and his fellow researchers concluded that smooth 
muscle cells in the vasculature were unable to produce vasodilation in the absence of endothelial 
cells, suggesting the contribution of an unknown endothelium-derived relaxing factor (EDRF).47 
During the effort to identify this hypothesized EDRF, work headed by Louis Ignarro at the 
University of California revealed the identical properties between EDRF and NO in 1986.48,49 Until 
these collective discoveries, it had not been previously considered that a chemically unstable, 
reactive radical gas such as NO could serve as an endogenous molecular signaling agent within 
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mammalian tissue. Taken together, this finding significantly advanced our understanding of the 
important role of NO in physiology. Consequently, Furchgott, Ignarro, and Murad received the 
1998 Nobel Prize in Medicine and Physiology for their identification of NO as a signaling 
molecule in the cardiovascular system.  
1.3.1 The biological activity of nitric oxide  
Today, the bioactivity of NO is well established and encompasses cardiovascular regulation, 
neurotransmission, promotion of wound healing, and antibacterial effects.50-52 Collectively, three 
different isoforms of the NO synthase enzyme are responsible for NO production in mammalian 
biology.53  These NO synthases are categorized as neuronal (NOS I or nNOS), inducible (NOS II 
or iNOS) and endothelial (NOS III or eNOS). NO production occurs through the NADPH-
dependent conversion of the amino acid L-arginine to L-citrulline and NO in the presence of 
molecular oxygen.53 Broadly speaking, eNOS and nNOS are Ca2+- dependent enzymes, whereas 
iNOS expression occurs through inflammatory agents such as cytokines.53 NO generation can also 
occur in a NOS-independent manner in the nitrate-nitrite-nitric oxide pathway which involves the 
reduction of nitrate or nitrite to NO.54 The nitrate-nitrite-nitric oxide pathway activity increases 
under low oxygen conditions (hypoxia) when the classical oxygen-dependent mechanism of NO 
synthesis is inhibited. During this process, bacteria, hemoglobin, myoglobin, and certain enzymes 
such as xanthine oxidase can reduce nitrate and nitrite to NO. Notably this pathway can be fueled 
by exogenous nitrate and nitrite sources in our diet that can produce therapeutic effects particularly 
for the treatment of cardiovascular disease.54-56  
Due to the high reactivity of NO, microenvironmental conditions (erythrocytes or oxygen 
concentration) are factors in determining the biological response to NO exposure. Consequently, 
NO exhibits diverse chemical behavior with numerous biological effects. NO exhibits 
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dichotomous behavior in physiology, and biological effects of NO classified as either direct or 
indirect.57 Biologically, NO reacts with metal centers or other radicals, the latter resulting in the 
production of reactive nitrogen species (RNS). Direct effects arise from chemical interactions 
between a receptor biomolecule and NO itself, such as the binding of NO to the Fe2+ of the heme 
moiety to form a metal nitrosyl adduct (Figure 1.3).57,58 Indirect effects involve the production of 
RNS such as peroxynitrite (ONOO-), nitrate (NO3
-), nitrite (NO2
-), dinitrogen trioxide (N2O3) and 
dinitrogen tetroxide (N2O4), which form through the reactions of NO with oxygen.
57-59 These RNS 
species proceed to target specific functions without the direct participation of NO. Vasodilation, 
platelet inhibition and aggregation, and various wound healing functions are typically attributed to 
direct effects of NO, while indirect effects are primarily responsible for antimicrobial activity.  
In 1984, it was discovered by Ignarro et al. that NO activates the enzyme guanylate cyclase, 
which synthesizes cGMP from GTP.60 Direct NO binding to the Fe2+ species in the heme moiety 
of the enzyme induces a conformational change to the heme by pulling the Fe2+ out of plane with 
respect to the planar porphyrin ring. This conformational shift causes stress between Fe2+ and the 
distal histidine of the enzyme causing this bond to break. Detachment from the distal histidine 
 Figure 1.3 Examples of direct and indirect in reactions of NO. The reactivity of NO allows 
the formation of RNS under physiological conditions which are highlighted red.  
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initiates enzyme activation of GC resulting in the conversion of the substrate GTP to cGMP.58,60 
The subsequent increase in cGMP levels triggers relaxation of the vascular smooth muscle cells, 
in addition to inhibiting platelet adhesion and activation to the surface of the cell walls that can 
lead to thrombosis.61 NO is continuously produced by healthy endothelial cells at a basal level and 
in response to physiological stimuli. For example, previously Rubanyi et al. proposed an 
environmental trigger responsible for NO release from endothelial cells is the vascular flow rate 
of blood, and this hypothesis has been experimentally supported on numerous occasions.62-64  
Rubanyi originally demonstrated this concept by correlating increased blood flow rate and 
enhanced pulsatile flow with increased production of NO by the femoral artery endothelium in 
dogs.62  
Nitric oxide prevents platelet adhesion and aggregation along the endothelium by increasing 
the intracellular concentration of cGMP. The presence of cGMP then decreases the intracellular 
concentration of Ca2+, a key regulatory promoter of platelet activation.63-66 Another route through 
which NO prevents platelet adhesion and activation is via inhibition of TXA2, a signaling molecule 
produced by activated platelets with prothrombotic properties. Previous research has shown that 
cGMP can directly inhibit TXA2 activity, thus minimizing platelet adhesion and activation.
65 A 
report by Mendelsohn et al. observed that use of a NO donor material can inhibit fibrinogen 
binding to activated platelets in a dose-dependent manner. Fibrinogen inhibition was correlated 
with a corresponding increase in platelet cGMP levels.68 This fibrinogen inhibition is potentially 
related in part to cGMP inhibition of PI3-K receptors, which activate the GP IIb-IIIa receptors on 
platelets that bind to fibrinogen. Ultimately, NO regulation of the cardiovascular system is largely 
through NO-induced formation of cGMP and its influence on a variety of receptors.  
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NO is also an important participant in the wound healing process where it is generated and 
secreted by inflammatory cells during wound healing, particularly in macrophages.51 Prior to the 
identification of NO’s role in wound healing, investigations by Albina et al. that evaluated arginine 
metabolism in wounds observed a corresponding increase in citrulline formation, a product of NO 
synthesis from L-arginine.69 In 1990, it was demonstrated that administration of supplemental 
arginine enhanced wound healing in adults.70 Shortly thereafter, a study by Smith et al. observed 
increased urinary nitrate levels in rats upon wound infliction, which they proposed was related to 
NO generation.71 Bulgrin et al. then correlated dietary arginine deficiency with decreased nitrate 
output.72 Bulgrin investigated nitrate outputs by feeding rats diets containing 0 or 3% L-arginine, 
then subjecting the rats to deliberate wound infliction.  While nitrate levels initially increased, the 
endogenous arginine levels were not sufficient to maintain elevated nitrate levels in rats fed a 0% 
arginine diet and levels quickly returned to baseline. Comparatively, rats fed the 3% arginine diet 
were able to maintain elevated nitrate levels during the duration of wound healing.72 The initial 
increase in nitrate levels following wound infliction and elevated nitrate levels in rats with a 
sufficient arginine supply supported the concept of increased NO production in wounds.71 Shi et 
al. investigated the role of NO in wound healing by addition of supplemental L-arginine to the diet 
of diabetic Lewis rats. Their results showed that L-arginine supplementation enhanced wound 
healing and increased wound fluid nitrate/nitrite levels.73 This outcome was also observed in the 
presence of NO supplied by a NO donor.74 Furthermore, the impact of inhibiting iNOS expression 
during the wound healing process has also been investigated. Reicher et al. demonstrated that 
expression of iNOS is active within the first 72 hours of injury and suppressed as the wound ages.75 
Additionally, studies investigating the impact of iNOS inhibition detected a decrease in NO 
metabolites, collagen synthesis, wound breaking strength and contraction, and epithelialization. 
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Another study by Shi et al. demonstrated that supplemental arginine did not aid wound healing in 
iNOS knock out mice, suggesting that the metabolism of arginine through iNOS is essential in 
wound healing.76 However, despite the lack of a comprehensive understanding of the role of NO 
in wound healing, it is clearly established to participate in the promotion and acceleration of the 
healing process.  
1.3.2 Therapeutic applications of nitric oxide  
In light of the numerous biological effects of endogenous NO, the use of NO as a therapeutic 
agent is a logical progression. However, effective use of NO for medical applications must take 
into account that varying concentrations of NO have very different physiological impacts. As such, 
understanding the relationship between NO concentration and biological activity has been the 
target of substantial research efforts. At low concentrations (1-30 nM), NO exhibits regulation 
such as vasodilation and formation of new blood vessels (angiogenesis).77 An increased NO 
concentration of approximately 100 nM results in protective effects towards cell apoptosis (anti-
inflammatory and wound healing), whereas concentrations above 400 nM induce cellular 
apoptosis.77 As NO is not cell specific, these high concentrations result in destructive cell damage 
towards all tissues. However, these higher concentrations prove beneficial for anticancer and 
antibacterial applications.70 From a clinical perspective, the varied biological effects of NO 
illustrates the need for fine control over NO delivery when developing NO-based materials. The 
non-thrombogenic endothelium is seen to release NO with a surface flux of 0.05-0.4 × 10-10 mol 
NO cm-2 min-1, thus materials for blood-contacting applications should fall within this target 
range.78 Due to its reactivity, localized surface delivery of NO is desirable for antithrombotic 
applications without the systemic implications, such as hemorrhaging from use of anticoagulants. 
However, the applicability of therapeutic NO gas is limited by the overall reactivity of the 
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molecule. Several factors can influence the consumption of NO within the body, including the 
availability of oxygen and hemoglobin. In aqueous solution, the rate of NO consumption with 
oxygen and hemoglobin is proportional to the square of NO concentration and follows second 
order kinetics.79 Thomas et al. reported the half-life of NO in extravascular tissue to fall within the 
range of 0.0λ to ˃ 2 s, depending on the concentration of oxygen present.80 A study by Liu et al. 
calculated the half-life of NO to be 1.8 × 10-3 s in whole blood and correlated to the concentration 
of erythrocytes.81 In blood, an additional route of NO consumption is through the reaction of NO 
with oxyhemoglobin or heme bound iron of the hemeproteins to yield iron(III)-peroxynitrite 
species.82 As such, strategies that are employed to increase the life span of NO frequently involve 
the use of NO donors materials such as RSNOs.  
1.4 S-Nitrosothiols and their therapeutic potential  
While NO is a short-lived biological messenger in a physiological environment, its effects 
can be harnessed using more stable NO precursors. RSNOs are NO-releasing compounds derived 
from thiols and are found to occur within the bloodstream.12 Given the fleeting nature of NO in 
the presence of the reactive components of blood, RSNOs are theorized to function as intermediate 
species that serve to stabilize NO and transfer it from its site of origin. Since NO inhibits platelet 
activity in the healthy endothelium, strategies incorporating an exogenous supply of NO for blood 
 
Figure 1.4. Generic structures for NONOates (top) and RSNOs (bottom).  
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contacting devices has been widely explored as a method for inhibiting thrombus formation.83-85 
These strategies aim to increase the lifespan of NO through the use of NO donors such as RSNOs 
or N-diazeniumdiolates (NONOates) (Figure 1.4). RSNOs occur in both natural and synthetic 
forms, and can be prepared through nitrosation of the sulfur atom of the thiol.83-85 In contrast, 
NONOates are strictly synthetic molecules formed through nitrosation of secondary and primary 
amines. NONOates exhibit spontaneous decomposition that generates two molecules of NO per 
NONOate.83-85 Comparatively, RSNOs decompose under certain conditions (heat, light, copper 
ions) to release one molecule of NO per RSNO. These synthesized NO donors have demonstrated 
their ability as potent antiplatelet agents and vasodilators and are therefore extremely promising 
for blood-contacting applications.84 
In order to achieve targeted and controllable release, NO donors are often incorporated into 
a polymer scaffold.  Two commonly used approaches include (a) covalently bound NO-releasing 
polymers and (b) direct blending of the NO donors through physical encapsulation in the 
polymer.83-85 Towards this end, numerous reports exist where these NO donors are incorporated 
into PVC, hydrogels, polyurethanes, poly(ethylene glycol), silicone rubbers, polymethacrylates, 
sol-gel, polyethylene oxide, and silica particles, to name a few materials.83-85 As an example, one 
of the first reports to incorporate NONOates into a blood-contacting polymer was by Smith et al. 
at the University of Akron in 1996.86 Here, Smith coated vascular grafts with cross-linked 
poly(ethylenimine) containing covalently attached NONOates. To determine the effect of the NO-
releasing polymer on platelet function, the vascular grafts were implanted in segments of artery-
vein shunts in baboons. When compared to the control (poly(ethylenimine) coated vascular grafts) 
the NO-releasing grafts had substantially less platelet deposition after 1 hour.86 The covalent 
attachment of RSNOs into polymers blends for blood-contacting surfaces has been investigated by 
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Seabra and coworkers at the State University of Campinas.87 In this work, Seabra synthesized 
polynitrosated polyester/poly(methylmethacrylate) blends which released NO at a rate of 1.8 ± 0.1 
nmol g h-1 for up to 24 h.87 Platelet adhesion experiments showed that the use of polynitrosated 
polyester/poly(methylmethacrylate) blends resulted in complete inhibition of platelet deposition, 
demonstrating its potential as a blood-contacting surface. Despite the availability of alternative 
NO donor species such as NONOates, RSNOs exhibit significant advantages that include limited 
toxicity, and a diverse selection of environmental triggers. However, while the use of RSNOs as 
therapeutic NO donors has expanded rapidly, their formation in vivo remains disputed.  
1.4.1 The biological role of S-nitrosothiols 
Plasma thiols are likely precursors for this role as well as nitrosating species and participate 
in the activation of nitrosovasodilators. In 1992, Stamler et al. were the first to demonstrate that 
the majority of S-nitroso adducts occur as S-nitrosoalbumin (SNO-albumin) through nitrosation of 
the lone cysteine residue.88 The balance was proposed to consist of RSNOs derived from low 
molecular weight (LMW) thiols, such as S-nitrosoglutathione (GSNO) (Figure 1.5).88 Scharfstein 




Figure 1.5. Examples of different RSNOs. 
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LMW thiols.89 To study the role of low molecular weight (LMW) thiols in NO transfer, Scharfstein 
investigated the effects on rabbits of intravenous SNO-albumin administration on rabbits before 
and after transfusion with LMW thiols. Their results showed that dose-dependent low blood 
pressure (hypotension) became significantly accelerated in rabbits infused with LMW thiols prior 
to SNO-albumin administration.89 Notably, the effects were mimicked by direct administration of 
the corresponding LMW RSNO. Based on this observation, Scharfstein proposed that SNO-
albumin served as a reservoir of NO which could then be transferred to LMW thiols when 
necessary as a smaller, less diffusion limited species.89 In 2000, Nedospasov et al. suggested an 
autocatalysis mechanism for albumin nitrosation.90 In this publication, Nedospasov proposed that 
an accumulation of NO and O2 within the hydrophobic compartments of the proteins catalyzed the 
formation of N2O3 followed by electrophilic attack on the nucleophilic thiol groups of cysteine 
residues.90 This mechanism was hypothesized to be dependent on the initial concentration of the 
reactants and the size and geometry of the hydrophobic portion of the protein. In 2002, Rafikova 
and coworkers claimed to demonstrate that saturation of albumin with NO accelerated the 
formation of LMW RSNOs both in vivo and in vitro by catalyzing the formation of RSNOs and 
extending the lifetime of the nitrosating species.91 To test this hypothesis, they evaluated thiol 
nitrosation with and without the presence of albumin. Their results showed that the presence of 
NO saturated albumin enhanced RSNO formation when compared to their control (absence of 
albumin).91 Additionally, by increasing the plasma thiol concentration, Rafikova observed newly 
formed RSNO at concentrations 2-fold higher than the preexisting RSNO. In rats, the direct 
administration of thiol was accompanied by up to a 4-fold increase in RSNO concentration and a 
corresponding decrease in arterial pressure. Overall, Rafikova concluded that the increased 
concentration of blood RSNOs following thiol administration was correlated with albumin-
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catalyzed formation through the transfer of nitrosonium (NO+) to LMW thiols.91 In 2003, 
Jourd’heuil et al. proposed an additional mechanism involving thiyl radical formation by NO2 
followed by subsequent reaction with NO.92 Another route for nitrosation of LMW thiols is through 
the mechanism proposed for metalloproteins such as ferric heme catalyzed oxidation of NO. This 
resulting NO+ species proceeds to react with surrounding thiols.93  
1.4.2 Basal blood S-nitrosothiol concentration: an ongoing debate 
There is considerable discussion regarding the quantification of physiological RSNO 
concentrations, with reports ranging from µM to nM.94 The feasibility of developing materials 
capable of generating therapeutically-relevant levels of NO from blood requires understanding of 
biological RSNO concentrations. In the initial 1992 report by Stamler, RSNOs were collectively 
quantified at a total blood plasma concentration of 7 µM through a chemiluminescence-based 
detection method.88 Of the reported concentration, 96% was due to nitroso-proteins with SNO-
albumin accounting for 82% of the nitroso-proteins with no LMW RSNOs being identified. A 
1998 report from Goldman et al. determined a blood plasma concentration of 220 nM using high-
performance liquid chromatography with a Griess assay.94 In 2000, using the same methodology, 
Jourd’heuil and colleagues determined a plasma concentration of 62 nM with the majority in the 
form of SNO-albumin.95 In parallel, reports by Marley (2000) and Rassaf et al. (2002) reported 
plasma concentrations of RSNOs ranging from 15-40 nM using a chemiluminescence detection 
method.96-98 Furthermore, Tyurin et al. reported RSNO plasma concentrations of 4.2 µM using 
spectrofluorophotometer techniques, whereas, Tsikas and colleagues used GC-MS to determine 
an SNO-albumin concentration of 156 nM.99,100 As can be inferred from these examples, the 
physiological concentration of RSNOs remains a debated subject with accurate measurements 
remaining a developing field. Nevertheless, physiologically-available forms seem well 
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established, with SNO-albumin and GSNO occurring as the dominant species in the body with the 
reported range falling between the low nM (<100) and the low µM (<10).  
1.4.3 Chemical and physical properties of S-nitrosothiols  
Since Jones and Tasker’s original synthesis of nitrite esters at the University of Cambridge 
in 1909, the understanding of RSNOs and their chemical reactivity continues to progress.101 
Interestingly, contradictory reports exist related to RSNO thermal stability in which they are 
alternately described as either extremely susceptible or resistant to thermolysis.102-105 Based on 
bond dissociation energies between 20 and 32 kcal mol-1, the half-lives of RSNOs should be as 
long as years.102,104 However, these calculated half-lives contradict experimental values ranging 
from minutes to hours. This led to the suggestion that thermally induced decomposition of the S-
N bond is not the most significant contributor to RSNO decomposition under physiological 
conditions. The stability of RSNOs varies greatly with certain tertiary examples such as S-
nitrosotriphenylmethanethiol and SNAP occurring as crystalline solids that can be isolated and 
stored for extended periods, while others exist only in the form of unstable solutions and 
decompose within minutes to hours of their synthesis.106 The majority of unstable RSNOs are 
primary or secondary, with GSNO being the exception with it demonstrating excellent stability 
and is isolated as a solid. RSNO stability is hypothesized to be depend on both the strength of the 
S-N bond and the rate of S-S disulfide formation (2 RSNO → RSSR + 2 NO).107 To investigate 
the stability of RSNOs, Bainbrigge et al. utilized differential scanning calorimetry (DSC) and 
thermogravimetric analysis (TGA) to evaluate the thermal stability of GSNO and SNAP. Notably, 
both RSNOs were found to exhibit NO-forming decomposition at 148 ⁰C.17 Based on these results, 
Bainbrigge suggested that the local chemical structure has little effect on the strength of the S-N 
bond. However, the combination of thiyl radicals formed from the decomposition of SNAP results 
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in a high energy, sterically hindered conformation compared to many primary RSNOs.107 
Therefore, it was proposed that thiyl radical dimerization was the rate determining process in 
solution due to the ability of the NO and thiyl radical to recombine with liberation of NO occurring 
only upon disulfide formation.  
RSNOs are observed to be red (primary and secondary RSNOs) and green (tertiary RSNOs) 
in color and are commonly characterized by UV-Vis spectroscopy. Bond lengths obtained from 
crystal structures are approximately 0.18 nm and 0.12 nm corresponding to values expected for 
formal S-N single bond and N-O double bond.108,109 However, RNSOs exhibit significant S-N 
double bond character and therefore occur in either syn or anti conformations (Figure 1.6). The 
preference for a specific orientation is driven by the degree of substitution on the R group. As such, 
primary and often secondary RSNOs exhibit syn orientations, whereas tertiary RSNOs will adopt 
an anti conformation. Interconversion between isomers does not readily occur and an appreciable 
barrier (11-12 kcal mol-1) to rotation has been calculated.110,111 Additionally, theoretical 
calculations have suggested a degree of delocalization over the RSNO molecule.111 Taken 
together, these findings strongly support the double bond character of the S-N bond. The bonding 
 
Figure 1.6. (a) Proposed conformations of RSNOs and (b) hypothesized resonance 
structures composed of (1) the convetional lewis acid structure, (2) zwitter ionic resonance 
structure, and (3) ion pair resonance structure.  
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of the RSNO functional group was further rationalized by Timerghazin et al. through a 
combination of three different resonance forms.112 Density functional theory calculations and 
natural resonance theory calculations were used to generate the proposed resonance structures 
(Figure 1.6). In addition to the conventional Lewis structure, (1) a zwitterionic structure with a S-
N double bond, (2) and an ion pair resonance (3) structure were proposed. The zwitterionic 
structure (2) was calculated to contribute to 15-25% of the overall structure and accounts for the 
observed syn-anti conformers of RSNOs, supporting the argument for delocalization of electrons 
around the S-N bond.112 Additionally, the experimentally observed S-N bond length can be 
explained by the ion-pair resonance structure (3) contributing to elongation of the bond.  
In comparison, factors influencing RSNO decomposition are fairly well understood, with RSNOs 
known to decompose through thermal and photochemical routes to yield the corresponding 
disulfide (RSSR) and NO (equation 1.1).13 Under deoxygenated conditions, these reactions can 
occur through homolytic cleavage of the S-N bond (equation 1.2). Following this homolytic 
scission, disulfide formation is proposed to occur through the reaction of two thiyl radical species 
as suggested by Bainbrigge (equation 1.3a).107 In an alternative mechanism, the thiyl radical is 
proposed to react with the more abundant RSNO molecules yielding the corresponding disulfide 
and generation of NO (equation 1.3b). The latter mechanism tends to be favored due to the relative 
abundance of the RSNO species compared to the thiyl radical.13 In the presence of oxygen, the 
RSOO• radical is hypothesized to be generated first (equation 1.4) followed by the reaction with 
another RSNO molecule to yield NO and the corresponding disulfide (equation 1.5).  
2 RSNO → RSSR + 2 NO (1.1) 
RSNO → RS• + NO (1.2) 
RS• + RS• → RSSR (1.3a) 
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RS• + RSNO → RSSR + NO (1.3b) 
RS• + O2 → RSOO• (1.4) 
RSOO• + RSNO → RSSR + NO + O2 (1.5) 
However, many results are erratic and generally inconsistent, leading to discrepancies in the 
literature with mechanistic pathways remaining unclear. As mentioned briefly, it has been 
observed that certain metal ions enhance RSNO decomposition in solution.  
1.4.4 S-Nitrosothiol decomposition: influence of copper ions  
In 1λλ3, the Williams’ group initially introduced this concept while investigating NO release 
from SNAP, where they observed that SNAP decomposition kinetics did not follow a simple rate 
law and displayed half-lives that varied every week with the same batch of SNAP.113 Based on 
these observations, Williams evaluated the impact of adding the chelator 
ethylenediaminetetraacetic acid (EDTA) on SNAP decomposition. Upon EDTA addition, the rate 
of SNAP decomposition was dramatically reduced, suggesting potential metal ion contamination 
of the solution. Subsequent addition of Cu2+ ions to the solution resulted in the reintroduction of 
rapid SNAP decomposition. Taken together, these results formed the foundation of the hypothesis 
that Cu2+ had a catalytic effect on RSNO decomposition that accounted for their erratic results.113 
Following that work, Williams and colleagues evaluated the impact of different metal ions 
including Zn2+, Ca2+, Mg2+, Ni2+, Co2+, Mn2+, Cr3+, Fe3+, Fe2+, and Cu2+ on the decomposition of 
multiple RSNOs decompositions.114 These studies firmly established that Cu2+ and Fe2+ (to a lesser 
extent), could substantially increase the rate of RSNO decomposition. To test the effect of each 
metal ion, an appropriate salt was added in slight excess of EDTA into solution and measured 
RSNO decomposition. They then halted the reaction by the addition of excess EDTA to the 
solution. In these particular experiments, the most reactive substrates included S-
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nitrosocysteamine (CysamNO), S-nitrosocysteine (CysNO), and S-nitrosopenicillamine (Figure 
1.6).114 In comparison, other structures such as 1,1-dimethyl-S-nitrosoethanethiol showed no 
activity. In general, many RSNOs showed rate constants and reactivity suggesting that the RSNO 
structure and its ability to interact with copper influenced catalytic efficacy. While no mechanistic 
details were proposed, Williams suggested the observed reactivity could be due to Cu2+ binding 
with the RSNO through the nitroso group and the amine or carbonyl group to form a bidentate 
complex via a six-membered ring (Figure 1.7).114  
In a follow-up paper, Williams and colleagues examined the decomposition of SNAP in the 
presence of Cu2+ ions with increasing concentrations of neocuproine, a molecule known for its 
ability to selectively bind Cu+.115 As the neocuproine concentration was increased, decomposition 
of SNAP became progressively hindered until it was completely suppressed, suggesting that the 
formation of Cu+ is a key component of copper-catalyzed RSNO decomposition. The formation of 
Cu+ was suggested to occur from the reduction of Cu2+ by adventitious thiolate arising from an 
impurity or hydrolysis of the RSNO (equation 1.7).115 To examine this concept, NAP (the 
corresponding thiol), was added to the reaction in increasingly higher concentrations. 
RSNO + 2OH
- → RS- + NO2- + H2O (1.7) 
 
Figure 1.7. The proposed intermediate species for copper catalyzed decomposition of 
RSNOs. Copper can form a bidentate species through binding with the nitroso group and 
the corresponding functional group of the RSNO such as an amine or carbonyl group. 
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Initially, a linear correlation existed between the concentration of thiol and the increased rate of 
SNAP decomposition, until high concentrations of NAP resulted in a drop in the observed rate. 
They explained this pattern as complexation of the Cu2+ by NAP to form a copper carboxylate 
species and the accompanying decrease in the available concertation of catalyst. Thus, at lower 
NAP concentrations, reduction of Cu2+ to Cu+ is favored, while higher concentrations result in the 
sequestration of copper ions through complexation.115 On this basis, Williams proposed a 
mechanism in which Cu2+ is reduced by RS-, yielding Cu+ and RS• (equation 1.8). This step is then 
followed by reaction between the Cu+ species and RSNO through an undetermined intermediate 
species [I] with the products being Cu2+, NO, and RS- (equation 1.9). The regeneration of the RS- 
allows for the continuous reduction of Cu2+ and the corresponding radical RS• species results in 
disulfide formation (equation 1.10).115 
Cu2+ + RS- ↔ [I] → Cu+ + RS• (1.8) 
Cu+ + RSNO ↔ [I] → Cu2+ + NO + RS- (1.9) 
2 RS• + → RSSR` (1.10) 
Following this work, Williams et al. evaluated the influence of Cu2+ specifically on GSNO 
decomposition.116 Similarly to SNAP, as the concentration of GSNO increased, the NO generation 
came to a halt. Williams hypothesized that the oxidized form of glutathione (GSSG) complexed 
with the Cu2+ in solution in a manner analogous to NAP, and the reaction was consequently 
suppressed at higher (mM) GSNO and increased at lower (µM) concentrations.116 In contrast to 
GSNO, evaluation of CysNO decomposition showed no great change in the rate of the reaction or 
the amount of NO recovered. This outcome was suggested to be correlated to the inability of Cu2+ 
to chelate with the disulfide species. Based on these findings, no correlation between RSNO 
structure and reactivity could be made for the observed rates of RSNOs when performed at mM 
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concentrations. Therefore, their previous reports, which invoked the requirement of a cyclic 
transition state, were rendered null.116 Williams et al. then reported a follow-up to investigate the 
structure-reactivity impacts of four RSNOs: S-nitrosocysteine (SNC), S-nitrosocysteinylglycine 
(SNO-CysGly), S-nitrosoglutamylcysteine (SNO-GluCys), and GSNO at mM and µM 
concentrations.117 These four were chosen due to the presence of glutamate residues in GSNO and 
SNO-GluCys, which could theoretically complex with the Cu2+ species upon disulfide formation. 
As predicted, they observed an increase in the reaction rate at µM concentrations for GSNO and 
SNO-GluCys that were suppressed at higher (mM) concentrations.117 In contrast, rates for SNC 
and SNO-CysGly remained relatively unchanged regardless of the concentration. These findings 
supported the concept that with certain RSNOs the reaction rates will be dependent on the 
concentration of the corresponding disulfide present.117  
The overall reactivity of RSNOs to metal ions is not solely limited to copper ions. Other 
reports have found that both mercury (Hg2+) and silver (Ag+) ions are able to substantially increase 
the rate of RSNO decomposition with marked differences observed between the different metal 
ions.118 In the presence of Hg2+, the major reaction product observed is nitrous acid (HNO2) which 
was not derived from NO. Additionally, the use of Hg2+ species was required in stoichiometric 
amounts compared to the catalytic quantities required for copper.118 Overall, while the 
coordination of certain metal species to sulfur in the RSNO decreases the bond strength causing 
breakage and subsequent NO generation, the precise mechanism remains unclear.  
1.5 Catalytic methods of generating nitric oxide from S-nitrosothiols for medical applications 
Understanding of the NO-forming properties of RSNOs, their biological relevance, and their 
susceptibility to accelerated decomposition in the presence of certain chemical species (e.g., 
copper ions, iron irons) has continued to expand over the years. As previously discussed, this has 
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led to their development as therapeutic materials intended for NO-forming decomposition through 
thermal or photolytic decomposition for the prevention of thrombus formation. However, the use 
of exogenous NO donors to produce NO-releasing medical implants for long-term applications is 
limited by a finite reservoir of the therapeutic agent. Once the donor species has been depleted 
through NO release, therapeutic effects from the action of NO are arrested. In the majority of cases, 
this depletion occurs within hours, days, or weeks. To transcend this limitation, alternative routes 
have proposed the generation of NO directly from these endogenous substrates. Materials that 
harness this concept have included polymer-immobilized organotellurium and selenium catalysts, 
as well as copper nanoparticles and complexes.14, 119-129  
The majority of this research originates from the University of Michigan, where work by 
Meyerhoff has pioneered the catalytic generation of NO from RSNOs that occur naturally in blood. 
The use of catalysts developed from the Group 16 elements selenium and tellurium was inspired 
by a biomimetic approach that sought to reproduce the biological activity of glutathione 
peroxidase, a selenium-containing enzyme that generates NO from RSNOs through a catalytic 
reaction.130 While selenide and telluride-based materials successfully generated NO from RSNOs 
such as GSNO and CysNO, the addition of thiol was necessary to maintain the catalytic cycle.119-
122 Other approaches have used copper species to induce the catalytic generation of NO from both 
RSNOs and nitrite.123-129,131 However, many of these approaches proceed through the intentional 
generation and release of copper ions into solution.124-129  
For example, research performed by Hwang et al. at the University of Michigan investigated 
the ability of Cu(II)-cyclen (cyclen= 1,4,7,10-tetraazacyclododecane) complexes to generate NO 
from both GSNO and CysNO following covalent attachment to cross-linked poly(2-hydroxyethyl 
methacrylate) (pHEMA).128 NO release experiments demonstrated that immersion of Cu(II)-
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cyclen/pHEMA films in solutions containing RSNOs could produce steady state NO surface fluxes 
in the realm of 2.5 × 10-10 mol cm-2 min-1, a value that is within the range observed for NO release 
from healthy endothelial cells.128 Copper leaching experiments showed that substantial copper 
leaching occurred (approximately 40%) after soaking the materials in phosphate buffer saline 
(PBS) with GSNO/GSH over 15 days. Subsequent evaluation of catalytic activity showed a 
resulting decrease in NO generation by 25-50%.11  Another report by Hwang and colleagues 
investigated the catalytic properties of Cu(II)-cyclen complexes covalently attached to a 
hydrophillic polyurethane.129 While this material generated an NO flux between 1-3 × 10-10 mol 
cm-2 min-1, 25% of copper leaching within the first 24 h, with an additional 25% leaching within a 
week. In another report, Major et al. incorporated 1, 5, and 10 wt.% copper nanoparticles into a 
hydrophilic polyurethane to develop a material which mimicked the tubing of an extracorporeal 
circulation (ECC) device.124 This approach was based on the slow corrosion of Cu0 to generate 
catalytically active Cu2+ ions. Addition of 1 µM GSNO resulted in NO flux measurements of 5, 
10 and 12×10-10 mol cm-2 min-1 with respect to the weight percentage of copper nanoparticles. 
Blood experiments performed using an ECC setup showed that the plasma copper concentration 
increased by a factor of 1-1.3 after 4 hours, suggesting a degree of leaching.124 Meyerhoff and 
coworkers have also demonstrated the ability to electrochemically generate NO in the presence of 
nitrite through a Cu+-mediated pathway. Generation of Cu+ proceeded either through the reduction 
of a Cu2+ or through the oxidation of Cu0 wire. The materials were able to generate NO in the 
range of 0.5-3.5×10-10 mol cm-2 min-1, corresponding to physiologically produced levels.132-134 
Two reports by Wonoputri and colleagues described the incorporation of a copper dibenzol 
[e,k]-2,3,8,9-tetraphenyl-1,4,7,10-tetraaza-cyclododeca-1,3,7,9-tetraene complex (CuDTTCT) 
into polymers for the catalytic generation of NO from nitrite.123,131 In 2015, they incorporated 
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CuDTTCT species into PVC and produced NO from nitrite using ascorbic acids as the reducing 
agent. NO generation occurs through a copper-nitrite-ascorbic acid pathway in which ascorbic acid 
reduces the Cu2+ to Cu+ the Cu+ species then goes on to react with nitrite to produce NO, which 
gets oxidized back to Cu2+ during the process.123 In 2016, they reported on an iron-based complex 
which was capable of facilitating the redox cycle for catalytic generation of NO from nitrite in the 
presence of the copper species.131 This reaction occurred through the oxidation of iron(II) to 
iron(III) and the simultaneous reduction of Cu2+ to Cu+. As in the previous system, the Cu+ species 
reacts with nitrite to generate NO, accompanied by regeneration of the Cu2+ species. In both 
reports, less than 1% of copper was leached after three days of incubation with nitrifying 
bacteria.131 While these reports hold merit for medical applications, the ability to generate NO 
from nitrite becomes more relevant for antibacterial applications because nitrite is an established 
product of bacterial metabolism.123,131  
While immobilized copper-based species generate NO from the decomposition of RSNOs, 
limitations arise with respect to long-term medical devices due to gradual loss of the catalytic 
materials and subsequent toxicity related to copper leaching. As such, research has progressed 
towards the development of a material in which the copper sites remain immobilized within the 
structural framework under physiological conditions, which is extremely desirable for medical 
applications. In particular, a promising alternative involves the use of metal–organic frameworks 
for NO generation.  
1.6 Metal–organic frameworks  
Metal–organic frameworks (MOFs) are hybrid inorganic-organic crystalline materials 
prepared through the self-assembly of metal ions with organic ligands to form porous crystalline 
structures that exhibit one, two, or three-dimensional architectures. The most common synthetic 
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routes for MOF synthesis include hydrothermal, solvothermal, electrochemical, 
mechanochemical, and sonochemical techniques.135 Factors such as solvents and structure-
directing agents will have a strong influence on crystal formation and pore size.135 The size and 
shape of MOF crystals can be manipulated through variation of the pH, metal ion, solvent, reaction 
concentrations, time, and temperature. MOF topology can be predicted by the atoms between the 
metal organic clusters and the linker that form defined geometric shapes referred to as secondary 
building units (SBUs).136 The organic linkers can be mono-, di-, tri-, or tetravalent and function as 
bridging units between neighboring metal ions. The metal and organic linkers dictate the structure 
and are easily varied to control the chemical and physical properties of the MOFs. Due to many 
MOF architectures exhibiting a high degree of porosity and surface area, researchers have 
proposed their use in gas storage applications.137 Uses of MOFs are not confined to gas storage; it 
has been demonstrated that MOFs show promise in sensing, catalysis, separations, magnetic, 
optical, electronics, and biomedical applications.138-140 In particular, the value of MOFs in medical 
pursuits is well established in the literature, with applications ranging from antibacterial agents to 
drug delivery carriers and as a contrasting agent for biomedical imaging.141,142 Due to the gas 
storage capabilities exhibited by certain MOFs, they were quickly recognized as potential carriers 
of therapeutic gases such as NO.143 NO-releasing frameworks are obtained from direct 
coordination of gaseous NO to an open metal site to form metal-nitrosyl complexes or through 
incorporation of NO donor groups such as NONOates through post-synthetic modification 
(PSM).143,144 While several reports have investigated PSM of MOFs, direct coordination of NO to 
open metal sites remains the most commonly utilized approach.145-147 MOFs for delivery of NO is 
advantageous considering the observed dose-dependent nature of NO. By altering the MOF 
composition, researchers have tailored MOFs to deliver different quantities of NO.143,144  
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1.6.1 Metal–organic frameworks for delivery of exogenous nitric oxide 
In particular, the Morris group at the University of St. Andrews has extensively studied the 
ability of MOFs to uptake and release NO through direct coordination to open metal sites. Xiao et 
al. evaluated the ability of copper(II) benzene 1, 3, 5-tricarboxylate (HKUST-1 or CuBTC) to 
adsorb NO. CuBTC demonstrated an NO adsorption capacity of 3 mmol g-1 at room temperature, 
a value significantly higher than the adsorption capacities of other porous materials such as 
zeolites(1-1.5 mmol g-1).148 Formation of a Cu-NO adduct was confirmed by IR spectroscopy 
through the appearance of a peak previously associated with NO stretching in Cu-NO zeolite 
complexes. Desorption of CuBTC occurred with significant hysteresis that was suggestive of 
irreversible NO adsorption to the open metal copper sites, with approximately 2.21 mmol g-1 
remaining adsorbed to the MOF.148 NO release from CuBTC under 11% relative humidity (RH) 
demonstrated a cumulative NO release of 1 µmol g-1 of CuBTC over 1 h, corresponding to only 
0.03% of theoretical adsorbed NO. This lack of NO release implies strong interactions between 
copper and NO, likely due to the formation of Cu-NO adducts, rendering CuBTC a less than ideal 
candidate for NO release applications.148  
In an effort to improve upon the NO release capabilities of CuBTC, McKinlay and coworkers 
evaluated two MOFs, based on cobalt and nickel, with 2, 5-dihydroxyterephthalic acid serving as 
the organic linking component (Co-CPO-27 and Ni-CPO-27).149 Adsorption capacities of the 
materials were approximately 6.0 mmol g-1 (Co-MOF) and 7.0 mmol g-1 (Ni-MOF) at room 
temperature, with both MOFs exhibiting hysteresis upon desorption. NO release measurements 
showed that the MOFs released nearly 100% of the adsorbed NO over 15 h under 11% RH.149 In 
this context, these NO uptake values correspond to a 400-700% increase in NO uptake compared 
to zeolite species and approximately 18-21% of the maximum theoretical storage capacity of NO 
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(based on the molecular weight of NO). While these MOFs demonstrate exceptional NO uptake 
and release the use of toxic Ni and Co produces biocompatibility concerns. The importance of 
coordinatively unsaturated metal nodes or open metal sites (OMS) in the NO storage capacity of 
MOFs is demonstrated by experiments performed using Al-MIL-53 and Cr-MIL-53.141 Al-MIL-
53 and Cr-MIL-53 are members of the MIL (MIL=Material Institut Lavoisier) family which is 
composed of different carboxylate-based MOFs. In this circumstance, the Al and Cr metal ions are 
coordinated with 1,4-benzenedicarboxylate with the extended framework lacking open metal sites. 
Correspondingly, gas sorption measurements revealed that these MOFs adsorb significantly 
smaller quantities of NO (1.0 mmol g-1 ˃) compared to CuBTC, Co-CPO-27, and Ni-CPO-27. 
Indeed, desorption measurements show little to no hysteresis suggesting that NO is simply 
physisorbed to the walls inside the pores.143 
Due to the potential for biocompatibility concerns arising from the use of MOFs derived 
from Ni, Co, and Cu, researchers proceeded to evaluate an iron carboxylate-based MOF in an 
attempt to circumvent toxicity concerns. McKinlay and colleagues assessed the iron(III) 
dicarboxylate MOFs with MIL architecture derived from either fumaric (MIL-88A) or terephthalic 
(MIL-88B) acid. Gas sorption measurements showed that the MOFs adsorbed 2.5 (MIL-88A) and 
1.6 (MIL-88B) mmol g-1 of NO at room temperature.150 IR spectroscopy suggested that some 
fraction of NO was chemisorbed to Fe(III) or Fe(II), however NO was only adsorbed to a total of 
1.6% (MIL-88-A) and 7% (MIL-88-B) of available sites based on their predicted number. Because 
these values only accounted for 2.4 and 13% of total NO adsorption, the authors suggested that the 
majority of NO was bound through physisorption.150 At 11% RH, NO release corresponded to 5% 
and 0% of adsorbed NO and continued to occur at low concentrations (10 ppb) for up to 24 h. 
MicKinlay et al. hypothesized that the decreased NO adsorption compared to the CPO-27 and 
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CuBTC MOFs was correlated with the flexibility of these particular structures. This flexibility 
could result in narrowed pores following removal of solvent molecules, limiting the accessibility 
of the metal sites to NO.150 From this notion, Eubank et al. investigated three MOFs with rigid 
frameworks and increased pore sizes.151 These MOFs were derived from inorganic trinuclear 
clusters (Fe, Cr) and tricarboxylate ([Fe, Cr] MIL-100) or tetracarboxylate ligands (Fe-MIL-127). 
NO adsorption studies for the MIL-100 MOFs demonstrated adsorption capacities of 2.7 (Fe) and 
3.2 (Cr) mmol g-1, corresponding to 75-88% of their theoretical uptake based on available metal 
sites. Interestingly, Fe-MIL-127 adsorbed 1.2 mmol g-1 NO, corresponding to only 44% of 
theoretical uptake. This decrease in adsorption was proposed to correlate with the retention of 
water molecules within the pores upon activation.151 NO release experiments at 11% RH yielded 
values of 0.6 (Cr-MIL-100), 0.35 (Fe-MIL-100,) and 0.2 (Fe-MIL-127) mmol g-1 of NO which 
corresponded to the release of 26, 15, and 27% of available NO. Additionally, the majority of NO 
release took place within the first hour, with small quantities (>10 ppb) released for up to 40 h.151  
While the Fe-based MOFs are beneficial for improving biocompatibility, they uptake and 
release significantly smaller quantities of NO compared to the CPO MOFs, rendering it a 
compromise between high NO adsorption capacity and biocompatibility. In an effort to obtain both 
high NO adsorption and biocompatibility, Bloch et al. reported on the formation of a new Fe-MOF 
that adopted the CPO-27 structure and used a non-toxic metal. The Fe-MOF architecture consists 
of coordinately unsaturated Fe(II) sites and 2,5-dihydroxyterephthalic acid as the linker 
(Fe2(dobdc)).
152 Due to the high density of accessible metal sites and the enhanced 
biocompatibility of iron, Fe2(dobdc) was investigated for NO storage and release by Bloch and 
colleagues.153 NO adsorption measurements demonstrated that Fe2(dobdc)  adsorbed 
approximately 6.21 mmol g-1 NO, similar to the quantities observed for other CPO-27 MOFs. 
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However, NO release measurements at 11% RH, showed that Fe2(dobdc) had released only 64% 
of NO over 10 days.153 While additional MOF systems composed of Ca (BioMIL-3), Co (Co-
vitamin B3), and Ni (Ni-vitamin B3) have been investigated for NO adsorption and release, CPO 
based architectures have the highest NO sorption capacities reported to date (Table 1.1).154,155 
1.6.2 Metal–organic frameworks for nitric oxide generation  
More recently, an alternative method of achieving NO release using MOFs has been derived 
from the known ability of copper ions to decompose RSNOs. As previously mentioned, one 
limitation of utilizing copper complexes for NO generation involves the large degree of copper 
leaching that occurs over the duration of use. In MOFs, the immobilization of the metals within 
the extended framework can result in their enhanced stability over other copper complexes, making 
them an attractive approach for NO generation.  
With the seminal work in 1994 by Fujita et al. which first demonstrated catalysis using a 
MOF, interest was triggered in the rational design and development of MOFs for catalytic 
applications has continued.156 To date, there are several main approaches for creating catalytically 
Table 1.1 Table of NO adsorption, release, and percent release reported in the literature for 
 different MOF complexes.  
MOF 
NO adsorbed 
 (mmol g-1) 
NO released under RH 
(mmol g-1) 
% NO release 
CuBTC 3.0 0.001 0.03 
Co-CPO-27 6.7 6.7 100 
Ni-CPO-27 7.0 7.0 100 
Fe-MIL-88-A 2.5 0.12 7.5 
Fe-MIL-88-B 1.6 0.0 0.0 
Cr-MIL-100 3.2 0.6 18 
Fe-MIL-100 2.7 0.35 13 
Fe-MIL-127 1.2 0.2 17 
Fe2(dobdc) 6.2 4.0 65 
BioMIL-3 0.8 0.005 0.6 
Ni-vitamin B3 3.3 2.6 79 
Co-vitamin B3
 4.5 2.0 44 
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active MOFs.157,158 First, catalytically-active MOFs can be created using the structurally embedded 
metal nodes within the SBUs of the extended framework. In this approach, catalysis relies on the 
existence of open metal sites that arise from structural defects or topographical prevention of 
complete saturation. In the second approach, catalytic metals are included within porphyrins that 
also function as organic linkers that bind to catalytically-inactive metal nodes to form the 
frameworks itself. Thirdly, the organic linker may also contain a functional group which is either 
directly catalytically active or becomes active following PSM.158 This functional group is 
considered terminal and does not connect to other portions of the MOF. Lastly, MOFs can 
encapsulate the catalytically active species, (either a molecule or metal nanoparticles) within the 
pore structure. The use of MOFs with unsaturated metal sites remains the most widely explored 
route for catalysis. Based on this logic, two copper-based MOFs have been investigated for their 
activity in the presence of certain NO donors. These include the copper-carboxylate based MOF, 
CuBTC and the copper triazoleate-based MOF, CuBTTri.15,16 
Chui and coworkers reported the initial synthesis of CuBTC from solutions of copper(II) 
ions in the presence of trimesic acid (1, 3, 5-benzenetricarboylic acid).159 CuBTC forms face-
centered cubic crystals composed of dimeric copper(II) ions at the vertices and four trimesate 
ligands, which form a paddle-wheel-type configuration (Figure 1.8). These units make up the SBU 
of CuBTC, which together with additional SBUs form the overall extended framework.159 The 
local environment around the copper centers consists of dimeric copper tetracarboxylate units 
through coordination with the carboxylate oxygens of trimesic acid. The environment around the 
copper sites is considered pseudo-octahedral with the presence of labile water ligands or solvent 
ligands which can be removed upon desolvation. CuBTC has remained the subject of ongoing 
study and has been proposed for numerous applications. In particular, Harding et al. evaluated the 
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ability of CuBTC to generate NO from the NO donor, S-nitrosocysteine (CysNO). Experiments 
performed in reagent alcohol in the presence of CysNO and cysteine (CysH), showed that CuBTC 
recovered nearly 100% of theoretical NO upon the addition of 2, 10, and 15-fold excesses of 
CysNO relative to theoretical copper sites in CuBTC.15 To ensure that the catalytic activity did not 
result from the presence of nonframework copper complexes, the MOF particles and the reaction 
solution were characterized further via powder x-ray diffraction and inductively coupled plasma 
atomic emission spectroscopy (ICP-AES). Use of pXRD following the experiment confirmed 
 
Figure 1.8. Structure of CuBTC (a) as viewed along the a-axis (b) viewed along the [110] 
plane (c) local environment around the copper centers which forms the SBUs. Image on the 
left illustrates the copper centers upon dehydration with two possible binding sites. Image 
on the right illustrates the hydrated version. Carbon atoms are represented in black, oxygen 
in red and copper in blue. Hydrogen atoms have been omitted for clarity.  
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retention of crystallinity after exposure to the experimental conditions, while analysis of the 
reaction solution via ICP-AES determines whether copper ions are leaching into solution. In this 
report, analysis of CuBTC and surrounding solution supported retention of the original structure, 
implying the catalytic activity was not produced from copper ions.15  
In 2009, Demessence et al. synthesized the robust, cubic sodalite-type metal-organic 
framework H3[Cu4Cl)3(BTTri)8(H2O)12]•72H2O (BTTri = 1,3,5-tris (1H-1,2,3-triazol-5-
yl)benzene) that featured open Cu(II) coordination sites (Figure 1.9).28 This MOF is described as 
isotypic to a previously reported copper tetrazole based MOF, 
H[Cu(CH3OH)6][(Cu4Cl)3(BTT)8(H2O)12]•3.5HCl•36CH3OH (BTT=1,3,5-tris(tetrazol-5-
yl)benzene).160 The CuBTTri framework consists of square planar chloride-centered [Cu4Cl]
7+ 
units that coordinated through the nitrogen atoms of the triazole rings on the BTTri3- ligands 
(Figure 1.9). Each individual [Cu4Cl]
7+is coordinated to eight individual BTTri3- ligands, and each 
BTTri3- ligand interacts with three different [Cu4Cl]
7+ units.160 The fundamental building unit of 
CuBTTri consists of six [Cu4Cl]
7+ and eight BTTri3- units which form a truncated octahedral 
structure. Sharing of each square face between adjacent neighbors provides the overall cubic 
structure. Additionally, the copper centers in the framework exhibit octahedral coordination with 
one labile site typically occupied by solvent molecules. The most advantageous property of 
CuBTTri is its enhanced water stability compared to CuBTC. Notably, CuBTTri tolerates 
immersion in boiling water for 3 days without appreciable loss of structure (as characterized by 
pXRD).160 These findings led to the initial studies by Harding and colleagues that assessed the 
promotion of NO from S-nitrosocysteamine by both CuBTTri itself and a CuBTTri/polymer blend. 
The presence of CuBTTri resulted in enhanced NO generation when compared to the baseline 
decomposition of the RSNO. The inclusion of CuBTTri into a polymer gave an 8-fold reduction 
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in the rate of NO generation, demonstrating that incorporation into a polymeric material can impact 
NO generation due to diffusion limitation of the RSNO.16 
While extremely promising, the use of MOFs as functional materials relies on the 
incorporation of particles into a secondary support system. Towards this end, MOFs are fabricated 
into thin films or membranes through two generalized approaches: the direct blending of the MOF 
within the polymer matrix and (b) chemical attachment of MOFs to a substrate via in situ growth. 
Direct incorporation of MOF particles into commercially available polymeric materials allows the 
potential to maintain properties of the parent material while adding the desired properties of the 
MOF.  
 
Figure 1.9 Components of the CuBTTri MOF (a) structure of the BTTri ligand that binds 
with six different copper species (b) SBU with square planar geometry (c) viewed along the 
a-axis (d) view along the [110] plane.  
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1.7 Dissertation overview 
This dissertation focuses on the fabrication and characterization of novel MOF-polymer 
composite materials and evaluation of their ability to generate NO from several different RSNOs 
(CysamNO, SNAP, and GSNO), which has never been previously demonstrated in the available 
literature (Figure 1.10). The initial reports by Harding et al. established that certain copper-based 
MOFs have the ability to accelerate NO generation from RSNOs, a concept never before 
demonstrated. However, these developed systems display certain limitations (non-aqueous 
conditions, non-physiological RSNOs) which will ultimately hinder their practical consideration 
in blood-contacting applications. This work expands on these initial reports through exploration 
of the factors which influence NO generation from these MOF-based systems. As such, this 
dissertation focuses on the identifying and optimizing key parameters necessary in these MOF-
based systems for their practical implementation for potential clinical use. 
As previously described, the use of MOFs for therapeutic enhancement of NO generation 
relies on their successful incorporation into a secondary support. To achieve this goal, two different 
approaches to the development of MOF/polymer composite materials have been explored: (1) in 
situ growth of MOF crystals directly on the surface of a polymeric substrate, and (2) blending of 
previously synthesized MOF particles into polymer matrices. The use of copper-based MOFs in 
the development of blood-contacting materials ideally requires their NO-forming function to occur 
within a certain set of parameters. In general, in order for these materials to be feasible for 
translation into clinical use, the MOF must maintain its structure and function upon incorporation 
into the polymeric material and under physiologically relevant conditions (pH 7.4, 37ᵒ C) with 
minimal to no leaching of copper or the organic ligand. Additionally, interactivity with the 
endogenous RSNOs should result in the generation of NO at physiologically relevant 
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concentrations (within the flux ranges associated with the endothelium 0.05-0.4 × 10-10 mol NO 
cm-2 min-1).  
The polymers examined by this work are frequently used for medical applications and 
include cotton fabric (primarily cellulose), PVC, chitosan (β-(1,4)-linked glucosamine and N-
acetyl-D-glucosamine units) and poly(vinyl alcohol) (PVA). In the medical industry, cotton fabric 
is found in the form of gauzes and swatches used as medical dressings. The primary constituent of 
cotton is cellulose, a polysaccharide composed of linear chains of β 1→4 D-glucose units. 
Functionalization of the hydroxyl units through carboxymethylation provides a carboxylate 
anchoring point for copper ions similar to CuBTC. Chapter 2 demonstrates CuBTC growth on 
carboxylate-functionalized cotton substrate via a layer-by-layer synthetic approach. The ability of 
this material to generate NO from S-nitrosocysteamine was evaluated using nitric oxide analyzers 
(NOAs) a chemiluminescence-based detection technique. While this work provides insight into 
the development of supported MOF catalyst systems, the instability of CuBTC in an aqueous 
environment renders it unsuitable for many biological applications. Because the MOF is required 
to not degrade physically in aqueous conditions, the remaining chapters focus on the incorporation 
of CuBTTri into several different polymeric materials. PVC is a polymer which is commonly used 
in the fabrication of medical devices, including the tubing used for blood flow in extracorporeal 
circulation. Chapter 3 describes the incorporation of CuBTTri into PVC and assessment of NO 
generation from SNAP, a non-physiological NO donor. In addition, the CuBTTri/PVA materials 
were evaluated for cytotoxicity with respect to 3T3 murine fibroblast and primary human 
hepatocytes. Prior to the development of CuBTTri, the preparation of materials that combine 
copper-based MOFs with polymers they are typically processed from aqueous solution was limited 
due to the instability of MOFs such as CuBTC in an aqueous environment. Chapter 4 focuses on 
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the fabrication of chitosan/CuBTTri membranes and their ability to generate NO from GSNO, the 
sole LMW RSNO that has been unambiguously identified in blood. Chitosan is a naturally derived 
polysaccharide produced through the deacetylation of chitin used medically for its hemostatic and 
wound healing properties. Notably, the wound healing properties of chitosan overlap with those 
of NO, suggesting the potential for synergistic effects as a therapeutic. Chapter 5 focuses on the 
development of CuBTTri/PVA membranes to further study NO generation from GSNO. PVA is a 
hydrophilic linear polymer derived from poly(vinyl acetate) that is widely used in blood contact 
applications as a non–toxic material. Notably, the lack of certain functional groups allows the 
material to act a secondary support without exerting a chemical impact on the system. Taken 
together, these chapters report on the linear progression of investigating the reactivity and 
therapeutic potential of MOF-based materials for biomedical applications.  
 
 Figure 1.10 Dissertation timeline showing the overall projects and the objectives that 
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IMMOBILIZATION OF COPPER(II) BENZENE-1,3,5-TRICARBOXYLATE ONTO 






The biological activity of nitric oxide (NO) includes antiplatelet activation, anti-
inflammatory, and antibacterial properties, making NO-releasing materials an important class of 
therapeutic systems. Because of the short physiological half-life of NO (0.09 to >2 s) due to 
scavenging, this radical species is an ideal candidate for localized therapeutics.1-6 To date, many 
researchers have explored the incorporation of NO donor species such as S-nitrosothiols (RSNOs) 
and N-diazeniumdiolates directly into polymeric materials to produce drug-eluting systems.7,8 A 
potential shortcoming of this approach is the limited overall lifetime of NO release due to finite 
reservoirs of the drug that can be incorporated into the polymer.9-13 Often, efforts to increase the 
incorporation of NO donors to achieve higher loading capacities result in changes to the 
mechanical properties of polymers rendering them unsuitable for clinical applications.10 Metal–
organic frameworks (MOFs) and nanoparticles have been used to achieve some of the highest NO 
loading capacities reported to date, yet this level of NO storage remains insufficient for long-term 
use.14,15 An approach that would eliminate limitations resulting from finite NO reservoirs and allow 
local therapeutic action at the surface of a material is an attractive possibility for improving long-
                                                          
1 This chapter was reproduced in part with permission from:  
Neufeld, M. J.; Harding, J. L.; Reynolds, M. M. Immobilization of Metal–Organic Framework Copper(II) 
Benzene-1,3,5-Tricarboxylate (CuBTC) onto Cotton Fabric as a Nitric Oxide Release Catalyst. ACS Appl. 
Mater. Interfaces 2015, 7, 26742-26750. Copyright 2015 American Chemical Society. 
http://pubs.acs.org/doi/full/10.1021/acsami.5b08773 
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term activity. Thus, the development of materials that do not rely solely on storage of the 
therapeutic agents within the polymeric matrix and permit generation of therapeutic agents at the 
material surface overcomes a significant challenge in NO storage and release applications. 
Previously, Harding et al reported on the ability of copper-based MOFs such as copper(II) 
benzene-1,3,5-tricarboxylate (CuBTC) to function as heterogeneous NO catalysts when reacted 
with endogenous RSNO substrates.16,17 RSNOs are available in the blood at concentrations ranging 
from 10 to 100 µM and decompose to liberate NO via thermal, pH-mediated, and copper ion-
catalyzed pathways.18-22 The translation of NO-generating MOFs for use in medical devices 
requires immobilization with a polymeric phase to formulate a composite material. Dispersion of 
MOF particles throughout the polymeric matrix is a frequently encountered and readily accessible 
approach.23,24 However, polymeric encapsulation of the MOFs increases the likelihood of reduced 
efficacy, because accessibility to the active copper sites is limited by the diffusibility of the RSNO 
substrates. An alternative approach is to immobilize MOFs on the surface of polymeric substrates, 
which may improve accessibility to the active sites. Surface immobilization would be useful for 
preparing filtration membranes, sensor coatings, and extracorporeal devices.25-28 In particular, the 
use of a copper-based MOF immobilized on a polymer surface would promote NO release from 
RSNOs at the biological interface. This has the potential to result in higher surface NO 
concentrations over time, an outcome that would be beneficial for long-term clinical applications. 
The utilization of surface treatments is highly advantageous as it allows for control over the 
growth of the MOF catalysts. Surface immobilization has been well-studied with preparative 
techniques including direct and seeded growth, dip-coating, gel synthesis, electrochemical routes, 
as well as hydrothermal or step-by-step epitaxial growth methods using microwave assistance or 
membrane diffusion to deposit MOFs onto the surface.29-35 Although many approaches have been 
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established, the majority of research has focused on MOF growth from rigid substrates such as 
gold, silica, and alumina, yet this substrate rigidity limits the applicability of these materials.36-44 
More recently, MOF immobilization has been expanded to include polymeric materials such as 
polyacrylamide, polyHIPE, polyester, polystyrene, silk, and cotton.45-49 Although these studies 
demonstrated that MOFs can be attached to polymeric surfaces, the functional utility of the 
surfaces for therapeutic applications remains limited. The utilization of cotton-based materials is 
an attractive option for functionalization due to the natural abundance of this cellulosic fiber. Many 
of these cotton-based materials are commonly used for development of biomedical materials. 
Previous reports have looked at modifying cotton fabrics with copper nanoparticles and CuBTC.50-
54 These reports focus on potential antibacterial effects resulting from the copper species acting as 
a biocide but have yet to utilize the functionalized material for the catalytic production of 
therapeutic molecules such as NO. 
Herein, we demonstrate that immobilization of CuBTC on a cotton substrate produces a 
material capable of generating NO from the RSNO substrate S-nitrosocysteamine (CysamNO). 
The CuBTC-cotton material was fabricated from commercial cotton functionalized with pendant 
carboxyl groups for growth of the archetypal MOF CuBTC. This was achieved via alternating 
immersion in aqueous solutions containing copper(II) acetate and the benzene-1,3,5-tricarboxylic 
acid ligand precursor. The resulting CuBTC-cotton swatches were characterized by powder X-ray 
diffraction (pXRD), ATR-IR, and UV-vis spectroscopy. SEM imaging showed excellent surface 
coverage on individual cotton fibers and uniform crystal growth. Overall, we demonstrate the first 
report of in situ growth of CuBTC on cotton for catalytic NO generation from RSNOs. As a proof 
of concept, the work highlights not only further expansion of MOF polymer interfaces, but also 
demonstrates a meaningful alternative route for the development of supported catalytic systems.  
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2.2 Experimental section 
2.2.1 Materials 
Natural cotton fabric (TIC/400 standard woven cotton) was obtained from SDL Atlas (Rock 
Hill, SC, USA) and used as received. Copper(II) acetate (98%) and tert-butyl nitrite (90%) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Benzene-1,3,5-tricarboxylic acid (BTC) 
(98%) was purchased from Acros Organics (Somerville, NJ, USA). Sodium chloroacetate (98%) 
was obtained from Alfa Aesar (Ward Hill, MA, USA). Cysteamine hydrochloride (99.3%) was 
purchased from Chem-Impex International (Wood Dale, IL, USA). N,N-Dimethylformamide 
(DMF), reagent alcohol, and sodium hydroxide were all purchased from Fisher Scientific 
(Lafayette, CO, USA). All reagents were used as received without any further purification. 
2.2.2 Carboxymethylation of cotton fabric 
 In order to obtain an anchoring point for the deposition of CuBTC onto the cotton fabric, 
the material was carboxymethylated with sodium chloroacetate in the presence of sodium 
hydroxide. A 1 M solution of sodium chloroacetate was prepared in 15% w/v sodium hydroxide, 
and the cotton fabric was immersed in this solution and stirred for 1 h. The resulting 
carboxymethylated material was thoroughly rinsed with Millipore water (3 × 10 mL) to remove 
any non adhered material and allowed to air dry. ATR-IR: νmax (cm-1) 3400 (cellulosic O-H 
stretches), 2897 (cellulosic C-H stretches), 1590 (C=O stretches), 1110-980 (cellulosic C-O 
stretches). 
2.2.3 Surface deposition of copper (II) benzene-1,3,5-tricarboxylate 
Copper(II) acetate (1.078 g) was dissolved in 15 mL of Millipore water (18.2 Ω•cm). 
Benzene-1,3,5-tricarboxylic acid (0.631 g) was dissolved in 15 mL of equal parts DMF, ethanol, 
and Millipore water. Cotton samples were immersed in the copper(II) acetate solution for 5 min, 
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rinsed thoroughly with water, then immersed in the benzene-1,3,5-tricarboxylic acid ligand 
precursor solution for an additional 5 min. The material was then thoroughly rinsed with water, 
and the procedure was repeated for a total of eight complete cycles. Afterwards, the samples were 
sonicated to remove CuBTC, copper(II) acetate, and benzene-1,3,5-tricarboxylic acid that was not 
directly adhered to the surface. ATR-IR: νmax (cm-1) 3400 (cellulosic O-H stretches), 1644 (CuBTC 
COO- asymmetric), 1447 (CuBTC C-C stretches), 1343 (CuBTC COO- symmetric stretching), 729 
(CuBTC C-H out-of-plane bending). 
2.2.4 Characterization techniques 
Images were taken at magnification values of 150×, 500×, 2000×, and 5000×, using a JEOL 
JSM-6500F scanning electron microscope with an accelerating voltage of 20.0 kV and a working 
distance of 10.1 mm (JEOL USA Inc., MA, USA). All data was processed using Thermo NSS 
Release candidate 7 software. Powder X-ray diffraction (pXRD) measurements were carried out 
using a Scintag X2 diffractometer (Scintag Inc., CA, USA) with Cu Kα radiation (  = 1.5406 Å), 
and the resulting data was plotted as intensity vs. theta in Origin Pro. ATR-IR spectra were 
recorded in the range of 600-4000 cm-1 on a Nicolet 6700 spectrometer (Thermo Electron 
Corporation, Madison, WI, USA). Absorption experiments were performed using a Nicolet 
Evolution 300i spectrometer (Thermo Electron Corporation). Surface robustness and durability of 
the material was evaluated with tensiometer measurements on an Instron 4442 (Instron Industrial 
Products, Grove City, PA, USA). A Varian (Agilent) SpectrAA 55B (Agilent Technologies, Santa 
Clara, CA, USA) was used for atomic absorption spectroscopy (AAS) studies. 
2.2.5 Determination of weight percent of copper (II) benzene-1,3,5-tricarboxylate 
AAS was used to determine the copper content of the CuBTC-cotton material. This value 
was subsequently used to calculate the average CuBTC content. This was achieved by suspending 
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samples of CuBTC-cotton (n = 7) in 5 mL of 3.5 × 10-3 M aqueous hydrochloric acid. Samples 
were then sonicated until the CuBTC crystals had dissolved (30 min) and the fabric returned to its 
original appearance. The solution was then analyzed for copper content by AAS, and the overall 
CuBTC content (% w/w) was calculated using the determined copper concentration. 
2.2.6 Evaluation of structural robustness and durability 
Tensiometer measurements were performed by extension measurements taken of the 
CuBTC-cotton samples (n = 3) cut into dimensions of 28 x 5 mm. Instrumental gauge length was 
set to 10 ± 1 mm at an extension rate of 2 mm/min. These experiments were repeated for a total of 
five extension cycles. The resulting material was then evaluated by SEM for any obvious changes 
to the structural robustness of the composite materials, such as the loss of material and changes to 
the overall morphology. 
2.2.7 Chemiluminescence analysis of nitric oxide 
NO release of S-nitrosocysteamine (CysamNO) was recorded in real time using a Sievers 
nitric oxide analyzer (NOA 280i, GE Analytical, Boulder, CO, USA). The instrument was 
calibrated with nitrogen (zero gas) and 45 ppm NO/nitrogen prior to all experiments. Rates of NO 
release were determined for NO releasing decomposition of CysamNO samples (n = 3) under 
ambient conditions, in the presence of unmodified cotton fabric as a control experiment. Catalytic 
NO generation from CysamNO (n = 3) was determined by copper-mediated NO release in the 
presence of CuBTC-cotton fabric. Total NO release was measured for a total time length of 6 h. 
The resulting NO emission was recorded and used to calculate the total release of NO. 
2.2.8 Preparation of S-nitrosocysteamine  
A stock solution of 5.0 × 10-2 M CysamNO was prepared in situ from 5 mg of cysteamine 
hydrochloride dissolved in 1 mL of Millipore water, followed by the addition of excess (1 × 10-4 
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mol) t-butyl nitrite. The reaction solution was protected from light and placed in an ice bath at 0 
°C. After the reaction proceeded for 15 min, the solution was placed under vacuum to assure 
complete removal of residual t-butyl nitrite. Complete removal of t-butyl nitrite was verified using 
UV-vis spectroscopy by following the disappearance of the characteristic six point absorbance 
features between 330 and 410 nm. The concentrations of the RSNO solutions were monitored by 
UV-vis spectroscopy by following the absorbance band at 545 nm (ε = 14.5 M-1 cm-1), for 
CysamNO. 
2.2.9 Measurement of nitric oxide generation catalyzed by copper (II) benzene-1,3,5-
tricarboxylate-cotton swatches 
The catalytic activity of CuBTC-cotton swatches was investigated using CysamNO as the 
RSNO substrate, and the total amount of generated NO was determined by NOA. CuBTC-cotton 
swatches were used that contained 1 mg of deposited CuBTC (5 × 10-6 mol Cu2+). The swatches 
were immersed in 20 mL of deoxygenated reagent grade alcohol in custom analysis cells connected 
to the NOA. A gas flow of ultra-high purity nitrogen (200 mL/min flow rate) was maintained to 
sweep released NO into the NOA, and this release was measured at 1 s intervals. The analysis cell 
was protected from light at ambient temperature. Initial baseline measurements of CuBTC-cotton 
swatch in the ethanol were recorded. The reactive CysamNO substrate was injected directly into 
the reaction medium for a starting solution concentration of 5 × 10-4 M (1 × 10-5 mol RSNO). The 
reaction was determined to have reached completion once the NO measurement returned to 
baseline. Control experiments to determine the role of cotton were examined by immersing 
unmodified cotton into the RSNO ethanol reaction solution. All experiments were performed in 
triplicate and the average and standard deviation reported for the total NO recovered (mol). 
 
70 
2.3. Results and discussion 
2.3.1 Carboxymethylation of cotton 
To immobilize CuBTC onto cotton fabric, the material was first functionalized with 
carboxylate linkers necessary for binding Cu2+ ions from solution. This was achieved by the base-
catalyzed carboxymethylation of cotton fabric with sodium chloroacetate (Figure 2.1). Cotton 
fabric was submerged in the solution and allowed to react for 1 h. Carboxymethylation of the 
cotton was confirmed by comparison to the IR spectrum of unmodified cotton. The appearance of 
an absorption peak at 1590 cm-1 for the carboxymethylated material indicates the presence of a 
C=O stretch corresponding to the incorporation of carboxylate functionalities, confirming the 
formation of the carboxymethylated cotton (CMC) substrate.  
2.3.2 Growth and immobilization of copper (II) benzene-1,3,5-tricarboxylate on cotton  
Surface immobilization of CuBTC on the CMC substrate was achieved by the alternating 
immersion of CMC for 5 min intervals in solutions of saturated copper(II) acetate and the BTC 




Figure 2.1. (a) Carboxymethylation of cotton fabric by submersion into an aqueous solution 
of sodium chloroacetate and sodium hydroxide (b) proposed mechanism of CuBTC 
formation and immobilization achieved through alternating submersion of cotton fabric into 
solutions of copper (II) acetate and 1,3,5-tricarboxylic acid. Reproduced by permission of 
the American Chemical Society. 
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The CMC substrate was immersed in the solutions for eight complete cycles. The resulting 
composite material was thoroughly washed to remove any nonadhered particles by rinsing with 
ethanol and sonicating until the wash solution was colorless. The resulting cotton fabric was 
transformed from white to deep blue, which underwent characteristic color changes associated 
with CuBTC upon dehydration from light to dark blue (Figure 2.2). The uniform dispersion of 
CuBTC particles on the surface of the cotton fibers was confirmed by the characteristic blue color 
of the material. These findings were confirmed by X-ray diffraction patterns of the CuBTC-cotton 
patterns of the CuBTC-cotton fabric corresponding to a superposition of the patterns observed for 
both crystalline CuBTC particles and cotton (Figure 2.3). The presence of the major diffraction 
peaks associated with CuBTC at 7.8, 9.5, 12, 13.5, 15, 17.8 and 19.3 degrees can be seen in the 
diffraction pattern of the CuBTC-cotton material. The additional broad diffraction peaks observed 
between 14-24 degrees are associated with amorphous cotton (Figure 2.3).  
Additionally, the ATR-IR spectrum of CuBTC-cotton is consistent with the spectrum of free 
CuBTC particles where, upon CuBTC deposition, strong absorption bands were observed at 1644 
cm-1 (COO-, asymmetric) and 1371 cm-1 (COO- symmetric) vibrations and 728 cm-1 (C-H, out-
of-plane bending) corresponding to BTC coordination with copper.46,55 Taken together, the 
diffraction patterns and IR spectra clearly confirm the formation and immobilization of CuBTC 
 
Figure 2.2. (a) Cotton fabric prior to CuBTC growth (b) CuBTC-cotton fabric following 
growth and cleaning (c) CuBTC-cotton fabric upon dehydration demonstrating the 
characteristic color change. Reproduced by permission of the American Chemical Society.  
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on the cotton fabric. Additional evidence of CuBTC growth and immobilization on cotton fabric 
was verified by diffuse reflectance UV-vis spectroscopy (Figure 2.4). Upon the synthesis of 
CuBTC on the cotton material, an absorbance feature at 704 nm appeared corresponding to the d 
to d transition band that is characteristic of copper(II) carboxylate complexes (Figure 2.4). These 
findings are consistent with previous reports of CuBTC growth on polymeric substrates.46,55,56 
Additionally, elemental analysis by AAS was utilized to determine the overall weight percentage 
of CuBTC on the composite material from the total copper concentration. The CuBTC content of 
the material was calculated by weight (to be 18 ± 2)%. Collectively, the utilization of pXRD, ATR-
IR, UV-vis and AAS techniques has provided indisputable evidence for successful surface 
immobilization of CuBTC onto the modified cotton fabric. 
 
Figure 2.3 pXRD diffraction patterns show intensity vs. 2 theta of CuBTC powder, 
CuBTC-cotton and unmodified cotton. ATR-IR spectra show absorbance vs. wavelength of  
CuBTC powder, CuBTC-cotton material where resonances seen at 1644 cm-1 (C=O), 1371 
cm-1 (C-C) and 728 cm-1 (C-H) correlate to CuBTC indicating that deposition was 
achieved,  carboxymethylated cotton where resonances at 1590 cm-1 (C=O) indicating 
functionalization of cotton and unmodified cotton. Reproduced by permission of the 
American Chemical Society.  
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2.3.3 Monitoring the growth and formation of copper(II) benzene-1,3,5-tricarboxylate over 
successive deposition cycles 
The growth and formation of CuBTC on cotton was monitored by diffuse reflectance UV-
Vis, ATR-IR and pXRD for each successive cycle. UV-vis measurements were taken every other 
cycle and were monitored for observed changes in the absorption at 704 nm corresponding to the 
coordination between Cu2+ and carboxylate species. As seen in Figure 2.5, a continuous increase 
in the absorption band can be observed at 704 nm, suggesting new CuBTC deposition with each 
successive cycle. Additionally, IR measurements showed the formation and increase of peak 
intensities at 1644 cm-1 (COO-, asymmetric), 1371 cm-1 (COO- symmetric) vibrations and 728 cm-
1 (C-H, out-of-plane bending) after every additional iteration, corresponding to BTC coordination 
with copper. Crystal formation was further supported by monitoring the appearance of diffraction 
peaks at 6.8, 9.5 and 12 degrees, after every successive cycle. These peaks were chosen because 
they are well-defined CuBTC peaks with little interference from the broad diffraction peaks of the 
 
Figure 2.4 Diffuse reflectance spectra comparing unmodified cotton fabric to blue CuBTC-
cotton fabric. The increase of absorbance seen at 704 nm is consistent with the formation 
of the Cu2+ carboxylate species in CuBTC. Reproduced by permission of the American 
Chemical Society.   
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cotton fabric. After consecutive cycles, the appearance of each diffraction peak became sharper 
with well-defined peaks observed after the completion of the sixth cycle (Figure 2.6). In summary, 
these results demonstrate continuous CuBTC growth and formation over successive deposition 
cycles.  
 
Figure 2.5 Monitoring of CuBTC growth on cotton fabric (left) diffuse reflectance spectra 
of the CuBTC-cotton materials after two, four, six and eight cycles showing the increase in 
absorbance at 704 nm due to the formation of the Cu2+ carboxylate species in CuBTC. 
(right) ATR-IR of the CuBTC cotton materials after two, four, six and eight cycles showing 
the increase in the peak intensities at 1644 cm-1 (COO- , asymmetric) , 1371 cm-1(COO- 
symmetric) and 728 cm-1 (C-H, out-of-plane)due to the formation of CuBTC. Reproduced 
by permission of the American Chemical Society.  
 
 
Figure 2.6 pXRD data obtained during monitoring of CuBTC growth and formation on the 
cotton fabric. Reproduced by permission of the American Chemical Society. 
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2.3.4 Morphology and surface coverage of copper(II) benzene-1,3,5-tricarboxylate -cotton 
materials 
SEM analysis provided evidence of crystal growth on the surface of the cotton fabric (Figure 
2.7). Panels a-d in Figure 2.7 show significant changes to the cotton fabric in comparison to the 
unmodified cotton with uniform crystal growth being seen along the bulk of the material at various 
magnification intensities. Analysis of the swatches at 500× (Figure 2.7c) revealed dense surface 
coverage of particles with growth along the fibrous strands that comprise the bulk material. This 
 
Figure 2.7 SEM images of unmodified cotton fabric at (a) 100× and CuBTC-cotton fabric 
at (b) 150× (c) 500× (d) 2,000× (e) 5,000× and (f) 15,000× magnification. These images 
show excellent surface coverage of the cotton surface as well as the crystalline nature of the 
MOF in comparison to unmodified cotton. Reproduced by permission of the American 
Chemical Society.  
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image clearly shows the formation of well-defined crystal particles along the material surface with 
a broad range in size. Upon closer examination at 5000× and 15,000× (Figure 2.7e, f) each MOF 
crystal is independently formed and adhered to the substrate. The crystal faces of the MOFs are 
also clearly defined showing an overall uniform truncated cubic morphology, which is 
characteristic of CuBTC. The dispersion of the CuBTC particles across the cotton fabric was also 
evaluated by SEM-EDX analysis using a copper probe. Figure 2.8b shows the EDX image with 
the copper content overlaid on the SEM image of the CuBTC-cotton material. From this 
experiment copper is uniformly dispersed over the entire surface area of the analyzed material. 
Previous reports of CuBTC immobilization onto cotton show distinct regions of fibers that 
remain unmodified following the MOF growth process. Excitingly, in contrast, these materials 
show that the cotton fibers have been completely coated by CuBTC crystal growth. In a prior 
report, cotton fabric was immersed into a solution of copper(II) acetate for a 24 h time frame. 
Immediately thereafter, a solution of benzene-1,3,5-tricarboxylic acid was added to the initial 
solution and allowed to react.46 Although this technique initially allowed for the fabric to 
coordinate with Cu2+ ions, the direct addition of the ligand solution may allow for an increase in 
 
Figure 2.8 (a) Representative SEM image of CuBTC-cotton material (b) Representative 
SEM image with EDX overlaid elemental map demonstrating copper distribution on the 
material as indicated in yellow demonstrating overall uniform distribution of Cu throughout 
the cotton fabric. Reproduced by permission of the American Chemical Society.  
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competing CuBTC nucleation sites, ultimately resulting in a decrease in the observed CuBTC 
immobilization. Excitingly, in contrast, the repeated cycling and immersion in separated MOF 
precursor solutions limits the potential sites for CuBTC deposition, affording the observed increase 
in surface immobilization of CuBTC. This dramatic increase in CuBTC surface uniformity is most 
likely associated with variations in the synthetic procedure. 
The integrity of the CuBTC particles adhered to the cotton fabric was evaluated by 
application of cyclic tensile force applied to the materials. In this study the sustained adhesion of 
CuBTC particles was investigated by applying a tensile force of 2N. The materials were relaxed 
and the tensile force was then applied again for a total of 5 cycles. Analysis of the materials by 
 
Figure 2.9. (a) SEM images of CuBTC-cotton fabric after testing for structural robustness 
at (a) 500× (b) 1,000× (c) 2,000× (d) 5,000×. Images clearly show no significant changes 
to the MOF content along the cotton fibers. Reproduced by permission of the American 
Chemical Society. 
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SEM found that the particles remained adhered to the substrate without incurring deformations of 
the crystalline phase after repeated stress was applied to the materials (Figure 2.9). 
2.3.5 Reactivity of copper(II) benzene-1,3,5-tricarboxylate materials toward S-
nitrosocysteamine for nitric oxide release 
CysamNO hydrochloride was chosen as the substrate for NO generation because it is similar 
in size to small molecule RSNOs responsible for storage and transport of NO in blood. In addition, 
CysamNO hydrochloride exhibits sufficient stability to permit reliable characterization of NO 
release properties as demonstrated previously in our group.16,17,57 The ability of the functionalized 
cotton fabric to catalyze NO release from S-nitrosothiols, was investigated using a Sievers 280i  
Nitric Oxide Analyzer. This method is widely utilized for monitoring NO emission through the 
formation of excited state nitrogen dioxide by reaction between NO and ozone (NO + O3 → NO2* 
+ O2). The excited state nitrogen dioxide subsequently relaxes through chemiluminescence, which 
can be used to quantify released NO. This specific technique permits highly selective detection of 
NO. Furthermore, for evaluating NO release as a therapeutic agent, chemiluminescent detection is 
vital toward measuring instantaneous NO release and total release over time. Although additional 
techniques including the Greiss assay and electrochemistry are available for NO detection, these 
methods can be subject to false positives from interfering species.58 Additionally, the utilization 
of the Greiss assay relies solely on indirect measurement of NO through the formation of nitrite. 
Thus by using a chemiluminescence detection technique the decomposition of RSNO and 
subsequent release of NO was monitored directly. NO release was monitored by recording the 
concentration of NO released over time using CysamNO in the absence (Figure 2.10) and in the 
presence of CuBTC-cotton catalyst materials (Figure 2.10). The concentration of total added 
CysamNO was determined using the previously reported molar extinction coefficients.17, 57 In 
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order to confirm that the observed increase in NO generation was a result of the presence of 
CuBTC, controls were performed with unmodified fabric and CysamNO. The total NO (µmol) 
released over time is depicted in Figure 2.11a for CuBTC-cotton swatches vs. unmodified cotton. 
After a six h reaction period, CuBTC-cotton material released a total concentration of 7.1 ± 1.2 
µmol NO (Figure 2.11). In comparison, the blank solutions released a total concentration of 0.74 
± 0.13 mol NO, or 10% of the total NO release observed for the catalytic material, see equation 
1. The overall rate of NO generation for CysamNO (n=3) in the blank solution (Figure 2.10) was 
2.1 ± 0.31 (nM s-1) relative to 19 ± 3.0 (nMs-1) in the presence of the catalytic material. In short, 
the CuBTC-cotton material results in a 7 to 9 fold enhancement of NO generation compared to 
that of the solution without any catalyst.  
To confirm that the observed catalytic activity was not due to Cu2+ chelated to the cotton 
swatches, we treated the cotton swatches in a copper (II) acetate solution used in the preparation 
of the CuBTC-cotton swatches. As shown in Figure 2.11a, with the copper-cotton swatch, the 
amount of NO generation was significantly reduced (4.3 ± 0.27 mol). Upon removal following 
completion of the reaction, it was observed that the cotton swatches had returned to white. 
Furthermore analysis of the solution following reaction completion determined by ICP-AES for 
Cu2+ was found to range from 200 to 600 nM, whereas with CuBTC-cotton material there was only 
 
Figure 2.10 (top) Equation of RSNO decomposition in the presence of heat or light, 
(control). (bottom) proposed reaction equation for RSNO in the presence of CuBTC. 
Reproduced by permission of the American Chemical Society. 
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trace amounts of Cu2+ in solution following the reaction, and the MOF particles remained affixed 
to the cotton substrate. These results indicate that Cu2+ particles not incorporated into the MOF are 
removed from the swatch upon reaction with CysamNO. As a result on the basis of the trace 
amounts of Cu2+ in solution, we can conclude that the observed activity of the CuBTC-cotton 
material is attributed to MOF bound copper particles. A summary of these results can be seen in 
Table 2.1. 
Furthermore, the behavior of the supported catalyst was compared with the release rate of 
the unsupported catalyst in solution and direct blending. In comparison, the unsupported CuBTC 
catalyst as a control shows an NO release rate of 21 ± 0.86 nMs-1. Whereas, the cotton-supported 
 
Figure 2.11 (a) Total NO release (µmol) over time for the CuBTC-cotton material (equation 
2), copper-cotton material, copper acetate and for the control solutions consisting solely of 
the corresponding RSNO in solution over time. The CuBTC content of the material was 
calculated by weight (to be 18 ± 2)%. All experiments were repeated in triplicate. (b) 
CysamNO pXRD data of the swatches after reaction demonstrating that the structural 
integrity of CuBTC remained intact. Reproduced by permission of the American Chemical 
Society. 
 
Table 2.1 Summary of Total NO ( mol) and NO Release Rates 
Experiment Total NO (µmol) NO Release Rate (nMs-1) 
CysamNO  0.74 ± 0.13 2.1 ± 0.31 
Copper acetatea + CysamNO 1.5 ± 0.53 8.5 ± 2.9 
Copper-cottona + CysamNO 4.3 ± 0.27 21 ± 1.3 
CuBTC-cottona + CysamNO 7.1 ± 1.2 19.0 ± 3.0 
a Materials were all prepared based on the theoretical copper concentration of the CuBTC-cotton 
material. 
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catalyst has a rate of 19 ± 3.0 nM s-1 with CysamNO that is the same within experimental error.17 
For an unsupported CuBTC catalyst, the reaction was complete within 90 min. In comparison, the 
supported CuBTC-cotton catalyst reached reaction completion in roughly 4 h. This observed 
variation in reactivity may be attributable to the uniform dispersion of unsupported CuBTC 
throughout the CysamNO solution, whereas immobilization of CuBTC on cotton confines the 
catalyst to the surface of the cotton fibers. In previous reports where CuBTC was directly blended 
into a polyurethane matrix, a 90 min induction period was observed, followed by completion of 
the reaction within 1 h. However, by surface immobilization of the material, a shorter induction 
period was observed for the CuBTC-cotton materials. 17 These findings provide valuable insight 
into the potential impact that material processing and development methods can have on catalytic 
activity.  
Lastly, when evaluating NO-generating materials for therapeutic uses, it is imperative for 
the biomedical community to be able to deliver the relevant NO dose for the intended therapy. As 
such, there exists a delicate balance regarding the physiological response of the body toward NO, 
with values in the nM range demonstrating beneficial outcomes (vasodilation, anti-inflammatory, 
wound-healing).58 Thus, we see that these materials fall within the range of acceptable values for 
these therapeutic applications. 
2.3.6 Evaluation of catalytic lifetime and integrity 
To probe the susceptibility of the catalyst toward degradation under the conditions used in 
the experiments, we tested the remaining solution was tested for the presence of unbound copper, 
and the catalytic material itself was evaluated for structural integrity. The possible degradation of 
the catalysts was monitored after the reaction occurred. ICP-AES was performed on the remaining 
solution to determine the concentration of any solvated copper and pXRD and UV-vis were 
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utilized for the catalytic material itself for structural integrity. The diffraction pattern of the reacted 
CuBTC-cotton material shows that all diffraction peaks corresponding to CuBTC remain present 
(Figure 2.11b). This can be compared to the diffraction pattern of the unreacted material (Figure 
2.3). UV-Vis measurements following reaction completion provided additional evidence of the 
retention of structural integrity due to the absence of significant changes to the absorption band at 
704 nm and the loss of the absorption band at 335 nm, which correlates to the absence of CysamNO 
in solution (Figure 2.12). Furthermore, analysis of solvated copper ions in the reaction solution 
using ICP-AES showed that any potential decomposition (˃5 nM) of the CuBTC particles was not 
substantial enough to result in catalysis from the presence of copper. These findings, taken together 
with copper analysis, suggest that CuBTC retains structural integrity following the reaction with 
CysamNO.  
The demonstrated stability of CuBTC adhered to cotton swatch after the catalytic generation 
of NO in an ethanol medium supports our claim for the preparation of an NO generating material. 
However from the perspective of use as a biomaterial stability in biological fluids is imperative. It 
is well known that upon immersion in an aqueous medium the structural integrity of the Cu-
carboxylated paddlewheel is compromised due to displacement of the carboxylates with strongly 
coordinating water molecules.59 Interestingly CuBTC is known to exist in a hydrated state (Figure 
2.2). In consideration of the intended use of the material as an external use only biomaterial in 
wound healing applications the low moisture environment will limit the degradation of the material 
while still providing an adequate supply of body fluids to promote NO generation upon contact.  
Although the mechanism of catalytic decomposition of RSNOs in the presence of copper 
ions has been well established, whether or not Cu-based MOFs will operate under the known 
mechanistic pathways remains an open question.22 The previously reported mechanism for NO 
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release from RSNOs in the presence of Cu2+ ions is suggested to proceed through the formation of 
five and six membered cyclic intermediates, followed by the catalytic release of NO.22 However, 
this mechanism seems less feasible due to the hindered environment around these coordinated 
copper sites. An alternative mechanistic pathway previously reported by the English group 
describes the use of Cu metal centers as Lewis acid sites for the decomposition of RSNOs resulting 
in the formation of NO.60 This represents a plausible reaction pathway given the evidence 
supporting the Lewis acidity of the Cu metal center in CuBTC. Conversely, there have been several 
reports of the reversible formation of Cu(I/II)-thiolate species in the presence of RSNO.61 The 
formation of such a species would suggest an equilibrium between the RSNO decomposition, 
Cu(I/II)-thiolate formation and resulting disulfide formation. In short, the precise mechanism for 
conversion of RSNO to NO with Cu-based MOFs is unknown at present and, hence, the focus of 
an ongoing, separate study. 
 
Figure 2.12 Diffuse Reflectance UV-Vis data showing the spectrum obtained before and 
after the CuBTC-cotton material was evaluated for catalytic activity with CysamNO. It can 
be clearly seen that there is no significant decrease in absorbance suggesting the CuBTC 
species remains intact following reaction completion. Reproduced by permission of the 




Overall, we have demonstrated the immobilization of Cu-based MOFs on cotton as an 
alternative approach to produce NO at a surface. The successful deposition of CuBTC crystals 
were validated by analysis techniques that included, pXRD, ATR-IR, UV-vis and SEM. Notably, 
excellent surface coverage with well-defined CuBTC crystals was evident on the cotton fibers. 
The crystals were found to remain intact after mechanical deformation of the material. Subsequent 
exploration of the material as a supported catalyst for the generation of NO from the NO-donor 
substrate, CysamNO were also reported. The CuBTC-cotton material demonstrated a reaction rate 
of 19.0 ± 3.0 nM s-1 or a 7-9 fold enhanced generation of NO in comparison to controls. Thus, we 
have reported a novel material for utilizing Cu-based MOFs for localized NO release via CuBTC 
immobilization at the material interface without impeding catalytic function. The underdeveloped 
area of literature regarding multifunctional hard/soft interfaces for catalytic NO generation makes 
our application particularly impactful. Further development of such materials can allow for a better 
understanding as to the impact of materials processing on catalytic functionality. Excitingly, these 
systems have strong potential for clinical applications and further development is currently 
underway. 
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Metal-organic frameworks (MOFs) are a versatile class of crystalline materials that consist 
of organic ligands coordinated to metal centers. Variation of both the organic linker and the 
incorporated metal has resulted in the development of a wide variety of structurally distinct MOFs 
that differ in their dimensionality, porosity, and physicochemical characteristics. Due to the 
diversity in possible MOF architectures and their unique properties, these self-assembled 
crystalline structures exhibit promise in the areas of gas storage, catalysis, chromatography, sensor 
applications, and drug delivery.1-8 The implementation of MOFs in a variety of fields has continued 
to expand over the past decade. In particular, the use of MOFs as vehicles for the encapsulation 
and delivery or catalytic generation of small molecule therapeutics has been proposed and 
investigated for efficacy in such applications. As drug delivery vehicles, the ability of MOFs to 
encapsulate and release anticancer, antiviral, antiarrhythmic agents, and therapeutic gases such as 
nitric oxide (NO) has been previously established.8-19 Certain copper-based MOFs such as copper 
benzene-1,3,5-tricarboxylate (CuBTC) are able to induce the formation of NO from the catalytic 
decomposition of S-nitrosothiols (RSNOs), which occur naturally in blood. 20, 21 When released 
from a material as a therapeutic agent, NO is capable of modulating interfacial responses to reduce 
                                                          
2 This chapter was reproduced in part with permission from: 
Neufeld, M. J.; Ware, B. R.; Lutzke, A. Khetani, S. R.; Reynolds, M. M. Water-Stable Metal–Organic 
Framework/Polymer Composites Compatible with Human Hepatocytes. ACS Appl. Mater. Interfaces 2016, 
8, 19343-19352. Copyright 2016 American Chemical Society. 
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the likelihood of thrombus formation, among other beneficial functions. For this reason, copper-
based MOFs have been incorporated within medical grade polymers to create potential blood-
contacting biomaterials that produce NO in the presence of endogenous RSNOs. Such materials 
may be advantageous if used to reduce the risk of thrombus formation in extracorporeal circuits 
(ECCs) or similar blood-contacting devices. However, important toxicity concerns arise when 
considering such materials for biomedical applications. CuBTC and many other MOFs are not 
stable under aqueous, physiological conditions and readily decompose into their constituent 
organic ligands and metal ions. Consequently, there are concerns regarding the medical use of 
CuBTC and similar copper-based MOFs due to potential accumulation of toxic levels of copper 
resulting from decomposition. For this reason, investigation of copper leaching from biomaterials 
that incorporate copper-based MOFs is a necessary step toward validating their extended use in 
physiological environments.  
To date, the investigation of MOF toxicity has been constrained to MOF particles and their 
toxic effects on a variety of cell lines. In one example, a magnesium-gallate MOF was assessed 
for the in vitro effects of its decomposition on human promyelocytic leukemia (HL-60), non-small 
lung cancer (NCI-H460), and murine leukemic monocyte (RAW-264-7) lines.27 Similarly, in vitro 
toxicity of lanthanide-based MOFs was assessed using human colon adenocarcinoma (HT-29) and 
with acute lymphoblastic leukemia human cells.28 Furthermore, a recent report evaluated 14 
different MOFs consisting of iron, zinc, and zirconium carboxylates or imidazolates for their 
effects on fetal cervical carcinoma (HeLa) and murine macrophage cell lines (J774).29Another 
study examined a zinc-based MOF loaded with busulfan on mouse bone marrow fibroblasts (3T3), 
mouse breast tumor cell (4T1), human lung cancer cell (A549), and human liver cancer cell 
(HepG2) lines.30 To the best of our knowledge, only four reports of in vivo experiments exist to 
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date, including two by Horcajada and colleagues that evaluated toxicity effects of a series of iron-
carboxylate based MOFs.31,32 Kundu and colleagues evaluated toxicity of a gadolinium-based 
MOF for anticancer drug delivery on murine models.33 Another report from Ruyra and colleagues 
investigated the toxicity of nine different MOFs on zebrafish embryos.34 In general, these studies 
have focused on evaluating toxicity on mutated cells as drug carriers as well as the short-term 
interaction of MOF particles with cells assessed through cell viability, metabolism, penetration, 
and excretion. However, there are few published data that investigate the incorporation of MOFs 
into biomedical grade polymers and the resulting cytocompatibility of such materials over an 
extended duration.  
Longer-term use of MOFs as components of polymer-based biomaterials requires prolonged 
exposure to a physiological environment. Therefore, it is crucial that MOFs intended for such 
purposes are comprehensively evaluated to either ensure their degradation into nontoxic (or low-
toxicity) components or confirmed to retain their structural integrity in a biological environment. 
In the case of copper-based MOFs used to produce NO from RSNO substrates, this goal is best 
achieved through both improved MOF stability under physiological conditions (reducing the 
likelihood of degradation) and appropriate toxicological assessment. While the carboxylate linkers 
present in CuBTC result in insufficient stability for long-term use, nitrogenous heterocycles are 
capable of forming exceptionally stable complexes with copper.35  
One such MOF developed by Long et al. is H3[(Cu4Cl)3-(BTTri)8] (CuBTTri), where the 
triazole 1,3,5-tris(1H-1,2,3-triazol-5-yl)benzene) (H3BTTri) serves as the coordinating ligand 
(Figure 3.1).36 CuBTTri exhibits high stability in organic solvents, boiling water, PBS, and 
importantly, whole blood.21 Furthermore, CuBTTri is capable of enhancing the rate of NO release 
from RSNOs similarly to CuBTC.21 As a result, CuBTTri is a promising candidate for potential 
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biomedical applications. We have tested a material formulation in which CuBTTri was 
incorporated within a mixture of poly(vinyl chloride) (PVC) and dioctyl sebacate (DOS) 
plasticizer to mimic the proprietary composition of medical grade Tygon® used in ECCs. This 
formulation was used to prepare plasticized PVC films containing CuBTTri, which were 
subsequently characterized by PXRD, ATR-FTIR, and SEM-EDX analysis. Additionally, the 
composite CuBTTri/polymer films were assessed for their ability to enhance NO generation from 
S-nitroso-N-acetyl-D-penicillamine (SNAP). The films were then monitored for copper leaching 
under physiological conditions over 4 weeks, and monitored for adverse effects in vitro on 3T3-J2 
fibroblasts and primary human hepatocytes (PHHs) to assess both general cytotoxicity and 
hepatotoxicity of the composite material. This is the first report to explore the potential cellular 
 
Figure 3.1 A portion of the structure of the sodalite framework of CuBTTri. Copper 
(purple), chlorine (green), carbon (black), and nitrogen (blue) atoms are depicted in the 
structure. Hydrogen atoms have been omitted for clarity. Reproduced by permission of the 
American Chemical Society. 
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toxicity of a copper-based MOF/polymer formulation intended for blood-contacting medical 
applications. 
3.2 Experimental details  
3.2.1 Materials  
All reagents and solvents were purchased from commercial vendors and used without further 
purification unless otherwise noted. 1,3,5-Tribromobenzene (98%), trimethylsilylacetylene (98%), 
trimethylsilyl azide (94%), diethylamine (99%), and dioctyl sebacate (95%) were purchased from 
Alfa Aesar (Ward Hill, MA, USA). Copper(I) iodide (99.5%) and PVC were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Copper(II) chloride dihydrate was purchased from EMD 
Chemicals (Gibbstown, NJ, USA). Bis(triphenylphosphine)palladium(II) dichloride (98%) was 
obtained from TCI America (Portland, OR, USA). Ultrahigh purity N2 and O2 gases were supplied 
by Airgas (Denver, CO, USA). Tissue culture polystyrene 24-well plates and phosphate buffered 
saline (PBS) were purchased from Corning Life Science (Tewksbury, MA, USA). The 
cryopreserved PHHs used in this study were from the HUM4055A donor (54 year old Caucasian 
female who died of stroke) purchased from Triangle Research Laboratories (Research Triangle 
Park, NC, USA). Murine embryonic 3T3-J2 fibroblasts were a gift from Howard Green (Harvard 
Medical School).37 Components for the culture medium for each cell type were purchased from 
Corning Life Sciences and Sigma-Aldrich unless noted otherwise. NucBlue® and propidium 
iodide LIVE/DEAD stain was obtained from Life Technologies (Carlsbad, CA, USA). 
3.2.2 Characterization techniques  
Images were taken at magnification values of 1000× and 2500×, using a JEOL JSM-6500F 
scanning electron microscope with an accelerating voltage of 20.0 kV and a working distance of 
10.1 mm (JEOL USA Inc., Peabody, MA, USA). All data was processed using TEAM Software. 
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Powder X-ray diffraction measurements were carried out using a Scintag X2 diffractometer 
(Scintag Inc., Cupertino, CA, USA) with Cu Kα radiation (  = 1.5406 Å), and the resulting data 
were plotted as intensity vs. theta in Origin Pro. ATR-FTIR spectra were recorded in the range of 
600-4000 cm-1 on a Nicolet 6700 spectrometer (Thermo Electron Corporation, Madison, WI, 
USA). Phase contrast and fluorescent images of cell cultures were acquired using the EVOS® FL 
Imaging System (Thermo Fisher Scientific, Carlsbad, CA, USA). Absorbance of samples was 
measured using the Synergy H1 multimode reader (BioTek, Winooski, VT, USA). 
3.2.3 Copper(II) benzene -1,3,5-tris(1H-1,2,3-triazole-5-yl) synthesis  
H3BTTri was synthesized following a previously reported method.
36 To prepare the MOF, 
225 mg H3BTTri was suspended in 40 mL of DMF and the solution was adjusted to pH 4 using 
dilute hydrochloric acid to dissolve the compound. In a separate vial, CuCl2·2H2O was dissolved 
in 10 mL of DMF and added to the triazole solution. The mixture was then heated at 100 °C for 3 
days. During this period, a crystalline violet precipitate formed and was isolated by centrifugation 
and washed thoroughly with water. The powder was then suspended in water and heated at 100 °C 
for 24 h. The mixture was filtered, washed with water, and allowed to air dry for several days. The 
resulting fine light purple crystals were characterized by PXRD to confirm formation of the 
product (Figure 3.2).  
3.2.4 Preparation of copper(II) benzene -1,3,5-tris(1H-1,2,3-triazole-5-yl)/polymer films 
Composite films were prepared from 150 mg/mL solutions of 3:1 high molecular weight 
PVC and DOS in 60 mL of THF. CuBTTri was ground by mortar and pestle until visually uniform, 
and, then suspended in a solution of PVC/DOS in THF at concentrations of either 0.1 or 0.5% w/v. 
In a typical procedure, the solution was agitated vigorously for 1 min followed by 10 min of 
sonication at room temperature. This resulted in the formation of a visually well-dispersed 
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solution. Immediately after sonication, the solution was slowly pipetted into a glass mold. The 
solution was then covered and allowed to cure. Upon complete curing (≥ 10 h), the films were 
punched into 13 mm diameter disks. 
3.2.5 Copper leaching analysis 
The stability of the CuBTTri composite materials was evaluated by immersing composite 
films in 5 mL of PBS or cell culture medium and incubating at 37 °C with constant agitation. For 
the first week, the solution was removed and replaced with an equivalent volume of PBS or cell 
culture medium every 24 h. For the remaining 3 weeks, the solutions were removed and replaced 
with an equivalent volume every 7 days. The concentration of copper present in the samples was 
determined by ICP-OES analysis. 
3.2.6 Chemiluminescence-based analysis of nitric oxide  
NO release from SNAP was recorded in real time using a Sievers nitric oxide analyzer (NOA 
280i, GE Analytical, Boulder, CO, USA). The instrument was calibrated with ultrahigh purity 
nitrogen (zero gas) and 45 ppm NO/balance nitrogen prior to all experiments. A gas flow of UHP 
nitrogen (200 mL/min) was maintained to sweep released NO into the NOA, and this release was 
measured at 1 s intervals. 
3.2.7 Preparation of S-nitroso-N-acetylpenicillamine 
1.00 g (5.2 mmol) of N-acetyl-D-penicillamine was suspended in 20 mL of 1 M hydrochloric 
acid, followed by the addition of 0.451 g (6.5 mmol) of sodium nitrite. The mixture was stirred 
rapidly at 0°C for 40 min, then filtered and washed thoroughly with 5 x 20 mL Millipore water, 
20 mL acetone, and 20 mL diethyl ether. The resulting green powder was placed under vacuum 
(0.1 Torr) for 3 h to remove residual solvent. The overall yield of SNAP was 54%: λmax 340 
(π→π*), 591 (n→π*) nm. 
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3.2.8 Measurement of nitric oxide generation  
The ability of the CuBTTri/polymer films to enhance the rate of NO generation from RSNOs 
was investigated using SNAP. CuBTTri/polymer films were punched into 13 mm disks and 
immersed in 2 mL pH 7.4 PBS in custom analysis cells connected to the NOA and protected from 
light at ambient temperature. SNAP was injected directly into the PBS solution at an initial 
concentration of 2.0 mM (4.0 µmol total RSNO). The resulting CuBTTri-accelerated SNAP 
decomposition was allowed to proceed for a total of 24 h, and the formation of NO was measured 
during this period. Control experiments were performed in the absence of CuBTTri/polymer films 
to establish the baseline level of NO release from SNAP. Total NO release was measured for a 
duration of 24 h. The resulting NO emission was recorded and used to calculate the total release 
of NO. All experiments were performed in triplicate, and the mean ± standard deviation reported 
for total recovered NO (mol). Following each experiment, the PBS solution was analyzed for trace 
copper content by ICP-OES. 
3.2.9 Cell studies  
The 3T3-J2 murine embryonic fibroblasts were passaged in T-150 tissue culture flasks for 
up to 12 times as previously described.38 Cells were plated at 90,000 per well in a standard tissue 
culture treated 24-well plate with culture medium change every 2 days. Cryopreserved PHHs were 
purchased from Triangle Research Laboratories (Research Triangle Park, NC), a vendor permitted 
to sell products derived from human organs procured in the United States by federally designated 
Organ Procurement Organizations. All studies were conducted using the HUM4055A donor (see 
Materials). PHH vials were thawed at 37°C for 120 s and diluted with 25 mL of prewarmed 
hepatocyte seeding medium, the formulation of which was described previously.39 The cell 
suspension was then spun at 500 rpm for 10 min, the supernatant was discarded, the cells were 
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resuspended in fresh hepatocyte seeding medium, counted, and plated. PHH viability was assessed 
using trypan blue exclusion (typically 80-95%). Liver-derived nonparenchymal cells were 
consistently found to be less than 1% of all the cells.   
Micropatterned cocultures (MPCCs) were created as previously described.39 Briefly, 
adsorbed collagen was lithographically patterned in each well of an industry standard 24-well plate 
to create 500 µm diameter circular domains spaced 1200 µm apart, center-to-center. PHHs 
selectively attached to the collagen domains leaving ~30,000 attached cells on ~90 collagen-coated 
islands within each well of a 24-well plate. 3T3-J2 murine embryonic fibroblasts were seeded 18 
to 24 h later in each well to create MPCCs. Serum-supplemented culture medium, the formulation 
of which has been described previously, was replaced on cultures every other day (300 µL/well).40 
Cellular morphology was observed using an EVOS-FL microscope (Thermo Fisher). 
3.2.10 Liver functionality assays 
Urea concentration in supernatants was assayed using a colorimetric endpoint assay utilizing 
diacetyl monoxime with acid and heat (Stanbio Labs, Boerne, TX, USA). Albumin levels were 
measured using an enzyme-linked immunosorbent assay (MP Biomedicals, Irvine, CA, USA) with 
horseradish peroxidase detection and 3,3’,5,5’-tetramethylbenzidine (TMB, Fitzgerald Industries, 
Concord, MA, USA) as the substrate.38  
3.2.11 Copper(II) benzene -1,3,5-tris(1H-1,2,3-triazole-5-yl)/polymer films toxicity assays on 
fibroblasts and micropatterned co-cultures 
Fibroblast-only cultures were allowed 3 days to stabilize, while MPCCs were allowed ~2 
weeks to stabilize prior to incubations with films. Throughout the duration of the studies, the media 
was changed on the cultures every other day. After the stabilization period, the CuBTTri/polymer 
films (0%, 0.1%, and 0.5%) were sterilized in 70% ethanol, rinsed in sterile ddH2O, and placed in 
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the culture medium with the cells. Albumin and urea secretions were assayed in the supernatants 
that were collected at each media change. The LIVE/DEAD staining (see Materials) on fibroblasts 
was carried out according to manufacturer instructions.  
3.3 Results and discussion  
3.3.1 Synthesis and characterization  
The CuBTTri ligand was synthesized according to a previously reported procedure.36 In 
brief, 1,3,5-tris((trimethylsilyl)ethynyl)benzene was prepared from the Sonogashira coupling of 
1,3,5-tribromobenzene and trimethylsilylacetylene in diethylamine. This intermediate was purified 
via column chromatography (silica gel) and subsequently deprotected by rapid stirring in a 
biphasic mixture of DCM, methanol, and aqueous sodium hydroxide. The resulting 1,3,5-
triethynylbenzene was converted to 1,3,5-tris(1H-1,2,3-triazol-5-yl)benzene through the copper-
catalyzed azide-alkyne reaction with trimethylsilyl azide in DMF/methanol. After isolation of the 
triazole ligand, the MOF was synthesized by reaction with CuCl2·2H2O for 3 days at 100 °C. After 
work-up, CuBTTri was obtained as a light purple powder.   
Once synthesized, the MOF was characterized using PXRD (Figure 3.2a) and ATR-FTIR 
(Figure 3.2b). PXRD was found to match the previously reported diffraction pattern.21,36 CuBTTri 
was then incorporated into a mixture of dissolved 3:1 PVC and DOS plasticizer in THF. The 
resulting MOF/composite material was then characterized using ATR-FTIR to confirm the 
incorporation of the MOF within the polymeric material. Figure 3.2 shows the ATR-FTIR 
spectrum obtained for CuBTTri powder, CuBTTri/polymer composite, and PVC:DOS control 
film. The IR spectrum of CuBTTri features characteristic peaks at 1614 (aromatic C=C), 830, and 
770 cm-1 (C-H out-of-plane bends). When incorporated within the polymer matrix, the absorptions 
from CuBTTri are predictably diminished, however all three diagnostic bands remain discernible. 
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Additional IR features appear at 1723 (C=O stretch), 1252, and 1174 cm-1 (C-O stretches) from 
DOS. Furthermore, the PXRD pattern obtained for the MOF/polymer film retained the 
characteristic peaks of CuBTTri, suggesting that the MOF remained intact. 
Examination of the CuBTTri/polymer film by SEM analysis provided additional evidence 
that CuBTTri was successfully incorporated into the polymeric material.  As shown in Figure 3.3, 
the majority of the MOF particles are directly embedded within the polymeric matrix. The 
dispersion of the MOF particles within the polymeric material was evaluated by SEM-EDX 
analysis using a copper probe. Figure 3.3a-e shows SEM images for a control PVC:DOS film, 
0.1% and 0.5% CuBTTri/polymer films with copper content (EDX) overlaid on the SEM image 
of the CuBTTri/polymer material in Figures 3.3c and e. From this experiment it can be observed 
 
Figure 3.2 (a) PXRD diffraction pattern of CuBTTri powder and CuBTTri/polymer films. 
Key diffraction peaks 2ϴ: 4.7, 6.7, 8.2, 9.5, 10.7, 13.5, 14.3, 16.5, 19.7, 20.3, 25, 28, and 
33. (b) ATR-FTIR spectrum for CuBTTri powder and CuBTTri/polymer film and 
PVC:DOS polymer films. Key characteristic peaks are highlighted and can be observed at 
1614 (aromatic C=C), 830, and 770 cm-1 (C-H out-of-plane bends). Reproduced by 
permission of the American Chemical Society.  
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that the copper content is distributed over the entire area of the material and is concentrated in the 
areas containing the crystalline MOF.  
3.3.2 Nitric oxide release analysis 
NO has received significant attention due to its multiple biological functions,  including anti-
inflammatory, antibacterial, and antiplatelet activation properties.41,42  NO also has an important 
role in the normal function of the endothelium, where it is known to exert protective antithrombotic 
effects.43 The use of NO as an exogenous therapeutic agent has been well established, and NO 
release has been widely used as a method of improving the performance of blood-contacting 
materials by reducing the likelihood of thrombosis or by acting as an antimicrobial agent to lower 
the risk of infection. As previously stated, certain copper-based MOFs such as copper benzene-
 
Figure 3.3 (a) 1000× magnification for control film. (b) 1000× for 0.1% CuBTTri/polymer 
film. (c) 1000× for 0.1% CuBTTri/polymer film with EDX overlay for copper analysis 
containing copper in the films concentrated at the areas containing the crystalline materials. 
(d) 1000× for 0.5% CuBTTri/polymer film. (e) 1000× 0.5% CuBTTri/polymer film with 
EDX overlay for copper analysis on 0.5% CuBTTri/polymer film with copper concentrated 
at the areas containing the crystalline materials. Reproduced by permission of the American 
Chemical Society. 
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1,3,5-tricarboxylate (CuBTC) are able to induce the NO-forming catalytic decomposition of 
RSNOs, which occur naturally in the blood. 20, 44 This method presents an opportunity for 
continuous NO generation using MOF particles to initiate the accelerated decomposition of 
endogenous RSNO.  
The ability of water-stable CuBTTri/polymer films to increase the rate of NO release from 
SNAP was assessed using chemiluminescence-based detection of NO. Like the majority of 
reported RSNOs, SNAP (Figure 3.4) is unstable in aqueous solution and continuously decomposes 
to form NO. It has been previously observed that this baseline rate of NO release can be 
significantly accelerated in the presence of CuBTTri. Prior work by Williams and others has 
proposed that copper ions form five- and six-membered cyclic intermediates with RSNOs to 
catalytically initiate their NO-forming decomposition, according to the overall reaction depicted 
in Figure 3.4b.45-47 This process is considered less feasible at hindered copper sites within the 
lattice of copper-containing MOFs, and alternative pathways involving Lewis acid-type catalysis 
or the formation of intermediate copper(I/II)-thiolates have been suggested.48,49 However, the 
 
Figure 3.4 (a) Structure of SNAP (b) proposed scheme of S-nitrosothiol (RSNO) 
decomposition in the presence of copper, resulting in the formation of NO and the 




mechanism by which copper-based MOFs initiate the accelerated decomposition of RSNOs 
remains under investigation. To demonstrate this acceleration in the case of CuBTTri/polymer 
films, the increased rate of NO release after exposure of SNAP to the MOF films was examined. 
When SNAP (2 mM initial concentration) was exposed to films prepared from 0.5% (w/v) 
CuBTTri/polymer solution in 2 mL of pH 7.4 PBS at ambient temperature over 24 h, a noticeable 
increase in NO production was observed relative to the baseline release of SNAP in the absence 
of the films (Figure 3.5). In the presence the CuBTTri/polymer film, NO release was observed to 
increase over time, with NO generation reaching a steady level after approximately 10 h. This 
increase in NO production may arise from the diffusion of SNAP into the polymeric material prior 
to interaction with the MOF particles. The presence of the CuBTTri/polymer film was determined 
to result in an average total NO release of 3.13 ± 0.34 mol over 24 h, corresponding to the release 
of 70 ± 7% of theoretical NO. In comparison, SNAP decomposition in the absence of the 
CuBTTri/polymer material was found to result in an average total NO release of 1.07 ± 0.18 µmol 
(23 ± 4% of theoretical NO). It was observed that the CuBTTri/polymer films continued to 
 
Figure 3.5 Real time NO release over 24 h from SNAP decomposition (heat and light) in 
the absence of CuBTTri and SNAP in the presence of the CuBTTri/polymer films (PBS, 
pH 7.4, 22 ºC). This figure depicts the enhanced generation of NO from the addition of the 
CuBTTri material with the generation reaching a steady level at approximately 10 h. 
Reproduced by permission of The American Chemical Society. 
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generate NO at a steady level at the 24 h time point. These findings show that the presence of the 
CuBTTri/polymer films results in a nearly 300% increase in NO generation over 24 h when 
compared to baseline SNAP decomposition.  
Figure 3.6 depicts the real-time NO flux observed for the CuBTTri/polymer films, with the 
dashed line representing the average physiological NO flux for endothelial cells. The mean NO 
flux of the CuBTTri/polymer films was determined to be 0.90 ± 0.13 nmol cm-2 min-1 after 
reaching a steady level. This NO flux can be compared to that exhibited by the endothelium, which 
has been reported to fall within the range of 0.05 - 0.4 nmol cm-2 min-1.50,51In addition, studies 
showing the impact of NO release on processes such as thrombus formation have reported an all-
inclusive flux in the range of 0.024 - 12 nmol cm-2 min-1 when antiplatelet and antithrombogenic 
effects are observed.52,53As such, the mean NO surface flux of a potentially antithrombotic material 
should fall within this range.54 The CuBTTri/polymer films have demonstrated the capability to 
generate an NO flux within the range of previously reported values, suggesting that the material 
has the potential to produce therapeutically-relevant quantities of NO. 
 
Figure 3.6 Real time NO flux observed for CuBTTri/polymer films (PBS, pH 7.4, 22
 oC). 
The dotted line represents the physiological NO flux that is seen in endothelial cells. The 
average NO flux of the films is 0.90 ± 0.13 nmol cm-2 min-1. Reproduced by permission of 
the American Chemical Society.  
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To ensure that the material remained intact and did not release large quantities of copper, 
PBS solutions were analyzed for trace copper content using ICP-OES following each NOA 
experiment. The results showed no statistical difference in copper concentration between 
experiments performed with (1.0 ± 0.5 µM) or without (1.6 ± 1.5 µM) CuBTTri/polymer films, 
suggesting that copper was not introduced through leaching from the materials. This contamination 
was attributable to the SNAP precursor N-acetyl-D-penicillamine, which was analyzed by ICP-
OES and found to contain trace copper. Since a steady release from SNAP was achieved in the 
presence of trace copper, additional purification of N-acetyl-D-penicillamine was not performed. 
Additionally, PXRD was taken post-reaction with SNAP and showed the retention of the 
diffraction peaks corresponding with CuBTTri following NO generation (Figure 3.7). Thus, we 
concluded that CuBTTri is likely to remain intact under these experimental conditions and that the 
enhanced NO generation was not attributable to copper leaching from the MOF, since any potential 
contribution would be minor relative to the background level of copper originating from N-acetyl-
D-penicillamine.  
3.3.3 Cytocompatibility towards fibroblasts and primary human hepatocytes 
The liver is the organ principally involved in the uptake and metabolism of many 
pharmaceuticals.55 In addition, the liver is the primary site for the storage and excretion of copper 
in the body.56 Copper is important in key biological processes such as being a co-factor for several 
types of enzymes.57 Excess copper in the body, beyond physiological requirements, is taken up by 
hepatocytes in the liver, where it can be either stored, bound to specific metal-binding proteins (i.e. 
metallothionein) or incorporated into several cuproenzymes. Hepatocytes can also excrete excess 
copper into the plasma or bile. However, if the storage and excretion capacities for copper are 
exceeded, unbound copper can generate hydroxyl radicals, that can lead to cytotoxicity. As a result, 
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evaluating effects of copper-based MOFs on liver cells in vitro constitutes an important step in 
better understanding any toxicological liabilities of MOFs resulting from copper accumulation.  
Given the differences in liver pathways between animals and humans, the use of human-
relevant liver models for evaluating material and drug effects has become necessary and is being 
encouraged by the US FDA and US EPA.58 PHHs, the main parenchymal cell type of the liver, are 
the ideal cell type to construct in vitro models of the human liver since these cells are relatively 
simple to use in medium-to-high throughput culture formats for screening applications.59 However, 
PHHs rapidly (hours) lose phenotypic functions under culture formats that rely exclusively on 
extracellular matrix (ECM) manipulations (i.e. adsorbed collagen), which limits their utility for 
evaluating the chronic effects of materials and drugs.60 Semiconductor-driven microfabrication 
tools can be used to control homotypic interactions between PHHs and stromal cells to prolong 
the functional lifetime in vitro. In particular, Khetani and Bhatia developed a MPCC platform in 
which PHHs are micropatterned onto collagen-coated domains of empirically optimized 
dimensions and subsequently surrounded by 3T3-J2 murine embryonic fibroblasts (Figure 3.8).38 
In this format, PHHs display high levels of major liver functions for 4-6 weeks in vitro and are 
more sensitive for detection of drug toxicities than when cultured in standard monolayers.60 In this 
 
Figure 3.7 pXRD diffraction patterns of CuBTTri/polymer films pre-reaction with SNAP 
and post-reaction resulting in NO generation. It can be seen that the diffraction peaks 
corresponding to CuBTTri remain intact following reaction with SNAP. Reproduced by 
permission of the American Chemical Society. 
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study, we sought to measure the cellular toxicity of films incorporating the water-stable, copper-
based MOF, CuBTTri, in a tiered strategy starting with 3T3-J2 fibroblasts to assess cytotoxicity 
and then MPCCs to assess hepatotoxicity. Time-dependent effects of CuBTTri/polymer films on 
the morphology and viability of the fibroblasts and morphology and liver-specific functions of the 
PHHs were evaluated.  
Films were added to a 24-well plate containing cells with media changes every other day 
and morphology pictures obtained every 4 days. Cellular morphology of fibroblasts was monitored 
with an EVOS-FL microscope under phase contrast. Initial results of fibroblast studies after an 
approximately 3-week time frame (22 days) showed no significant aberrations in fibroblast 
morphology. Figure 3.9a-c shows phase contrast images obtained from the control, 0.1% CuBTTri, 
and 0.5% CuBTTri. Cell viability studies were performed by LIVE/DEAD staining assays using 
NucBlue® and propidium iodide. NucBlue stains all cells, whereas propidium iodide stains only 
 
Figure 3.8 MPCC of PHHs and stromal fibroblasts. (a) Collagen is micropatterned onto 
tissue culture polystyrene using soft lithographic techniques. PHHs selectively attach to the 
collagen domains. Once these cells have spread on the collagen, stromal cells (i.e. 3T3-J2 
murine embryonic fibroblasts) are seeded the next day in the surrounding bare areas to 
create the MPCCs.  Reproduced with permission from reference 61. Copyright 2015 Oxford 
University Press. (b) Left: 24-well plate in which hepatocytes are patterned in each well 
(500 microns diameter, 1200 microns center-to-center spacing) and stained with a purple 
formazan dye. Middle: Enlarged image of 4 wells from plate image on left. Right: Phase 
contrast image of single PHH island surrounded by 3T3-J2 fibroblasts. Reproduced with 
permission from reference 62. Copyright 2015 John Wiley and Sons. Reproduced by 
permission of the American Chemical Society. 
 
108 
cells with a compromised cell membrane (i.e. dead cells). All cells were imaged using the EVOS-
FL microscope using different fluorescent light cubes, specifically 357 nm excitation/447 nm 
emission for all cells (NucBlue) and 531 nm excitation/593 nm emission for dead cells (propidium 
iodide).  The images of all cells and dead cells were superimposed to obtain the overall viability 
images (Fig. 8d-f). Fibroblast viability was found to be at least 98% across triplicate wells of the 
control, 0.1% CuBTTri, and 0.5% CuBTTri after the 22 day time frame, suggesting that no 
significant cytotoxicity was observed. Based on these initial findings, PHH studies were carried 
out as the next step in a tiered strategy of testing cytotoxicity followed by hepatotoxicity.  
PHHs stability was qualitatively assessed by evaluating morphology at the 16 day time frame 
and found that it was maintained relative to the control wells (Figure 3.10). The fibroblast 
morphology was also maintained in co-cultures as we observed in the aforementioned fibroblast-
 
Figure 3.9 (top) Representative phase contrast images of fibroblasts taken at 2 weeks: (a) 
control films, (b) 0.1% CuBTTri, and (c) 0.5% CuBTTri. Cell viability studies (staining 
with NucBlue for nuclei and propidium iodide for dead cells) conducted at 22 days: (d) 
control films, (e) 0.1% CuBTTri, and (f) 0.5% CuBTTri. Scale bars = 400 µm. Reproduced 
by permission of the American Chemical Society.  
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only studies. For the 0.1% and 0.5% CuBTTri film conditions, the opacity of the films somewhat 
limited the quality of phase contrast images. Therefore, PHH stability was quantitatively assessed 
by monitoring liver-specific functions, in particular albumin (surrogate for liver protein synthesis) 
and urea (surrogate for liver nitrogen metabolism) secretions in the supernatants.  
These markers have been shown to previously correlate with drug toxicity and are more 
sensitive than measurements of ATP.60,61 The fibroblasts in MPCCs do not secrete albumin and 
urea per our experience (data not shown). The films placed on the cultures caused some down-
regulation of albumin and urea levels over ~2 weeks of incubations relative to no-film controls 
(Figure 3.11); however, these effects were not due to the copper incorporation when comparing 
the secretion levels in cultures containing 0% and 0.1% CuBTTri/polymer films. More 
importantly, albumin and urea were not down-regulated to 50% (or less) of controls, suggesting 
that the material with incorporated CuBTTri is not hepatotoxic based on previous studies using a 
set of drugs with available clinical information.60 Interestingly, the 0.5% CuBTTri film placed on 
the cultures led to higher functions than the 0% and 0.1% CuBTTri/polymer films. The mechanism 
underlying this observation merits additional study in the future, but further shows that these films 
with copper-MOFs are not inherently toxic to PHHs. 
 
Figure 3.10 Phase contrast images of MPCCs at 16 days (with PHH islands and 
surrounding fibroblasts): (a) no-film control, (b) control film, (c) 0.1% CuBTTri, and (d) 
0.5% CuBTTri. Scale bars = 400 µm. Reproduced by permission of the American Chemical 
Society. 
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3.3.4 Copper leaching from copper(II) benzene -1,3,5-tris(1H-1,2,3-triazole-5-yl)/polymer 
composites   
In order to address the possibility of toxicologically significant copper leaching, the 
CuBTTri/polymer films were assessed for their ability to tolerate a physiological environment. 
CuBTTri/polymer films were prepared in the exact same manner as the films used in the cell 
studies. Films were incubated at 37 oC and pH 7.4 in PBS or cell culture medium (Dulbecco’s 
modified eagle’s medium or DMEM) over the duration of a month. For the first week, all liquid 
was removed and replaced with an equivalent volume of the appropriate solution every 24 h. The 
combined solutions from the first week were tested for the presence of copper by ICP-OES. For 
the remaining 3 weeks, the solutions were replaced every week and similarly tested for the 
presence of copper. Cell media solutions were shown to have a cumulative total of 0.84 ± 0.21% 
copper of the theoretical amount of copper present in the films (Figure 3.12). PBS solutions were 
determined to have a total of 0.18 ± 0.01% of the total theoretical amount of copper present. While 
 
Figure 3.11 (a) Albumin and (b) urea production for 0%, 0.1%, and 0.5% CuBTTri/polymer 
films. All data has been normalized to no-film controls and presented as days after the 
addition of CuBTTri/polymer films on day 12 of culture. Error bars represent standard 
deviation (n = 3). Reproduced by permission of the American Chemical Society.  
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these results indicate that small amounts of leachable copper are initially present in the materials, 
the rapid decline in rate of leaching suggests that this may be primarily attributable to the presence 
of residual trace copper rather than deterioration of the MOF. This outcome was anticipated since 
both the H3BTTri ligand and the water-stable CuBTTri are synthesized under conditions where 
copper salts are employed. Considering that copper is known to exist in the body at appreciable 
levels (68 µM) and the general cytocompatibility of the materials with both fibroblasts and PHHs, 
these findings suggest that the observed trace copper leaching does not produce a toxicological 
impact under the conditions used.57  
3.4 Conclusion 
Overall, cell compatibility studies performed suggest that MOF/polymer composite 
materials prepared from PVC/DOS and CuBTTri are compatible to stable cultures of both murine 
embryonic fibroblasts and PHHs. While PHHs constitute ~70% of the liver cell mass and are the 
 
Figure 3.12 Percent degradation of CuBTTri in cell media and PBS solutions (37 oC, pH 
7.4) for 0.5% CuBTTri/polymer films for copper leaching. Percent degradation is based on 
the theoretical total amount of copper in the films. Films were agitated in 5 mL solutions in 
a water bath with the solutions being replaced every 24 h for the first week followed by 
removal every week for the remaining three. Cell media solutions were shown to have a 
total of 0.84 ± 0.21 % copper of the theoretical amount of copper present in the films. PBS 
solutions were shown to have a total of 0.18 ± 0.01 % of the total theoretical amount of 
copper present in the films. Inset shows 0-1% on the y-axis. Reproduced by permission of 
the American Chemical Society.  
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principal cell type involved in the uptake, storage and excretion of copper, it is conceivable that 
additional cell types of the liver (such as Kupffer macrophages, sinusoidal endothelial cells, stellate 
cells, and cholangiocytes) may also be susceptible to these materials. As culture methods for these 
specialized cell types become more standardized in the tissue engineering field, copper-based 
MOFs can be tested further in vitro for any toxic effect. Additionally, testing lead copper-MOF 
designs on microfluidic human-on-a-chips being designed by several groups may be useful to 
provide an assessment of interactions between different tissue types in either mitigating or 
exacerbating copper-MOF toxicity.63 Ultimately, before copper-MOF materials can be tested in 
patients, FDA-required live animal studies will need to be carried out. The use of in vitro testing 
on different cell types as the first phase of a tiered toxicity screening strategy can greatly streamline 
the in vivo animal testing with respect to reduction in the number of animals used as well as which 
animal species (i.e. rat, mouse, dog, or monkey) constitutes a good model of any human liabilities 
for a given MOF design. The results presented here exemplify a strategy to test the toxicities of 
MOFs in a continuum of in vitro to in vivo models. Thus, we have successfully incorporated 
CuBTTri into a medically-relevant polymer as validated through PXRD, ATR-FTIR, and SEM 
analysis techniques. The MOF-composite materials were investigated for stability and 
cytotoxicity. Additionally, as an application, the materials were explored as a material for 
enhanced generation of NO from an NO donor. The MOF-composite material was found to have 
an NO flux in the range of 0.90 ± 0.13 nmol cm-2 min-1 which correlates to physiologically relevant 
levels. Subsequent evaluation of material stability and copper leaching was performed under 
physiological conditions and found to result in a cumulative percentage of theoretical copper 
released of 0.84 ± 0.21% in cell media and 0.18 ± 0.01% in PBS. Evaluation of cytocompatibility 
showed that the MOF/composite materials are not inherently toxic to fibroblast or hepatocyte 
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culture as albumin and urea secretions were not down-regulated by 50% or more of the controls, 
nor was morphology of either cell type affected to any considerable degree over extended culture 
(16-22 days). 
MOFs have been proposed for a range of biomedical applications including drug delivery 
systems, medical imaging, and small molecule applications. While these applications have been 
projected, the lack of investigation into the toxicological impacts of these next generation materials 
presents a major concern limiting further advancement toward clinical use including MOF-
polymer composites for ECCs. In order for this to be achieved, steps need to be taken toward the 
development of methods that provide insight into the biological interactions of MOF-based 
materials. Overall, we have provided the first evidence of the cytocompatibility (i.e. lack of overt 
toxicity) of a copper-based MOF/polymer composite with both fibroblasts and PHHs. While 
further testing is ongoing to determine the full potential of using these materials in a therapeutic 
setting. The results shown herein demonstrate the exciting potential for MOF-based materials 
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CHITOSAN/COPPER(II) BENZENE-1,3,5-TRIS(1H-1,2,3-TRIAZOL-5-YL) HYBRID 
MATERIALS PROMOTE NITRIC OXIDE RELEASE FROM S-NITROSOGLUTATHIONE 




4.1 Introduction  
Metal-organic frameworks (MOFs) are crystalline structures consisting of organic linkers 
bound to metal centers, producing highly porous lattices that are frequently utilized in gas storage 
and heterogeneous catalysis, among other applications.1 It has been previously reported by Harding 
et al. that copper-based MOFs may be capable of inducing the nitric oxide (NO)-forming 
decomposition of S-nitrosothiols (RSNOs), a class of NO-donating compounds that are unique in 
their biological occurrence.2 NO itself is produced endogenously by a family of NO synthase 
enzymes, where it contributes to the immune response, neurotransmission, and regulation of 
vascular tone.3 Biological NO production is essential to the wound-healing process, and exogenous 
NO supplementation has been shown to promote accelerated wound closure.4-6 These properties 
have led to the exploitation of copper-based MOFs for their ability to induce the release of NO 
directly from RSNOs. Biological RSNOs are believed to function collectively as a physiological 
reservoir of NO, most commonly in the form of S-nitrosoglutathione (GSNO) and S-
nitrosoalbumin, which exist in blood in the nM to M range.7,8 Biologically-relevant GSNO and 
other RSNO species have been established to produce NO through thermal decomposition or 
                                                          
3 This chapter was reproduced in part with permission from: 
Neufeld, M. J.; Lutzke, A.; Tapia, J. B.; Reynolds, M. M. Metal–Organic Framework/Chitosan Hybrid 
Materials Promote Nitric Oxide Release from S-nitrosoglutathione. ACS. Appl. Mater. Interfaces 2017, 9, 
5139-5148. Copyright 2017 American Chemical Society. 
http://pubs.acs.org/doi/full/10.1021/acsami.6b14937 
123 
photolysis that leads to the formation of disulfide, according to the equation 2RSNO → 2NO + 
RSSR.9 In addition to these reaction pathways, it has been shown that exposure to copper ions 
induces the catalytic, NO-forming decomposition of many RSNOs.10 This phenomenon has led to 
the development of copper-based materials intended to produce a localized supply of NO through 
the controlled decomposition of bioavailable RSNOs, typically through inclusion of simple copper 
salts or complexes.11,12 
The ability of copper-based MOFs to promote NO release from RSNOs is exemplified by 
the decomposition of S-nitrosocysteine and S-nitrosocysteamine by copper benzene-1,3,5-
tricarboxylate (HKUST-1) under nonaqueous conditions.2,13 It was later discovered that the 
triazolate-bridged framework (Figure 4.1a) derived from reaction of 1,3,5-tris(1H-1,2,3-triazol-
5-yl)benzene (H3BTTri) with CuCl2·H2O in DMF (H3[(Cu4Cl)3-(BTTri)8], or CuBTTri) exhibits a 
similar ability to promote the decomposition of both S-nitrosocysteamine and S-nitroso-N-
acetylpenicillamine (SNAP) under aqueous, physiological conditions and exhibits an exceptional 
degree of aqueous stability.14,15 For this reason, CuBTTri represents a useful candidate for the 
development of MOF-based biomaterials that are intended to trigger NO release from RSNOs in 
a physiological environment. However, the feasibility of utilizing copper-based MOFs for this 
application depends on their effective incorporation within a supporting polymeric matrix, and the 
retention of useful activity thereafter. Consequently, the identification of polymers that allow the 
productive, NO-forming interaction between aqueous-phase RSNOs and CuBTTri is a prerequisite 
to biological implementation. Nevertheless, previous work has been confined to hydrophobic 
polymers that are unlikely to permit the rapid diffusion of polar (and potentially charged) RSNO 
substrates. For this reason, hydrophilic materials such as polysaccharides may represent a useful 
alternative. 
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Chitosan is a versatile, naturally-derived polysaccharide consisting of β-(1,4)-linked 
glucosamine and N-acetyl glucosamine units (Figure 4.1b). Because chitosan is biodegradable, 
typically regarded as nontoxic, and exhibits important therapeutic properties, it has been widely 
utilized for biomedical applications ranging from drug delivery to tissue engineering.16  The 
conversion of chitosan to water-soluble polycationic salts or other easily-processed derivatives 
 
Figure 4.1 (a) Fundamental building unit of CuBTTri. Copper (red), chlorine (green), 
carbon (black), and nitrogen (blue) atoms are depicted. Hydrogen atoms have been omitted 
for clarity. (b) Structure of the glucosamine (x) and N-acetyl glucosamine (y) units of 
chitosan. Reproduced by permission of the American Chemical Society. 
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permits the preparation of films, fibers, hydrogels, and other materials with useful characteristics.17 
As a biomaterial, chitosan has been reported to exhibit inherent bacteriostatic/antimicrobial 
properties, in addition to well-characterized hemostatic properties that have resulted in its 
commercial adoption for the treatment of hemorrhagic injuries.18 Furthermore, numerous studies 
have shown that chitosan-based wound dressings can significantly accelerate the wound healing 
process.19,20 Notably, both the wound-healing and antimicrobial properties of chitosan overlap 
significantly with those of NO, suggesting the possibility for combined action. Due to the potential 
for NO and chitosan to exhibit synergistic effects as a therapeutic, multiple publications have 
reported the development of NO-releasing materials based on chitosan. NO-releasing chitosan 
derivatives have been proposed as potential candidate polymers for the development of wound-
healing dressings, while NO-releasing chitosan oligosaccharides have been utilized as solution-
phase antibacterial agents.21-23 These previous examples of NO-releasing chitosan derivatives have 
been universally prepared through the inclusion of unstable synthetic NO-donor species that 
release a finite quantity of NO through irreversible decomposition processes. In wound dressings, 
this may produce complications arising from both storage limitations and toxicity concerns.24 For 
these reasons, an alternative method of producing localized NO release is desirable. In the case of 
potential blood-contacting materials, this goal may be achieved through the recruitment of natural 
RSNOs.25,26  
Herein, the concept of promoting accelerated NO release from naturally-occurring GSNO 
using chitosan membranes containing water-stable CuBTTri was investigated. This work 
represents the first inclusion of a water-stable MOF within chitosan, and expands the potential 
biological utility of CuBTTri blends to nonsynthetic polymers. CuBTTri was incorporated within 
a chitosan matrix and characterized by pXRD, ATR-FTIR, and SEM. The chitosan/CuBTTri 
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membranes were subsequently exposed to GSNO at physiological temperature and pH, and 
chemiluminescence-based NO detection was utilized to confirm that the MOF retained its ability 
to accelerate the NO-forming decomposition of the RSNO substrate. Confinement of CuBTTri 
within the polysaccharide was not observed to significantly impact the enhanced NO generation 
observed when unbound CuBTTri particles were tested separately with GSNO. Additionally, mass 
spectrometry was used to qualitatively determine the major product of the MOF-promoted 
decomposition of GSNO as oxidized glutathione (GSSG). Although it is known that thermal or 
photolytic RSNO decomposition typically results in the formation of the corresponding disulfide 
(2RSNO → 2NO + RSSR), this is the first report to definitively identify the production of disulfide 
from an RSNO by CuBTTri.27 These findings reveal that CuBTTri may be successfully 
immobilized within chitosan membranes without impairment of its ability to induce NO release 
from GSNO, providing further insight into the function of such MOF/polymer systems. The ability 
of CuBTTri to generate an enhanced level of NO release from GSNO complements the existing 
therapeutic uses of chitosan, particularly in the realm of future wound-healing applications. While 
previous reports have examined promotion of NO release from putatively endogenous S-
nitrosocysteine, this structure primarily occurs in the form of S-nitrosated cysteine residues in 
biological macromolecules, which may limit the ability of a MOF to interact with the RSNO and 
induce NO release.26 Similar efforts have been constrained to S-nitrosocysteamine and SNAP, 
which are not known to occur biologically. This work is the first to expand the substrate scope to 
include GSNO, a biologically available RSNO identified in human blood. Furthermore, the use of 
water-stable and potentially reusable CuBTTri and naturally-derived chitosan represents a new 
and potentially more environmentally-benign approach to achieving NO release from RSNOs 




1,3,5-Tribromobenzene (98%), trimethylsilylacetylene (98%), trimethylsilyl azide (94%), 
and diethylamine (99%) were purchased from Alfa Aesar (Ward Hill, MA, USA). Sodium nitrite 
(97%), phosphate buffered saline (PBS) tablets, and copper(II) chloride dihydrate were obtained 
from EMD Chemicals (Gibbstown, NJ, USA). Glutathione (98%) was purchased from AMRESCO 
(Solon, OH, USA). Low molecular weight chitosan (96% deacetylated) and copper (I) iodide 
(99.5%) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Deionized water (18.2 
MΩ·cm) was obtained from a Millipore Direct-Q water purification system (EMD Millipore, 
Billerica, MA, USA). Ultrahigh purity nitrogen and oxygen gases were supplied by Airgas 
(Denver, CO, USA). Bis(triphenylphosphine)palladium(II) dichloride (98%) was purchased from 
TCI America (Portland, OR, USA). All materials were used as received without any further 
purification. 
4.2.2 Characterization methods 
Powder X-ray diffraction (pXRD) measurements and ATR-FTIR were used to examine the 
incorporation of CuBTTri within chitosan. All pXRD measurements were made using a Bruker D-
8 Discover DaVinci X-ray diffractometer (Cu-Kα X-ray source, line focus) (Bruker, Billerica, MA, 
USA). A 0.6 mm divergent slit was placed on the primary beam side and a high-resolution energy-
dispersive LYNXEYE-XE-T detector on the diffracted beam side during the XRD studies. XRD 
measurements were performed with Soller slits on the primary and diffracted beam side (2.5° 
separation). The instrument alignment was tested using the NIST 1976b SRM. All measurements 
were performed from 4 – 50ϴ with a step count of 1.0.  ATR-FTIR spectra were obtained in the 
range of 600 – 4000 cm-1 on a Nicolet 6700 FTIR spectrometer equipped with a Smart iTR ATR 
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sampling module and ZnSe crystal plate (Thermo Electron Corporation, Madison, WI, USA). 
Images of chitosan/CuBTTri membranes were acquired using a JEOL JSM-6500F scanning 
electron microscope with an accelerating voltage of 10.0 kV and a working distance of 10.0 mm 
(JEOL USA Inc., MA, USA). All samples were placed under vacuum and coated with 20 nm of 
gold prior to runs. Images were taken at magnifications of 250×, 1000×, 2000×, and 3000×. All 
data were processed using TEAM Software. Thermogravimetric analysis (TGA) was performed 
under nitrogen on a TA Instruments Q500 thermogravimetric analyzer at a rate of 5 oC/min from 
25 to 500 oC (New Castle, DE, USA), and data was processed using TA Instruments Universal 
Analysis 2000.  
4.2.3 Preparation of copper(II) benzene -1,3,5-tris(1H-1,2,3-triazole-5-yl) 
1,3,5-Tris(1H-1,2,3-triazol-5-yl)benzene (H3BTTri) was synthesized following the method 
reported by Demessence et al. and suspended (225 mg) in 10 mL of DMF.28 This mixture was 
treated with 0.1 M hydrochloric acid to dissolve the triazole, and then copper(II) chloride dihydrate 
(383 mg) was added to the solution. After thorough agitation to ensure dissolution of all solids, the 
mixture was heated at 100 °C for 3 d to form CuBTTri-DMF as a dark violet precipitate. CuBTTri-
DMF was isolated by centrifugation and washed with DMF and Millipore water, then heated in 
water at 80 °C for 3 d to produce CuBTTri-H2O as a light purple solid. This solid was isolated by 
centrifugation, dried, and subsequently characterized by ATR-FTIR and pXRD. 
4.2.4 Preparation of chitosan membranes.  
Chitosan (2.5 g) was dissolved in 100 mL of 1% acetic acid, and the resulting water-soluble 
chitosan acetate was isolated by lyophilization. To prepare chitosan membranes, chitosan acetate 
(180 mg) was dissolved in 6 mL of Millipore water, followed by the addition of CuBTTri-H2O (20 
mg) to form a suspension. This mixture was allowed to air-dry within a PTFE mold and the 
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prepared film was treated twice with 100 mL of 250 mM pH 8.0 sodium phosphate buffer to 
produce a flexible hydrated sheet. This material was washed with 5 × 100 mL of Millipore water, 
and subsequently punched into smaller 13 mm diameter membranes. Chitosan control membranes 
were prepared without CuBTTri-H2O, following an otherwise identical procedure.   
4.2.5 Synthesis of S-nitrosoglutathione.  
GSNO was prepared using a protocol adapted from a previously reported synthesis.29 1.53 g 
of glutathione was suspended in 8 mL of water at 0 °C, followed by the addition of 2.5 mL of 2 M 
hydrochloric acid and 0.345 g of sodium nitrite. This mixture was stirred at 0 °C for 40 min, then 
the precipitated solid was isolated by filtration and washed with ice-cold water, acetone, and 
diethyl ether. The resulting light pink powder was placed under vacuum to remove residual solvent 
and stored at -20 °C in the absence of light. Following synthesis, ICP-AES analysis of an aqueous 
GSNO solution showed no copper detected. UV-visμ  335 (π→π*), 545 nm (nN→π*). 
4.2.6 Membrane swelling properties.  
Water swelling of chitosan and chitosan/CuBTTri membranes was determined 
gravimetrically by obtaining their dry masses (Wd), followed by immersion in Millipore water for 
24 h. Samples were then withdrawn and reweighed (Ww) after the removal of excess water. The 
following calculation was then applied to determine the overall water uptake and swelling ratio of 
each sample.30 
% Swelling =  ��−���� ∗ % 
4.2.7 Measurement of nitric oxide formation. 
 NO release measurements were obtained using Sievers chemiluminescence-based nitric 
oxide analyzers (NOA 280i, GE Analytical, Boulder, CO, USA). Calibration was performed with 
ultrahigh purity nitrogen (0 ppm NO) and 45 ppm of NO/nitrogen. Prior to use, dry membranes 
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were immersed in Millipore water overnight to produce 13 mm diameter hydrated membranes. In 
each experiment, a single chitosan/CuBTTri (n ˃ 3) or chitosan control (n ˃ 3) membrane was 
suspended in 5 mL deoxygenated PBS (pH 7.4) in a custom analysis cell connected directly to an 
NO analyzer under a constant flow/purge of nitrogen gas and protected from exposure to light. 
Baseline was acquired for several minutes, then an aqueous GSNO solution was injected into the 
cell to produce an initial concentration of 20 µM. After GSNO injection, each experiment was 
allowed to continue until NO detection returned to the baseline level. As an additional control, the 
NO release profile from the decomposition of GSNO in the absence of membranes was also 
obtained. In all cases, gas phase NO concentration (ppb/ppm) was used to determine total NO 
release (mol) using an instrument-specific calibration constant obtained from the reduction of 
sodium nitrite. Following each experiment, the membrane was removed and the buffer solution 
was analyzed for copper content using ICP-AES. To evaluate reuse of the chitosan/CuBTTri 
membranes, each previously tested membrane was re-suspended in Millipore water overnight and 
the previously described experimental procedure was repeated. 
4.2.8 Mass spectrometry analysis.  
The products formed following exposure of CuBTTri to GSNO were determined by 
suspension of approximately 20 mg of chitosan/CuBTTri membrane in a 1 mM solution of 
GSNO/Millipore water. The experiment was protected from light and maintained at 37 oC until 
disappearance of the characteristic red/pink color of GSNO. A control experiment was similarly 
conducted using chitosan membrane without CuBTTri (intended to reflect thermal decomposition 
of GSNO), while a second control experiment involved exposure of GSNO to 365 nm UV light 
using a 100 W Blak-Ray B-100AP UV lamp (UVP, Upland, CA, USA). The solutions were 
subsequently analyzed using an Agilent 6224 LC-MS (Agilent Technologies, Palo Alto, CA).  
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4.3 Results and discussion 
4.3.1 Synthesis and characterization of copper(II) benzene -1,3,5-tris(1H-1,2,3-triazole-5-yl) 
and chitosan/ copper(II) benzene -1,3,5-tris(1H-1,2,3-triazole-5-yl) composite materials 
Chitosan-based biomaterials have been shown to accelerate the wound healing process, 
resulting in significant overlap with the wound-healing properties of NO. Although previous 
reports have examined the inclusion of NO donor moieties within chitosan, this report is the first 
to evaluate an alternative approach involving the incorporation of CuBTTri, a copper-based MOF 
that has demonstrated the ability to promote release of NO from endogenous RSNOs. As 
previously described by Demessence et al., the cubic sodalite framework of CuBTTri consists of 
[Cu4Cl]
7+ square planar units bound to BTTri3- ligands. Within this structure, each triazolate ligand 
interacts with six distinct copper sites in [Cu4Cl]
7+ units. This fundamental building unit is depicted 
in Figure 4.1a. Interactions between the triazolate ligands and copper produce an increase in metal-
ligand bond strength, conferring greater water stability in comparison to many copper carboxylate 
based structures.  
To prepare chitosan/CuBTTri membranes, water-soluble chitosan acetate was dissolved in 
Millipore water and CuBTTri was blended into the mixture to produce membranes containing 10% 
w/w MOF (Figure 4.2). The polysaccharide was deprotonated and rendered insoluble by treatment 
with 250 mM pH 8 phosphate buffer, resulting in 13 mm diameter circular chitosan membranes 
containing 295 ± 8 nmol of Cu mg-1 (11% w/w CuBTTri), as determined by dissolution and 
subsequent copper determination via ICP-AES. While aqueous sodium hydroxide is typically 
utilized to cure chitosan membranes, it was observed that treatment of CuBTTri with concentrated 
base had an adverse effect on the integrity of the MOF.31 Similarly, immersion of chitosan 
acetate/CuBTTri membranes in 10% sodium hydroxide produces a visual color change (dark violet 
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to blue) and the loss of CuBTTri diffraction peaks when examined by pXRD. In order to ensure 
preservation of the MOF, comparatively mild pH 8 phosphate buffer was used as an alternative 
method of neutralizing the membranes. To isolate the effect of CuBTTri in subsequent analyses, 
control membranes were prepared without addition of the MOF. Both chitosan/CuBTTri and 
chitosan control membranes were characterized by ATR-FTIR, pXRD, and SEM. IR absorptions 
characteristic of chitosan are present in the control membranes, including the broad hydroxyl O–
H stretch feature occupying the region of 3650–3000 cm-1 (Figure 4.3). This feature overlaps with 
the bands associated with the C2 primary amine, and both asymmetric and symmetric N–H 
stretching modes are identifiable at 3355 and 3278 cm-1.  Additional diagnostic bands are observed 
at 2849 (C–H stretch), 1636 (amide I), 1577 (amide II), 1056, and 1025 (C–O stretch).  These 
typical features are accompanied by new absorptions at 2917 (acetate CH3), 1542 (acetate salt) and 
1258 cm-1 (phosphate), arising from preparation of the membrane. Incorporation of CuBTTri 
produces additional features characteristic of the MOF at 1617 (C=C stretch), 830, and 775 cm-1 
(C-H out-of-plane bend). Furthermore, finished membranes exhibited the major pXRD diffraction 
 
Figure 4.2 Images of (a) chitosan membrane and (b) chitosan/CuBTTri membrane, 
depicting the dispersion of CuBTTri throughout the material. Images were taken after the 
materials had been hydrated by immersion in deionized water. Reproduced by permission 
of the American Chemical Society. 
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peaks associated with CuBTTri (Figure 4.3b). The pXRD spectrum in conjuction with ATR-IR 
data indicates that the MOF is indeed present and has retained crystallinity after incorporation into 
the chitosan membrane. 
Imaging of the membranes by SEM showed clear incorporation of CuBTTri within the 
chitosan matrix (Figure 4.4c – f) with distinct crystals observed at the membrane surface. In Figure 
4.4b, the distribution of CuBTTri at the surface of the membrane is shown. At greater 
 
Figure 4.3 (a) ATR–FTIR spectrum for (i) CuBTTri, (ii) chitosan/CuBTTri membrane, and 
(iii) chitosan. In (a), the weak C=C stretch and more prominent C-H out-of-plane bend from 
CuBTTri (i) are conserved in the spectrum of chitosan/CuBTTri (ii). (b) pXRD diffraction 
patterns of (i) CuBTTri, (ii) chitosan/CuBTTri membrane, and (iii) chitosan. Inset: 4-25ϴ. 
Reproduced by permission of the American Chemical Society. 
 
134 
magnification, the octahedral morphology of CuBTTri was evident, and the crystals displayed an 
apparent trimodal particle size distribution with an overall range of 1 to 15 m (Figure 4.4e, f). 
The materials were further evaluated for overall copper distribution by SEM-EDX using a copper 
analysis probe. Figure 4.4e and Figure 4f depict the copper overlay on the SEM image of the 
chitosan/CuBTTri membrane. As can be observed, the overall distribution of copper is 
concentrated in regions that contain CuBTTri. Cross-sectional SEM images of non-hydrated 
chitosan/CuBTTri membrane indicated a thickness of 150 m. Additionally, SEM-EDS was 
 
Figure 4.4 (a) 250× magnification of chitosan membrane, (b) 250× (c) 2000×, and (d) 
3000× of chitosan/CuBTTri membrane. (e) 1000× magnification of chitosan/CuBTTri 
membrane and (f) 1000× magnification with EDX copper analysis overlaid. (g) 500× 
magnification of cross-sectional of chitosan/CuBTTri membrane (h) EDX copper analysis 
overlay of cross-section. Reproduced by permission of the American Chemical Society.  
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performed on the cross-section to assess CuBTTri particle distribution throughout the bulk of the 
membrane (Figure 4.4 g, h). This analysis showed copper distributed within the membrane, with 
greater concentration in regions of noticeable particle agglomeration (Figure 4.5). Taken together, 
these findings suggest dispersion of CuBTTri throughout the entire membrane, with certain areas 
of higher concentration indicative of CuBTTri agglomeration following incorporation within the 
polymer matrix.32 
Additionally, the water swelling ratio of each material was determined gravimetrically after 
24 h of immersion to assess if incorporation of CuBTTri into the chitosan membrane produced 
changes to the ability of the polymer to uptake water. Chitosan/CuBTTri membranes exhibited 
244 ± 26% swelling, while chitosan control membranes swelled by 240 ± 26%. These results 
suggest that incorporation of CuBTTri does not have a significant impact on the ultimate water 
uptake of the chitosan materials. The stability of both the chitosan membrane and incorporated 
CuBTTri at pH 8 was established by characterization carried out subsequent to a preparatory step 
 
Figure 4.5 Cross sectional SEM images of chitosan/CuBTTri (a) 1000× magnification (b) 
1000× magnification with EDS overlay for copper distribution where it can been seen the 
copper is concentrated in areas with high concentrations of CuBTTri. (c) 2000× 
magnification (d) 7500× magnification. Reproduced by permission of the American 
Chemical Society. 
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performed in pH 8 phosphate buffer (Figure 4.3b). Behavior of the membrane under other pH 
conditions was assessed by immersing the materials in Millipore water and adjusting the pH with 
dilute hydrochloric acid or sodium hydroxide. The stability of the membrane when  directly 
exposed to either 1 M hydrochloric acid or sodium hydroxide was also examined. Immersion in 1 
M hydrochloric acid produced rapid decolorization and deterioration of the membrane, resulting 
from both the dissolution of chitosan and digestion of the MOF. At pH 4-5, the membrane 
exhibited swelling and a change in appearance consistent with the early stages of dissolution. This 
outcome was anticipated from the known solubility of chitosan following protonation in 
hydrochloric acid. Despite the onset of polymer dissolution, pXRD of the membrane indicated that 
 
Figure 4.6 pXRD diffraction patterns (a) CuBTTri powder (b) chitosan/CuBTTri 
membranes (c) after exposure to platelet-rich plasma (d) after exposure to whole blood (e) 
after exposure to pH 4 water (f) after  exposure to pH 5 water (g) after exposure to pH 6 
water (h) after exposure to pH 9 water (i) after exposure to 1M NaOH. Chitosan/CuBTTri 
membranes exposed to 1 M HCl resulted in complete dissolution of the material. 
Reproduced by permission of the American Chemical Society. 
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CuBTTri remained intact under mildly acidic conditions (Figure 4.6e, f). At pH values of 6 and 
9, the membrane retained a normal appearance and did not exhibit signs of swelling or 
deterioration. Subsequent pXRD characterization supported the survival of the MOF within this 
pH range, as well (Figure 4.6g, h). Immersion of the membrane in 1 M NaOH resulted in a 
pronounced color change from dark violet (imparted by CuBTTri) to blue and associated loss of 
the MOF diffraction pattern (Figure 4.6i). To examine the ability of the chitosan/CuBTTri 
membrane to tolerate biological media, samples of the material were immersed in both whole 
blood and platelet-rich plasma for two hours, followed by rinsing with water. The stability of the 
MOF was then evaluated by pXRD, which showed the retention of all major diffraction peaks 
(Figure 4.6c, d). Analysis of chitosan/CuBTTri membrane by TGA yielded an onset 
decomposition temperature of 232 ± 0.12 oC, a value that was consistent with the decomposition 
of chitosan alone (Figure 4.7). In general, CuBTTri membrane appeared to demonstrate 
appropriate chemical and thermal stability for potential use in biomedical applications, where 
extreme pH or temperature conditions are not anticipated. 
 
Figure 4.7 Representative thermogravimetric analysis of chitosan and chitosan/CuBTTri 
membrane under nitrogen flow. Reproduced by permission of the American Chemical 
Society. 
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4.3.2 Evaluation of enhanced nitric oxide generation from S-nitrosoglutathione with 
chitosan/ copper(II) benzene -1,3,5-tris(1H-1,2,3-triazole-5-yl) membrane 
As previously noted, NO exhibits numerous beneficial properties, including the ability to 
accelerate healing when delivered to the site of an injury.4-6 It was reasoned that the ability of 
CuBTTri to significantly enhance the rate of NO release from biologically-relevant RSNOs could 
potentially permit the conscription of these endogenous species as useful sources of NO. The 
retention of this function when incorporated within a chitosan membrane may allow for the future 
development of blood-contacting materials exhibiting both the desirable antimicrobial and wound-
healing effects of chitosan, as well as the ability to generate enhanced levels of therapeutic NO 
from endogenous sources. To assess the ability of chitosan/CuBTTri membranes to generate NO 
from physiologically-relevant GSNO, membranes were swelled in Millipore water (18.2 MΩ·cm) 
and subsequently immersed in pH 7.4 10 mM phosphate buffered saline (PBS) at 37 oC inside 
custom gas-flow analysis cells connected to Sievers chemiluminescence-based NO analyzers 
(NOA 280i) (Figure 4.8). The effect of chitosan/CuBTTri membranes on NO formation from 
GSNO was evaluated through the addition of 100 nmol of GSNO to the analysis cell (sufficient to 
produce a 20 M initial concentration), and the resulting gas-phase NO concentration (ppb) was 
 
Figure 4.8 Schematic illustrating the NO analyzer cell, where chitosan/CuBTTri membrane 
is suspended in pH 7.4 PBS at 37 oC, followed by injection of GSNO and subsequent 
chemiluminescence-based monitoring of NO formation. Reproduced by permission of the 
American Chemical Society. 
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recorded under nitrogen atmosphere until reaching baseline levels (n > 3) (Figure 4.8). 
Subsequently, a predetermined NO calibration constant (mol of NO ppb-1 s-1) was used to 
determine the overall NO release (mol). Control experiments (n > 3) were performed using GSNO 
alone, chitosan membranes without incorporated CuBTTri, and CuBTTri in free particulate form 
(equivalent to the mass incorporated within chitosan/CuBTTri membranes). In all cases, 
experiments were protected from light to avoid photolytic decomposition of GSNO. At the end of 
experiments involving chitosan/CuBTTri membranes, the reaction medium was exposed to light 
to test for the presence of residual, non-decomposed GSNO.  
When GSNO was added to analysis cells containing chitosan/CuBTTri membranes, a 
noticeable increase in NO generation was observed in comparison to the behavior of GSNO alone 
(Figure 4.9a). In the presence of chitosan/CuBTTri membranes, NO generation was found to 
continuously increase over the duration of the experiment until depletion of the available GSNO 
after approximately 4 h (Figure 4.9a). In contrast, the decomposition and corresponding NO 
release of GSNO alone remained steady over the same interval, indicating the clear role of 
chitosan/CuBTTri membranes in promoting NO formation from the RSNO substrate. 
Chitosan/CuBTTri membranes induce a mean release of 97 ± 3 nmol NO (mean ± SD) over 4.3 ± 
0.3 h, resulting in 97% recovery of total theoretical NO (Figure 4.9b, Table 4.1). Comparatively, 
GSNO decomposition in the absence of chitosan/CuBTTri membranes resulted in the recovery of 
1.5 ± 0.7 nmol NO (1.5% of theoretical) over the same mean interval (Figure 4.9b, Table 4.1). In 
order to provide support that membrane-enhanced NO generation was primarily attributable to the 
inclusion of CuBTTri, chitosan membranes without incorporated MOF were assessed, and a 
moderate increase in GSNO decomposition (9.8 ± 0.3 nmol NO, 9.8% of theoretical) was observed 
(Figure 4.9b, Table 4.1). This elevation was constant and did not result in the distinctive NO 
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release profile produced by CuBTTri/membranes, and may be attributable to the presence of trace 
metal ions chelated by the chitosan matrix (e.g. Fe2+), which have been previously demonstrated 
to enhance NO generation.33,34 Overall, it was observed that chitosan/CuBTTri membranes are 
capable of producing a 65-fold increase in NO generation over the thermal baseline decomposition 
of GSNO, with a significantly smaller 7-fold elevation seen for the chitosan control membranes. 
 
Figure 4.9 (a) Representative real-time NO release from (i) CuBTTri + GSNO (ii) 
chitosan/CuBTTri membranes + GSNO (iii) chitosan + GSNO, and (iv) GSNO assessed 
under physiological conditions (PBS, pH 7.4, 37 oC). (b) Cumulative NO release from (i) 
CuBTTri + GSNO (ii) chitosan/CuBTTri membranes + GSNO (iii) chitosan + GSNO, and 
(iv) GSNO all under physiological conditions  (PBS, pH 7.4, 37 oC). For (i) and (ii) data 
collection ended after the depletion of GSNO. (c) (i) pXRD diffraction pattern of 
chitosan/CuBTTri materials taken after NO analyzer experiment and (ii) prior to the NO 
analyzer runs, pXRD clearly shows the retention of all diffraction peaks. Inset 4-25ϴ. 




After the chitosan/CuBTTri membranes were demonstrated to successfully enhance NO 
generation from GSNO, they were reused to produce NO from subsequent additions of GSNO (up 
to 3 additional times). Following initial experiments, the membranes were removed from the 
reaction medium and suspended in Millipore water for 1 d. The NO generation experiment was 
then repeated as described previously (3 times), with a consistent quantitative NO recovery (Table 
4.2). This result suggests that the chitosan/CuBTTri membranes possess the capability for reuse, 
potentially indicating the ability to continuously generate NO from endogenous GSNO. This 
property may reduce concerns related to the finite loading currently associated with many NO-
releasing polymeric materials. 
4.3.3 Impact of copper(II) benzene -1,3,5-tris(1H-1,2,3-triazole-5-yl) immobilization on 
enhancement of nitric oxide generation 
To evaluate the effect of CuBTTri immobilization within chitosan on the activity of the 
MOF, the ability of free CuBTTri particles to decompose GSNO was examined for comparison. 
CuBTTri particles were found to promote the release of 97 ± 6 nmol NO (97% of theoretical) over 
5.0 ± 1.6 h, indicating the absence of a statistical difference between the performance of 
Table 4.1 Total average NO release from GSNO. Data reported as the mean ± SD (n > 3) 
Substrate Total NO Release (nmol) Total Recovery (%) 
GSNO 1.5 ± 0.7 1.5 ± 0.7 
Chitosan + GSNO 9.8 ± 0.3 9.8 ± 0.3 
Chitosan/CuBTTri + GSNO 97 ± 3 97 ± 3 
CuBTTri + GSNO 97 ± 6 97 ± 6 
 
Table 4.2 Total average NO release for chitosan/CuBTTri membranes after reuse. Data 
reported as the mean ± SD (n > 3). 
Chitosan/CuBTTri membrane + GSNO Total NO Release (nmol) 
Cycle 1 97  ± 3 
Cycle 2 107 ± 7 
Cycle 3 98 ± 3 
 
142 
chitosan/CuBTTri membranes and free CuBTTri particles (Figure 4.9a and 4.9b, Table 4.1). In 
contrast, it was previously shown that incorporation of CuBTTri within a biomedical grade 
polyurethane resulted in an 8-fold reduction in the activity of CuBTTri.14 Additionally, CuBTTri 
particles incorporated into poly(vinyl chloride) (PVC) were shown to require 10 h to reach a steady 
rate of NO release in the presence of SNAP.15 These observed differences in NO generation may 
be attributable to the restricted ability of RSNO to diffuse through hydrophobic polymer matrices, 
inhibiting interaction with incorporated CuBTTri.15,35 This hypothesis is supported by the 
calculated swelling ratio of 244% for chitosan/CuBTTri membranes, indicating significant uptake 
of water, while PVC and polyurethane compositions exhibit weight increases from water uptake 
ranging from 0.02% to 20%.36-38 Since hydrophilic chitosan membranes readily swell in the 
presence of water, this process may encourage uptake and diffusion of GSNO, permitting more 
rapid interaction with the MOF. It was also observed that CuBTTri particles showed wider 
variability in the overall time required to fully decompose GSNO, which ranged from 3 to 7 h. 
This variability may be due to random particle agglomeration resulting in decreased access to 
CuBTTri active sites, while immobilization of the MOF within the chitosan membrane limits this 
outcome. Because incorporation of CuBTTri within chitosan reduces variability in reaction time, 
it allows for increased control of NO generation from GSNO. For this reason, further 
understanding of these types of MOF/polymer composite systems may provide valuable insight 
into the tunability of such materials for future applications.  
4.3.4 Evaluation of structural integrity and copper leaching 
Following NO release experiments with GSNO, the chitosan/CuBTTri membranes were 
analyzed by pXRD to ensure that they remained structurally intact following NO generation. The 
observed pXRD pattern retained all major diffraction peaks corresponding to CuBTTri, supporting 
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that the MOF remains intact over the course of the experiment (Figure 4.9c). Furthermore, the 
buffer solutions remaining at the end of each experiment were subjected to copper content 
determination by ICP-AES after the removal of the chitosan/CuBTTri material. This analysis tests 
for the presence of copper that may have been released by deterioration of the MOF or detachment 
of fine MOF particles. Results indicated that 1.5 ± 1.1 × 10-9 mol copper was present in solution 
following exposure to GSNO during NO release experiments, corresponding to 0.10 ± 0.07% of 
theoretical (based on the mass of incorporated CuBTTri) and resulting in a mean copper 
concentration of approximately 3 × 10-7 M. This lack of significant copper leaching was 
particularly encouraging due to the fact that solution-phase glutathione (the parent thiol of GSNO) 
is an established copper chelator.39  
GSNO decomposition experiments performed in the presence of copper(II) chloride at a 
concentration of 3 × 10-7 M did not result in a greater rate of NO production, as evaluated by 
chemiluminescence-based detection. This outcome reduces the likelihood that dissolved copper 
ions contribute to the acceleration of the NO-forming decomposition of GSNO, and is consistent 
with reports from Williams et al., where higher copper concentrations of 10-6 M were needed to 
initiate decomposition.9 Over a total of three subsequent cycles (each performed in quadruplicate), 
a mean copper quantity of 5.2 ± 3.5 × 10-9 mol copper was found in solution (corresponding to 0.3 
± 0.2% of theoretical), with individual cycles varying from 1.9 ± 0.3 × 10-9 to 8.8 ± 9.6 × 10-9 mol. 
These values were not found to statistically differ from the amount of copper determined in the 
original experiment, and generally indicate that loss of copper from the membranes remains low. 
To contrast potential MOF-related copper leaching from chitosan/CuBTTri membranes with that 
from copper(II) ions directly chelated to chitosan, 13 mm chitosan membranes were exposed to 
copper(II) chloride to prepare additional control materials containing an average of 300 nmol of 
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Cu mg-1. These membranes were exposed to GSNO as described in previous experiments, and the 
buffer solution was subsequently tested for copper content. Notably, the NO-forming reaction 
completed within 0.68 ± 0.08 h and resulted in the recovery of 86 ± 6 of theoretical NO, indicating 
a significantly faster rate of GSNO decomposition. More importantly, ICP-AES was used to 
determine a solution-phase copper content equivalent to 3.6 ± 0.8% of theoretical, indicating up to 
36-fold greater leaching than in the case of chitosan/CuBTTri membranes.  
Previous publications have described the incorporation of copper nanoparticles or copper 
complexes within polymers to produce materials capable of promoting NO release from RSNOs. 
These approaches often rely upon the deliberate generation of copper ions or use of labile 
complexes that readily release copper ions into solution.40,41 In one significant report, Hwang et 
al. covalently attached copper(II)-cyclen complexes to biomedical polymers and evaluated these 
materials for their ability to induce NO-forming RSNO decomposition.42 In this example, copper 
leaching as high as 25% was observed, which may limit applicability due to toxicity concerns. In 
comparison, the substantially lower copper leaching observed for chitosan/CuBTTri membrane 
suggests greater retention of copper attributable to the stability of the MOF. In the case of potential 
biological applications, this lower level of copper leaching may reduce concerns related to copper 
toxicity.43  
4.3.5 Determination of reaction products  
To complement data supporting the preservation of CuBTTri following NO release 
experiments with chitosan/CuBTTri membranes, an additional experiment was performed in 
which chitosan/CuBTTri membrane was exposed to a higher 1 mM concentration of GSNO in 
Millipore water at 37 oC. This solution was subsequently analyzed via mass spectrometry to screen 
for evidence of CuBTTri degradation, which was anticipated to regenerate the triazole ligand 
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H3BTTri. This compound was not detected in solution following the experiment, supporting the 
lack of MOF degradation. The thermal decomposition of GSNO in the presence of chitosan 
membrane (without incorporated CuBTTri) and the UV-initiated decomposition of GSNO in the 
absence of any polysaccharide were carried out for comparative purposes. In all cases, GSSG 
(C20H32N6O12S2) was identified as the major organic decomposition product of GSNO (Figure 
4.10). In comparative experiments performed using chitosan membrane at 37 oC or GSNO alone 
in the presence of UV light, the formation of GSSG was anticipated by the equation 2RSNO → 
2NO + RSSR, which describes the decomposition of RSNO to form the corresponding disulfide 
dimer.9 In the case of chitosan/CuBTTri membranes, the identification of GSSG provides new 
evidence that the end products of the MOF-accelerated reaction are consistent with the 
decomposition under thermal or UV-mediated conditions. In general, the mass spectra resulting 
from analysis of GSNO decomposition solutions containing either chitosan/CuBTTri or chitosan 
membranes were consistent with one another, while the GSNO solution exposed to UV light 
(without the presence of any material) predictably did not exhibit the peaks associated with the 
polysaccharide (e.g. monomeric glucosamine or N-acetylglucosamine). In the case of thermal or 
UV-induced decomposition, NO-forming homolytic cleavage of the S-N bond is believed to be 
followed by the combination of thiyl radicals to form disulfide.9 It has been observed that dissolved 
copper ions are capable of catalyzing NO release from RSNOs, with five- and six-membered 
copper chelates described as potential mechanistic intermediates.44 Previous reports examining the 
use of copper-based MOFs for the generation of NO from RSNOs have suggested that the MOF 
behaves similarly to copper ions by reduction of the copper(II) sites to copper(I), producing both 
NO and disulfide (Figure 4.10).9,27,44 However, it has not been previously verified that CuBTTri 
(or any MOF) forms products consistent with those generated in other known decomposition 
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pathways. In this study, it is shown that the formation of GSSG accompanies the accelerated NO 
release from GSNO in the presence of chitosan/CuBTTri membranes, indicating that the ultimate 
fate of GSNO remains the same when decomposed by the MOF. While the overall mechanism 
remains unknown, it has been argued that steric considerations prevent the formation of the ring 
intermediates often invoked in the case of dissolved copper ions. For certain systems, it has been 
proposed that MOF copper sites may act as Lewis acids that facilitate the formation of NO from 
RSNOs.45 A computational study carried out by Li et al. suggests that free copper ions interact 
with an initial RSNO molecule in solution to form a Cu-S bond, accompanied by the release of 
NO. This process is repeated with a second RSNO molecule to form a CH3S-Cu-SCH3
+ species, 
which subsequently leads to disulfide formation and regeneration of the copper species. 
Comparison of this solution-phase scenario to the MOF Cu-BTC indicated that the approach of 
the initial RSNO molecule was nearly isoenergetic with free copper, but the addition of a 
subsequent RSNO molecule to the same copper site or adjacent copper sites displayed a higher 
energy barrier. This suggests that this particular reaction would only be plausible for a flexible 
MOF that could allow for distortion around the copper center to accommodate the additional 
RSNO molecule.46 Regardless of actual mechanism, the identification of GSSG is a crucial step 
toward understanding the interaction of copper-based MOFs with RSNOs. 
 
Figure 4.10 Proposed overall reaction for GSNO in the presence of solution-phase copper 
ions, resulting in the subsequent formation of NO and oxidized glutathione. Reproduced by 
permission of the American Chemical Society. 
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4.4 Conclusions 
These findings demonstrate the ability of chitosan/CuBTTri membranes to generate an 
enhanced level of NO release from GSNO, a compound that occurs naturally in blood as a 
hypothesized NO storage and transport agent. Preservation of CuBTTri following incorporation 
within chitosan was verified by pXRD and ATR-FTIR, and SEM revealed the clear distribution of 
octahedral CuBTTri crystals on the surface of the material. In the presence of 20 M (100 nmol 
total) GSNO at physiological temperature and pH, chitosan/CuBTTri membranes produced 97 ± 
3 nmol over 4.3 ± 0.3 h, representing a 65-fold increase in NO generation relative to the baseline 
thermal decomposition of GSNO. Under otherwise identical conditions, CuBTTri powder (without 
immobilization in chitosan) produced 97 ± 6 nmol NO over 5.0 ± 1.6 h, indicating no significant 
difference in performance compared to chitosan/CuBTTri membranes. While CuBTTri has been 
previously shown to induce the accelerated decomposition of synthetic RSNOs such as S-
nitrosocysteamine and SNAP, this is the first extension of that function to GSNO. Furthermore, 
inclusion of CuBTTri within chitosan membranes did not result in a significant impairment of 
function, contrasting with earlier polyurethane and PVC-based systems, where polymeric 
incorporation diminished the activity of the MOF. Following initial experiments, 
chitosan/CuBTTri membranes were capable of promoting accelerated NO release for at least three 
additional cycles. Characterization by pXRD and SEM subsequent to GSNO exposure supported 
the lack of extensive CuBTTri decomposition, and this outcome was corroborated by the low level 
of copper leaching as determined by ICP-AES. Moreover, mass spectrometry was used to identify 
GSSG as the major product of GSNO decomposition in the presence of chitosan/CuBTTri, 
substantiating the hypothesis that disulfides are formed from RSNOs by copper-based MOFs. 
Taken together, this work indicates that chitosan-based materials incorporating CuBTTri may be 
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capable of inducing NO formation from endogenous GSNO in the blood. Examining the assembly 
and properties of these and similar materials facilitates the use of MOFs for localized NO release, 
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NITRIC OXIDE GENERATION FROM ENDOGENOUS SUBSTRATES USING 
COPPER(II) BENZENE-1,3,5-TRIS(1H-1,2,3-TRIAZOL-5-YL): INCLUSION WITHIN POLY 






Over the past two decades, there has been considerable growth in the proposed use of metal–
organic frameworks (MOFs) for a variety of wide-ranging applications. These unique materials 
are characterized by ordered networks formed from metal nodes and organic linkers, and may 
display one, two, or three-dimensional architectures. The remarkable degree of porosity exhibited 
by many MOFs confers correspondingly large surface areas and pore volumes that have led to 
their implementation in gas storage and separation.1 Furthermore, the density of potential active 
sites and the ability to controllably alter the physical and chemical properties within the framework 
through variation or modification of the metal ion or organic constituents have facilitated their use 
in heterogeneous catalysis.1 More recently, the utility of MOFs in biomedicine has been 
recognized, including use in drug delivery and antibacterial applications.2,3 This biomedical 
potential has been united with the well-characterized gas storage properties of MOFs in the form 
of nitric oxide (NO)-releasing frameworks.4 These efforts were prompted by the broad therapeutic 
action of NO, which is produced endogenously as a crucial signaling molecule and exhibits potent 
                                                          
4 This chapter was reproduced in part with permission from: 
Neufeld, M. J.; Lutzke, A.; Jones, W. M.; Reynolds, M. M. Nitric Oxide Generation from Endogenous 
Substrates Using Metal–Organic Frameworks: Inclusion within Poly(vinyl alcohol) Membranes to 
Investigate Reactivity and Therapeutic Potential. ACS Appl. Mater. Interfaces 2017, 9, 35628-35641. 
Copyright 2017 American Chemical Society. http://pubs.acs.org/doi/full/10.1021/acsami.7b11846  
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antithrombotic, antimicrobial, and wound-healing effects.5 As examples, the adsorption and 
subsequent release of NO have been demonstrated with iron-based MIL-88 and copper-based Cu-
BTC (HKUST-1).6,7 This function has been expanded with the postsynthetic modification of Cu-
BTC to include NO-forming N-diazeniumdiolate functional groups.8 An alternative approach has 
utilized copper-based MOFs such as copper benzene-1,3,5-tricarboxylate (CuBTC, or HKUST-1) 
to promote the release of NO from S-nitrosothiols (RSNOs), compounds that naturally occur in 
blood as a component of mammalian biochemistry.9,10 Because RSNOs decompose to form NO 
and disulfide (2 RSNO → 2 NO + RSSR) upon exposure to environmental triggers such as heat, 
light, and certain transition metal ions (e.g., copper), the controlled recruitment of these natural 
compounds for therapeutic applications has been the target of substantial prior research.11 The 
established ability of particular copper-based MOFs to initiate NO-formation from RSNOs permits 
the development of polymeric biomaterials that also exhibit this property.  
However, biological application of this phenomenon requires the immobilization of copper-
based MOFs within polymer matrices while retaining the NO-generating therapeutic activity. As 
an example, it has been demonstrated that the water-stable, triazolate-bridged MOF CuBTTri 
(H3BTTri = 1,3,5-tris[1H-1,2,3-triazol-5-yl]benzene) (Figure 5.1a) can be dispersed within 
polymers such as plasticized poly(vinyl chloride) (PVC) and chitosan (a polysaccharide primarily 
consisting of glucosamine repeating units) to produce processable formulations that retain the NO-
generating properties of the MOF in the presence of RSNOs.12,13  
Predictably, it was observed that the physical properties of the polymer exert a considerable 
influence on the ability of the MOF to interact with aqueous-phase RSNOs in vitro. Limited 
diffusion of the dissolved RSNO into hydrophobic polymer formulations resulted in an 8-fold 
reduction in NO generation relative to an aqueous suspension of CuBTTri powder (i.e., not 
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blended within a polymer).14 In comparison, a 10 wt. % CuBTTri/chitosan formulation induced a 
65-fold increase in NO generation over the baseline thermal decomposition of S-nitrosoglutathione 
(GSNO) (Figure 5.1b), the most abundant small molecule RSNO present in blood.13 In this earlier 
example, no statistically significant difference in CuBTTri performance was observed following 
incorporation within the polymer. From these prior results, it is clear that polymers exhibiting 
substantial water uptake facilitate the interaction of aqueous-phase RSNOs with blended MOFs. 
 
Figure 5.1 (a) The structure of CuBTTri. Carbon (black), nitrogen (red), chlorine (green), 
and copper (blue) atoms are depicted with hydrogen atoms omitted for clarity. (b) The 
structure of S-nitrosoglutathione (GSNO). (c) The repeating unit of poly(vinyl alcohol) 
(PVA). Reproduced by permission of the American Chemical Society. 
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For this reason, the use of copper-based MOFs to promote NO release from RSNOs may be best 
achieved through selection of hydrophilic polymer systems that permit optimization of this process 
for blood-contacting, therapeutic applications. In this respect, poly(vinyl alcohol) (PVA) (Figure 
5.1c) represents a uniquely suitable candidate due to its hydrophilicity, hemocompatibility, and 
broad use in biomedicine. This polymer is a linear, water-soluble derivative of poly(vinyl acetate) 
produced through hydrolysis of ester groups. Cross-linking of PVA through various physical or 
chemical means produces insoluble materials that have been investigated for a wide range of 
medical applications, including drug delivery and tissue engineering.15 Moreover, various NO-
releasing, PVA-based materials have been used to fabricate wound dressings as well as promote 
vasodilation for treatment of cutaneous endothelial dysfunction associated with cardiovascular 
disease.16-18 
Herein, we report the synthesis and characterization of hybrid materials prepared from water-
stable CuBTTri and PVA for the generation of NO from GSNO. The MOF was blended into 
aqueous solutions of PVA at 1, 5, and 10 wt. % relative to the polymer, and the PVA host material 
was subsequently cross-linked by exposure to glutaraldehyde (GA) under mildly acidic conditions. 
The water-swollen membranes prepared through this procedure were examined for their ability to 
promote NO release from GSNO under varying conditions and compared to the performance of 
aqueous suspensions of CuBTTri powder. While PVA has been frequently used as a biomaterial, 
previous efforts involving the combination of PVA with MOFs or zeolites have generally targeted 
nonmedical applications such as chemical separation or water treatment.19,20 This work describes 
the first material combining a water-stable MOF with PVA for potential therapeutic applications, 
and demonstrates that physiologically relevant levels of NO release can be induced from GSNO. 
Furthermore, the unique properties of CuBTTri/PVA membranes permit the controlled study of 
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the NO-forming interaction between GSNO and CuBTTri in a manner that has not been previously 
possible. As a highly hydrophilic material, cross-linked PVA allows the comparatively rapid 
transport of GSNO to active sites within the polymer matrix. Unlike chitosan, PVA does not 
exhibit an independent ability to induce the decomposition of GSNO, thereby constraining 
observed effects to the influence of CuBTTri alone. Taken together, the attributes of 
CuBTTri/PVA membranes indicated the possibility for therapeutic use and provided the 
opportunity to evaluate critical performance parameters needed to facilitate the adaptation of 
copper-based MOFs to medical applications. 
5.2 Materials and Methods 
5.2.1 Materials 
Copper(I) iodide (98%), diethylamine (99+%), N-ethylmaleimide (NEM, 99+%), 
glutaraldehyde (25% aqueous solution), high molecular weight poly(vinyl alcohol) (PVA, 98-99% 
hydrolyzed), 1,3,5-tribromobenzene (98%), and trimethylsilyl azide (94%) were purchased from 
Alfa Aesar (Ward Hill, MA, USA). Reduced glutathione (GSH, 98%) was purchased from 
AMRESCO (Solon, OH, USA). Trimethylsilylacetylene (99+%) was purchased from Chem-
Impex International, Inc. (Wood Dale, IL, USA). Phosphate buffered saline (PBS) tablets and 
sodium nitrite were obtained from EMD Chemicals (Gibbstown, NJ, USA). Chelex 100 resin (200-
400 mesh, sodium form) was procured from Bio-Rad (Hercules, CA, USA). 
Bis(triphenylphosphine)palladium(II) dichloride was purchased from Sigma-Aldrich (St. Louis, 
MO, USA). For NO analysis, ultra high purity (UHP) N2 and O2 gases were obtained from Airgas 
(Denver, CO, USA). Nitric oxide (NO; 43.6 ppm NO, balance N2) calibration gas was purchased 
from Air Liquide (Houston, TX, USA). Deionized water (18.2 MΩ·cm) was supplied by a 
Millipore Direct-Q water purification system (EMD Millipore, Billerica, MA, USA) and used in 
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all experiments. N2 (UHP) was passed through activated charcoal and potassium permanganate 
filters prior to use as an NO carrier gas. Diethylamine was distilled prior to use. All other chemicals 
were used as received without any further purification. 
5.2.2 Synthesis of copper(II) benzene -1,3,5-tris(1H-1,2,3-triazole-5-yl) 
The ligand 1,3,5-tris(1H-1,2,3-triazol-5-yl)benzene (H3BTTri) and MOF 
H3[(Cu4Cl)3(BTTri)8] (CuBTTri) were prepared following the general protocols given by 
Demessence et al.1 The MOF was used in the hydrated form with the theoretical formula 
H3[(Cu4Cl)3(BTTri)8-(H2O)12]·72H2O. 
5.2.3 Synthesis of cross-linked copper(II) benzene-1,3,5-tris(1H-1,2,3-triazole-5-yl) 
/poly(vinyl alcohol) membranes.  
Poly(vinyl alcohol) was dissolved by heating a 10 wt. % suspension of PVA in Millipore 
water at 90 °C for 4 h. To prepare 1, 5, and 10 wt. % CuBTTri/PVA membranes, an appropriate 
quantity of MOF (4, 21, or 44 mg) was suspended in 0.75 mL of Millipore water and placed in an 
ultrasound bath for 2 min to uniformly disperse the crystalline powder. This mixture was added to 
4 mL of 10 wt. % aqueous PVA, and an additional 0.25 mL Millipore water rinse was used to 
ensure the quantitative transfer of MOF into the polymer solution. The final PVA concentration 
was 80 mg·mL-1, and this viscous solution was combined with 0.364 mL of 25 wt. % aqueous 
glutaraldehyde and 52 L of glacial acetic acid. The mixture was agitated by vortex mixer until 
uniform then cast into a 5 cm circular polytetrafluoroethylene (PTFE) mold, and the solvent was 
allowed to evaporate for 2 days. The dry membrane was heated at 80 °C for 2 h, then immersed in 
200 mL of Millipore water for 30 min. Following this initial immersion, the membrane was washed 
with 5 × 100 mL of Millipore water, then immersed for 1 day in 200 mL of Millipore water. The 
washing procedure was repeated with Millipore water, and the membrane was placed in 200 mL 
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of 0.1 % w/v Chelex 100 resin (adjusted to pH 7-8) for an additional day. After a further repetition 
of the washing procedure, the membrane was immersed in 200 mL of Millipore water for 2 days 
(with replacement of the medium after 1 day), then punched into smaller 15 mm diameter circular 
membranes that were air-dried and used in subsequent experiments. Control membranes were 
prepared without the addition of CuBTTri following an otherwise identical procedure. 
5.2.4 Synthesis of Tecoflex SG-80A Polyurethane Films.  
Tecoflex SG-80A (400 mg) was dissolved in 6 mL of freshly distilled THF. Separately, 44 
mg of CuBTTri was suspended in 2 mL of THF and placed in an ultrasound bath for 2 min to form 
a uniform dispersion. This mixture was added to the polymer solution and vortexed until uniform, 
producing a final Tecoflex concentration of 50 mg·mL-1. The mixture was cast into a 5 cm circular 
PTFE mold, and the solvent was allowed to evaporate. Circular films (15 mm diameter) were 
punched for use in subsequent experiments. 
5.2.5 Synthesis of S-nitrosoglutathione.  
S-Nitrosoglutathione (GSNO) was synthesized following an adaptation of the method 
reported by Hart.2 Glutathione (GSH; 1.54 g, 5.0 mmol) was suspended in 8 mL of Millipore water 
and dissolved by the addition of 2.5 mL of 2 M hydrochloric acid. This solution was cooled to 0 
°C using an ice bath, and 0.345 g (5.0 mmol) of sodium nitrite was added in a single portion. After 
stirring for 40 min in the dark, the mixture was filtered to isolate a red precipitate that was 
subsequently washed with 5 × 5 mL of ice-cold Millipore water, 3 × 5 mL of acetone, and 3 × 5 
mL of diethyl ether. The product was placed under vacuum (1 Torr) for 1 h to remove residual 
solvent, and afforded 0.865 ± 0.076 g (51 ± 5%) of GSNO. 1H NMR (400 MHz, D2O): 4.70-4.61 
(m, 1H), 4.20-3.90 (m, 2H), 3.93 (s, 2H), 3.78 (t, 1H, J = 6.4 Hz), 2.42 (t, 2H, J = 7.6 Hz), 2.18-
2.01 (m, 2H). UV-vis (H2O)μ 335 (π → π*), 545 (nN → π*).  
162 
5.2.6 General characterization.   
Proton nuclear magnetic resonance (1H NMR) spectra were acquired with an Agilent 
(Varian) Inova 400 MHz FT-NMR spectrometer (Agilent Technologies, Inc., Santa Clara, CA). 
Ultraviolet-visible (UV-vis) spectra were obtained in quartz cuvettes using a Nicolet Evolution 
300 spectrophotometer (Thermo Electron Corp., Madison, WI). Attenuated total reflectance 
Fourier transform infrared (ATR-FTIR) spectra were obtained with a Nicolet 6700 FTIR 
spectrometer (Thermo Electron Corp.) equipped with a Smart iTR ATR sampling accessory fitted 
with a ZnSe crystal plate. Powder X-ray diffraction (pXRD) was carried out using a Bruker D-8 
Discover DaVinci X-ray diffractometer (Cu-Kα X-ray source, line focus) (Bruker, Billerica, MA, 
USA). Scanning electron microscopy (SEM) images of materials were acquired using a JEOL 
JSM-6500F scanning electron microscope (JEOL USA Inc., MA, USA) at a working distance of 
10 mm and an accelerating voltage of 5.0 kV. Samples were sputter coated with 15 nm of gold 
prior to imaging. 
5.2.7 Thermogravimetric analysis.  
Dynamic rate thermogravimetric analyses (TGA) were performed on TA Instruments TGA 
Q500 instrumentation (New Castle, DE, USA). Samples (~ 5-10 mg) were contained in ceramic 
holders using platinum sample pans. N2 was used as the furnace purge gas at a flow rate of 60 
mL·min−1. Samples were heated at a rate of 10 °C·min−1 with Hi-Res™ settings of resolution 
number 5.0 and sensitivity value 3.0. 
5.2.8 Differential scanning calorimetry.  
Differential scanning calorimetry (DSC) was performed using TA Instruments DSC2500 
instrumentation with a RCS 90 cooling system. Samples (~5-10 mg) were contained in 
hermetically sealed aluminum sample pans. N2 was used as the cell purge gas at a flow rate of 50 
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mL·min−1. Samples were cycled at a rate of 10 °C·min−1. The 1st cycle (−50 °C to 185 °C) ensured 
full desolvation and removal of each membrane’s thermal history prior to studies. The 2nd and 3rd 
cycles (−50 °C to 220 °C) were used to assess thermal transitions and reversibility of each film. 
5.2.9 Water uptake studies. 
 For all CuBTTri/polymer materials, the degree of water uptake was determined as follows: 
dry initial weights (Wi) were obtained for samples of each material (n  = 3) using an Ohaus 
Discovery DV215CD analytical balance (0.01 mg readability). Samples were subsequently 
immersed in 5 mL of Millipore water for 24 h, then re-weighed to determine a final wet mass (Wf) 
after blotting to remove excess water. The degree of swelling was calculated according to the 
following equation: 
% swelling = �� − ����  ×  
5.2.10 Nitric oxide release measurements. 
Nitric oxide (NO) release was quantified by chemiluminescence using Sievers nitric oxide 
analyzers (NOA 280i, GE Analytical, Boulder, CO, USA). Instruments were calibrated with UHP 
N2 (0 ppm NO) and an NO standard (43.6 ppm NO, balance N2). Using custom glass analysis 
vessels, samples (either 15 mm diameter membranes/films or CuBTTri powder) were 
immersed/suspended in 10 mL of deoxygenated 10 mM PBS (at varying pH and temperature) with 
continuous UHP N2 sparging and headspace flow. Aliquots of an aqueous GSNO solution were 
then injected into analysis vessels to produce a final GSNO concentration of 10 µM. The NO 
generated by decomposition of GSNO was swept into the instrument and quantified as gas-phase 
NO concentration (ppb), which was subsequently converted to NO release (mol) using an 
instrument-specific calibration constant previously obtained from reduction of sodium nitrite. 
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5.2.11 Statistical analysis 
Analytical results are reported as the mean ± standard deviation of a minimum of triplicate 
measurements. Where appropriate, statistical significance was determined by Student’s t-test or 
one-way analysis of variance (ANOVA) at the 95% confidence level. Post hoc analysis consisted 
of Tukey’s range test or the Tukey-Kramer method, as dictated by sample size. 
5.3 Synthesis and characterization of copper(II) benzene-1,3,5-tris(1H-1,2,3-triazole-5-yl) 
/poly(vinyl alcohol) membranes 
S-Nitrosothiols occur naturally in human blood at concentrations that have been reported to 
range from nanomolar to micromolar, depending on analytical methodology, natural variation, and 
donor morbidity.21 This fact has prompted the development of therapeutic materials that are 
intended to induce the NO-forming decomposition of biological RSNOs when placed in contact 
with flowing blood. These materials have included polymer-immobilized organoselenium and 
tellurium catalysts as well as various systems based on immobilized copper complexes, 
nanoparticles, and MOFs.12-14,22-25 The use of MOFs to induce the generation of NO from 
endogenous substrates could permit sustained production without adsorption of finite quantities of 
gaseous NO or incorporation of NO-forming functional groups. This concept was initially limited 
by the susceptibility of Cu-BTC to water-induced degradation, which does not permit extended 
exposure to physiological media such as blood.26 It was later discovered that the water-stable, 
triazolate-bridged framework CuBTTri (originally proposed by Demessence et al. for CO2 capture) 
similarly promotes NO release from RSNO substrates.14,27 The MOF was found to remain 
crystalline after exposure to both boiling water and dilute hydrochloric acid, and retained its ability 
to induce NO release from RSNOs following immersion in whole blood. Moreover, CuBTTri does 
not exhibit the significant level of copper ion leaching observed from certain copper complexes 
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used to catalyze NO release from RSNOs.12-14, 26,28 This retention of MOF function permits the 
development of polymer-based materials with the ability to produce therapeutic levels of NO 
directly from blood. For example, CuBTTri has been blended with biomedically-relevant polymers 
such as plasticized PVC, where it demonstrated the ability to promote NO release from RSNOs 
such as S-nitrosocysteine and S-nitroso-N-acetylpenicillamine (SNAP).12,14 However, the ability 
of aqueous-phase, biological RSNOs to interact with blended CuBTTri (or other copper-based 
agents) is limited by the poor water uptake of hydrophobic polymers like PVC. In comparison, the 
promotion of NO release from an RSNO exposed to blended CuBTTri occurred more rapidly when 
the MOF was incorporated within chitosan, a hydrophilic polysaccharide.13 Despite this improved 
performance, the potential blood-contacting applications for this material were constrained by the 
inherent hemostatic attributes of chitosan.29 As additional complications, the basic glucosamine 
repeating units of chitosan are capable of reacting with acidic functional groups that occur as part 
of the structure of physiological RSNOs, and may also strongly bind transition metal ions that are 
independently capable of initiating RSNO decomposition.30,31 As such, it is clear that MOF-based 
materials combining the water permeability of chitosan with the structural simplicity of PVC may 
permit NO generation from RSNOs and examination of the parameters influencing this behavior 
without interference from the polymer matrix. 
5.3.1 Membrane preparation.  
Poly(vinyl alcohol) is a highly hydrophilic linear polymer derived from hydrolysis of 
poly(vinyl acetate). The CuBTTri blends prepared from hydrophilic PVA represent promising 
alternatives to previous systems due to the existing use of PVA in numerous blood-contacting 
applications, its lack of hemolytic properties, and the potential for considerable water permeability 
and transport of GSNO.32 Moreover, the absence of acidic or basic functional groups (e.g., the 
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primary amine groups of chitosan) and the general structural simplicity of PVA allows it to 
function as a comparatively inert host for the MOF. Implementation of this concept is particularly 
beneficial in the case of studies intended to elucidate the NO-forming behavior of CuBTTri under 
varying conditions. For example, incorporation within a polymer matrix permits straightforward 
isolation and re-characterization of the immobilized MOF following experiments without 
requiring the separation of fine MOF particle suspensions. Because PVA has been frequently 
examined as a nontoxic biomaterial, there has been notable prior interest in the utilization of PVA 
or PVA-based materials as NO delivery platforms. For example, Masters et al. modified PVA 
hydrogels with N-diazeniumdiolate NO donor groups to prepare wound dressings, while the 
vasodilatory effect of NO was exploited by Marcilli and de Oliveira in the development of NO-
releasing PVA films for the treatment of microvascular skin disorders.16,17,33,34 In addition to these 
examples of NO-releasing derivatives, physically cross-linked PVA films were used to uptake and 
subsequently release GSNO itself as a therapeutic. Since PVA exhibits solubility in water, physical 
or chemical cross-linking techniques are frequently used to produce stable materials for use in 
biomedicine.15 Cross-linking by reaction with dialdehydes such as GA occurs through the 
formation of acetal linkages between GA and the 1,3-diol units of independent PVA chains.35 This 
type of cross-linking process permits the synthesis of water-insoluble membranes that encapsulate 
crystalline CuBTTri. The MOF was synthesized following the original protocol published by 
Demessence et al., and was characterized by powder X-ray diffraction (pXRD) and attenuated total 
reflectance Fourier transform infrared spectroscopy (ATR-FTIR) prior to use (Figure 5.2a and 
5.2b).27 The MOF was then blended into aqueous solutions of PVA in the presence of GA and 
acetic acid at 1, 5, and 10 wt. % loading relative to the polymer. It was observed that the direct 
addition of CuBTTri powder to aqueous PVA resulted in substantial MOF particle agglomeration 
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that reduced the visual uniformity of the mixture, potentially resulting from physical 
incompatibility between the MOF and polymer solution. This phenomenon was limited by adding 
CuBTTri as an aqueous suspension, which was gradually mixed with the polymer phase to promote 
a more uniform dispersion. Similar effects in organic solvents have been noted by multiple prior 
authors and may be attributable to the formation of a polymer coating on the MOF that inhibits 
agglomeration.36,37 While strong acid catalysts (e.g., sulfuric or hydrochloric acid) are commonly 
used to produce highly cross-linked PVA, the sensitivity of CuBTTri to harshly acidic conditions 
prompted the use of acetic acid as a milder alternative. After 2 days of curing at ambient 
 
Figure 5.2 (a) Powder X-ray diffraction patterns of CuBTTri, cross-linked PVA control 
membrane, and 10 wt. % CuBTTri/PVA membrane. The diffraction pattern of 
CuBTTri/PVA membrane displays peaks attributable to both PVA and CuBTTri, 
demonstrating retention of the MOF structure following incorporation within the polymer. 
(b) The ATR-FTIR spectra of CuBTTri, cross-linked PVA control membrane, and 10 wt. 
% CuBTTri/PVA membrane. Infrared absorption bands associated with CuBTTri are 
present at 1616 (C=C stretching) and 775 cm-1 (C-H out-of-plane bending). Reproduced by 
permission of the American Chemical Society. 
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temperature, followed by 2 h at 80 °C, membranes were immersed in Millipore water for 1 day to 
remove residual acetic acid and GA. This immersion was followed by treatment with a 0.1 % w/v 
aqueous suspension of Chelex 100 resin to capture trace metal ions (chiefly iron or copper) that 
may diffuse from membranes into the surrounding aqueous medium. The membranes were 
immersed in Millipore water for an additional 2 days, punched into 15 mm diameter circles (water-
swollen), then air-dried prior to characterization. 
5.3.2 Membrane characterization.  
Characterization of the 10 wt. % CuBTTri/PVA membranes by pXRD revealed the expected 
diffraction pattern of CuBTTri overlapping with a broad feature originating from semicrystalline 
PVA, supporting retention of the crystalline structure of the MOF following incorporation within 
the polymer matrix (Figure 5.2a).27 At lower loading of 1 and 5 wt. % CuBTTri, key diffraction 
 
Figure 5.3 pXRD patterns of (a) PVA, CuBTTri and 1, 5 and 10 wt. % CuBTTri/PVA 
membranes. (b) pXRD of the region between 4 and 16 degrees to better show the diffraction 
peaks associated with CuBTTri in the lower weight percent membranes. Patterns 
demonstrate the retention of major diffraction peaks associated with CuBTTri, indicating 
successful incorporation of CuBTTri into the PVA matrix. Reproduced by permission of 
the American Chemical Society. 
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peaks remain defined (Figure 5.3). Control membranes prepared from PVA alone exhibit 
characteristic IR absorption bands at 3600-3000 (O-H stretching), 2937, 2916, 2850 (CH 
stretching), 1709 (acetate C=O stretching), 1655 (H2O), 1418 (CH2 bending), 1377 (CH2 rocking), 
1327, 1238 (CH rocking), 1086 (CO stretching), 916, and 830 cm-1.38  The incorporation of 10 wt. 
% CuBTTri is accompanied by the appearance of bands at 1616 (C=C stretching) and 775 cm-1 
(C-H out-of-plane bending) associated with the triazolate-bridged MOF (Figure 5.2b).  At 5 wt. 
% CuBTTri, these absorption bands are less pronounced but remain present (Figure 5.4). At a 
lower concentration of 1 wt. % CuBTTri, the absorption bands of the MOF are no longer clearly 
resolved (Figure 5.4). In all cases, no peaks directly assignable to GA are detectable. This outcome 
was predictable due to the comparatively mild cross-linking conditions, which are unlikely to 
result in extensive acetal formation and incorporation of GA within the PVA matrix.  
 
Figure 5.4 ATR-FTIR spectra of CuBTTri, cross-linked PVA control membrane, and 10 
wt. % CuBTTri/PVA membrane. The IR bands associated with CuBTTri are present at 
1616 (C=C stretching) and 775 cm-1 (C-H out-of-plane bending). At 5 wt. % CuBTTri 
these absorptions remain present but less pronounced, whereas at 1 wt. % CuBTTri, the 
major peaks associated with CuBTTri are no longer clearly resolved. Reproduced by 
permission of the American Chemical Society. 
170 
However, the presence of cross-linking was qualitatively demonstrated by heating samples 
of GA cross-linked CuBTTri/PVA, cross-linked PVA, and non-crosslinked PVA in Millipore 
water. The PVA membrane prepared without exposure to GA readily redissolves in water, while 
cross-linked CuBTTri/PVA and PVA do not exhibit solubility at temperatures as high as 90 °C. 
Cross-linking under mild conditions is not an unexpected outcome since it has been previously 
observed that a degree of GA-mediated cross-linking occurs in the total absence of catalytic acid.39 
While PVA is capable of chelating copper ions through a variety of proposed binding mechanisms 
(particularly under strongly alkaline conditions), there is no spectroscopic evidence supporting the 
possibility that similar interactions occur between CuBTTri and PVA.40,41 In general, both pXRD 
patterns and IR spectra of CuBTTri/PVA membranes are additive with respect to the spectra of 
individual constituents and do not indicate a detectable change in crystallinity or chemical structure 
of CuBTTri or PVA as a consequence of membrane preparation. 
The thermal properties of 10 wt. % CuBTTri/PVA membranes were examined by 
thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC). For TGA, studies 
were performed on the PVA control membranes and CuBTTri powder as well as the 10 wt. % 
CuBTTri/PVA membranes taken both before and after the materials were studied in NO release 
experiments. Samples were analyzed as prepared with the respective thermograms shown in 
Figure 5.5a The thermal transitions observed for both the PVA and CuBTTri starting materials 
were consistent with the literature. Dehydration of the PVA control began at ~65 °C with 
membrane decomposition (colorless to light brown color change) beginning at ~225 °C.42,43 The 
MOF showed significant dehydration at room temperature followed by desolvation beginning at 
~145 °C with onset of decomposition observed at ~295 °C.27 For 10% CuBTTri/PVA membranes, 
incorporation of the MOF as a polymeric dopant did not significantly alter the thermal stability of 
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the synthesized membranes. For the initial membrane, dehydration was observed at the same 
temperature as the PVA control with an onset of membrane decomposition (purple to tan/light 
brown color change) observed at ~245 °C. After the membrane was subjected to NO release 
studies, the thermal behavior of the membrane showed no differences compared to the initial 
membrane (with the exception of a slightly lowered onset of dehydration). Further studies 
examining the starting materials and membranes after dehydration at 90-95 °C for 24 h (Figure 
5.5b) showed no significant differences in the thermal behavior of the materials (with only 
CuBTTri starting material showing less desolvation shifted to higher temperatures, beginning 
around 205 °C).   
 
Figure 5.5 (a) TGA of cross-linked PVA, CuBTTri, and 10 wt. % CuBTTri membranes 
before and after NO release experiments and exposure to GSNO. (b) TGA of dehydrated 
cross-linked PVA, CuBTTri, and 10 wt. % CuBTTri membranes before and after NO 
release experiments and exposure to GSNO. Both the as-prepared (a) and dehydrated (b) 
PVA membranes showed no decrease in thermal stability upon incorporation of CuBTTri 
into the PVA matrix. Reproduced by permission of the American Chemical Society.  
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For DSC, PVA control membranes were assessed as well as the synthesized 10 wt. % 
CuBTTri/PVA membrane both before and after the membranes were subjected to NO release 
experiments. Samples were placed under vacuum at 65 °C for 3 h prior to DSC analysis. For the 
PVA control membrane, two reversible thermal transitions were observed: an endothermic glassy 
transition (Tg) recovered at 56.5 °C and an endothermic melting transition (Tm) recovered at 201.5 
°C with an enthalpy of 42.86 J·g-1 (Figure 5.6). Thermal transitions for PVA are well known to 
shift in temperature with respect to differences in molecular weight.42,44 Thermal transitions of the 
10 wt. % CuBTTri/PVA membrane matched strongly with the PVA control: an endothermic Tg 
recovered at 56.8 °C and an endothermic Tm recovered at 196.1 °C with an enthalpy of 27.55 J·g
-
1. The slight depression in the Tm of the MOF-doped membrane is attributed to an eutectic effect 
as the MOF particles represent solid impurities as compared to the neat PVA membrane. Thus, the 
additional disorder and microstates within the doped polymer matrix allow melting to occur at 
slightly lower temperatures. Following NO release experiments, the 10 wt. % CuBTTri/PVA 
membrane showed no significant differences in the observed thermal transitions seen for the initial 
membrane. 
 
Figure 5.6. DSC of cross-linked PVA and 10 wt. % CuBTTri membranes before and after 
NO release experiments and exposure to GSNO. Both the initial and post NO release 
membranes showed no significant differences in thermal cycling as compared to the neat 
PVA membranes. Reproduced by permission of the American Chemical Society. 
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Incorporation of CuBTTri within the PVA matrix was demonstrated by scanning electron 
microscopy (SEM) imaging, which revealed the anticipated octahedral morphology of individual 
MOF crystallites (Figure 5.7a-f). Because the membranes were cured in poly(tetrafluoroethylene) 
(PTFE) molds, the sides of the membranes were expected to exhibit a degree of non-equivalence 
resulting from physical differences between the air and PTFE interfaces and gradual settling of the 
MOF suspension. As compared in Figure 5.7c and 5.7e, the apparent surface distribution of 
CuBTTri crystallites is relatively consistent between the air and PTFE interfaces of 10 wt. % 
CuBTTri/PVA membrane. However, images acquired of 1 and 5 wt. % CuBTTri/PVA membranes 
depict more pronounced differences in CuBTTri surface distribution as the overall concentration 
 
Figure 5.7 Scanning electron microscopy images of (a) PVA control at 2,000× 
magnification and (b) 10 wt. % CuBTTri membrane (air side) at 500× magnification. (c) 
The 10 wt. % CuBTTri membrane (air side) at 2,000× magnification with (d) EDX copper 
overlay. (e) The 10 wt. % CuBTTri membrane (PTFE side) at 2,000× magnification with 
(f) EDX copper overlay. Scale bars (lower right corner) correspond to 10 µm. Reproduced 
by permission of the American Chemical Society.  
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of the MOF decreases (Figure 5.8). This outcome is most directly attributable to settling of 
CuBTTri crystallites/agglomerates prior to evaporation of water. To further characterize the 
materials following incorporation of the copper-based MOF CuBTTri, the overall surface 
distribution of copper was imaged by energy-dispersive X-ray spectroscopy (EDX). Figures 5.7d 
and 5.7f show concentration of copper in regions of the 10 wt. % CuBTTri/PVA membrane that 
contain CuBTTri particles for both the air and PTFE interfaces. This analysis was also performed 
for 1 and 5 wt. % CuBTTri/PVA membranes, which display a similar concentration of copper at 
the location of MOF crystallites (Figure 5.8). Additionally, cross-sectional SEM imaging of the 
10 wt. % CuBTTri/PVA membrane indicated a dry thickness of approximately 56 µm with EDX 
confirming dispersion of copper throughout the interior of the membrane (Figure 5.8). Taken 
together, these results demonstrated successful incorporation of CuBTTri with improved 
uniformity between the air and PTFE interfaces at higher MOF loading. Although MOF particle 
agglomeration was observed in all images, the typical size of individual crystallites was relatively 
uniform at approximately 1 µm in diameter. The outcome of blending CuBTTri into the PVA 
solution as an aqueous suspension was evident in the qualitatively improved uniformity of the 
MOF dispersion compared to prior work. 
5.4 Nitric oxide generation from S-nitrosoglutathione 
Nitric oxide exhibits antithrombotic properties that are crucial in the maintenance of the 
healthy vascular endothelium, and is also produced by the immune system as an antimicrobial 
agent.5,45 As a diatomic radical that readily reacts with O2 and biomolecules such as hemoglobin, 
NO exhibits a physiological half-life ranging from seconds to milliseconds, permitting localized 
action in a biological environment.46 In biomolecules, the S-nitrosation of thiol groups (such as 
those present in cysteine residues) produces natural RSNOs.47 In principle, the use of copper-based 
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MOFs such as CuBTTri permits the continuous generation of NO directly from RSNO substrates 
in blood, obviating the use of exogenous NO sources that are often limited by finite storage 
capacity. The possibility of generating NO from endogenous RSNOs is particularly attractive in 
the case of blood-contacting medical devices, such as extracorporeal circuits, venous catheters, 
 
Figure 5.8 SEM images of (a) 1 wt. % CuBTTri membrane (air side) at 2,000× 
magnification, (b) EDX copper overlay, (c) 1 wt. % CuBTTri membrane (PTFE side) at 
2,000× magnification, (d) EDX copper overlay, (e) 5 wt. % CuBTTri membrane (air side) 
at 2,000× magnification, (f) EDX copper overlay,  (h) 5 wt. % CuBTTri membrane (PTFE 
side) at 2,000× magnification, (g) EDX copper overlay, (i) cross-section of 10 wt. % 
CuBTTri membrane at 1,000× magnification, and (j) EDX copper overlay. Scale bars 
(lower right corner) correspond to 10 µm. Reproduced by permission of the American 
Chemical Society.  
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and hemodialysis membranes, where the natural antithrombotic function of NO may inhibit the 
formation of thrombi that are associated with artificial polymeric surfaces.5,11 Similarly, the ability 
to produce NO in this fashion may facilitate the development of wound dressings that accelerate 
the healing process in the presence of perfusing blood. While it has been determined that RSNOs 
are present in blood at concentrations as high as the µM range, these compounds commonly occur 
in the form of macromolecules such as S-nitrosoalbumin (approximately 67 kDa) that are unlikely 
to rapidly interact with blended CuBTTri.48 In contrast, GSNO (336 Da) is widely reported to be 
the most abundant low molecular weight RSNO available in blood.47 For this reason, GSNO was 
utilized in NO release experiments as the most relevant endogenous RSNO. Although there has 
been controversy concerning the actual physiological level of RSNOs in blood, a concentration of 
10 µM GSNO was selected due to the use of similar µM-range concentrations in prior 
work.13,24,28,49 Measurement of NO release was carried out using Sievers chemiluminescence-
based NO analyzers, which rely on the gas phase reaction of NO with ozone to form excited state 
nitrogen dioxide (NO + O3 → NO2* + O2). The return of excited state NO2 to the ground state is 
accompanied by the emission of light, which is transduced and used to continuously measure the 
production of NO as a function of time. Chemiluminescence-based analysis is highly selective and 
permits detection of NO from solutions containing as little as 1 pmol of RSNO.50 Using this 
technique, the ability of CuBTTri/PVA membranes to promote NO release under varying 
conditions was examined. 
5.4.1 Performance at physiological pH and temperature.  
To assess the ability of 10 wt. % CuBTTri/PVA membranes to generate NO from GSNO at 
physiological pH and temperature, membranes were submerged in pH 7.4 phosphate buffered 
saline (PBS) at 37 °C, and this mixture was deoxygenated by sparging with N2. Prior to use, PBS 
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was treated with Chelex 100 resin to remove trace metal ions and was subsequently filtered and 
adjusted to the appropriate pH with dilute hydrochloric acid. Following deoxygenation, an aqueous 
solution of GSNO was injected to produce an initial GSNO concentration of 10 µM. The reaction 
was then shielded from ambient light and allowed to progress until NO release returned to baseline 
levels (<1 ppb). During this period, N2 was continuously bubbled through the solution to remove 
NO as it formed, and a flow of N2 was used to transport NO from the headspace of the analysis 
vessel into the NO analyzer. The NO yield was calculated using the quantity of recovered NO 
determined by chemiluminescence and the theoretical amount of NO based on the quantity of 
added GSNO. After an average of 3.5 ± 0.4 h (mean ± SD), 97 ± 6% of theoretical NO was released 
and quantified by chemiluminescence. The complete consumption of the initial quantity of GSNO 
produces the dramatic decline in NO release observed in the representative NO release profile 
plotted in Figure 5.9a. In comparison, control experiments using cross-linked PVA membrane 
(without CuBTTri) resulted in an NO yield of 2.5 ± 0.1% over the same duration, a result that was 
representative of the baseline decomposition rate of GSNO under prevailing experimental 
conditions. This finding was confirmed by evaluating the decomposition of GSNO alone (without 
added membrane), which resulted in an NO recovery of 2.7 ± 0.3%. These results indicate that the 
presence of 10 wt. % CuBTTri/PVA membrane induces a 36-fold increase in the rate of NO 
generation from GSNO. Furthermore, the absence of any statistically significant elevation in NO 
release in the presence of PVA controls indicates that the performance of the 10 wt. % 
CuBTTri/PVA membranes is wholly attributable to inclusion of the MOF. The essentially 
quantitative recovery of NO and the previous observation that oxidized glutathione is formed 
during the reaction indicate that the products likely correspond to those produced by thermal, light-
induced, or copper ion-catalyzed decomposition (2 RSNO → 2 NO + RSSR).13 
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The pXRD patterns of the 10 wt. % CuBTTri/PVA membrane and CuBTTri powder after 
NO release experiments showed retention of the characteristic peaks associated with CuBTTri, 
providing qualitative support for the lack of MOF degradation (Figure 5.10 and 5.11). Following 
each experiment, inductively coupled plasma atomic emission spectroscopy (ICP-AES) was used 
to determine the amount of trace copper in the buffer solution, which was limited to 0.34 ± 0.08% 
of the theoretical quantity present in 10 wt. % CuBTTri membrane. Because copper may produce 
 
Figure 5.9 (a) Representative NO release profiles depicting enhanced NO generation in the 
presence of CuBTTri and 10 wt. % CuBTTri/PVA membrane, compared with PVA control 
membrane and the thermal decomposition of GSNO. Consumption of available GSNO is 
accompanied by a rapid decrease in detected NO release, as shown by arrows. (b) 
Cumulative NO release plots for thermal GSNO decomposition, GSNO in the presence of 
PVA control membranes, and GSNO in the presence of 10% CuBTTri/PVA membranes. 
Experimental conditions: pH 7.4 PBS at 37 °C, with a 10 µM initial GSNO concentration 
(n ≥ 3). Reproduced by permission of the American Chemical Society.  
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toxicological concerns at sufficient levels, this lack of appreciable copper leaching supports, at 
minimum, the use of CuBTTri/PVA membranes in short-term blood-contacting applications. To 
evaluate the potential for copper leaching under harsher conditions, samples of 10 wt. % 
CuBTTri/PVA were immersed in pH 7.4 PBS at 37 °C for 24 h at a thousand-fold higher, non-
physiological GSNO concentration of 10 mM. At the end of this exposure period, ICP-AES was 
used to determine a quantity of copper in the buffer solution equivalent to 2.5 ± 0.2% of the 
theoretical amount present in the membrane. In contrast, no leaching was observed in PBS alone 
under otherwise identical conditions. This result indicates that the MOF exhibits a remarkable 
degree of stability even at a GSNO concentration that vastly exceeds potential physiological levels. 
 
Figure 5.10 pXRD of 10 % wt. CuBTTri/PVA membranes following NOA experiments 
under varying reaction conditions. Diffraction patterns show the retention of key peaks 
associated with CuBTTri, providing qualitative evidence that CuBTTri remains intact 
following promotion of NO from GSNO under varying conditions. Reproduced by 
permission of the American Chemical Society.  
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Furthermore, this resistance to leaching compares favorably to previously reported polyurethane-
bound copper(II)-cyclen complexes that were similarly used to promote NO release from GSNO.49 
In that example, 25% of available copper was removed after 24 h of immersion in PBS at a GSNO 
concentration of only 10 µM.49  
The MOF CuBTTri has previously been blended within chitosan membranes at 10 wt. % 
loading, where a similar ability to rapidly induce the decomposition of GSNO was observed.13 
However, control membranes prepared from chitosan alone independently produced a 7-fold 
increase in NO production relative to the baseline rate of GSNO decomposition. Because the 
 
Figure 5.11 pXRD diffraction patterns for CuBTTri particles upon completion of NO 
release experiments. Diffraction patterns show the retention of key peaks associated with 
CuBTTri, providing qualitative evidence that CuBTTri remains intact following promotion 
of NO from GSNO under varying conditions. Reproduced by permission of the American 
Chemical Society.  
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primary amine groups of chitosan facilitate chelation, this phenomenon was attributed to the 
presence of trace metal ions bound to the polymer. The absence of this behavior in PVA suggests 
that the polymer matrix functions as an encapsulating support for CuBTTri without exerting a 
chemical influence on the reaction itself. The maximum NO flux observed from 10 wt. % 
CuBTTri/PVA was 0.20 ± 0.02 nmol·cm-2·min-1, falling within the 0.05 to 0.41 nmol·cm-2·min-1 
range often associated with natural endothelial NO production (Figure 5.12).45,51,52 This range has 
frequently been used as a benchmark to indicate antithrombotic therapeutic potential.51 As an 
additional point of comparison, a quantity of CuBTTri powder equivalent to the mass contained in 
10 wt. % CuBTTri/PVA membranes was exposed to 10 µM GSNO under identical conditions  
(Figure 5.9). The use of this suspension of CuBTTri powder did not result in statistically 
significant differences in total NO yield (90 ± 1%) or completion time (3.3 ± 0.2 h) relative to 10 
wt. % CuBTTri/PVA membrane (Figure 5.13). However, comparison of the NO release profiles 
of 10 wt. % CuBTTri/PVA and an equivalent mass of CuBTTri powder shows significantly slower 
initial release kinetics in the case where the MOF is incorporated within PVA. As a consequence, 
 
Figure 5.12 NO flux (nmol·cm-2·min-1) produced by 1, 5, and 10 wt. % CuBTTri/PVA 
membranes. Dashed line corresponds to an NO flux of 0.05 nmol·cm-2·min-1, a value that 
is frequently invoked as the lower limit of physiological endothelial flux.3 Experimental 
conditions: pH 7.4 PBS at 37 °C, with a 10 µM initial GSNO concentration (n ≥ 3). 
Reproduced by permission of the American Chemical Society. 
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50% of available NO is recovered in only 1.3 ± 0.1 h in the case of CuBTTri powder, while the 
required time for 50% recovery is 2.0 ± 0.3 h for 10 wt. % CuBTTri/PVA. This difference in 
kinetics likely arises from diffusion of GSNO into the membrane prior to interaction with 
CuBTTri. Following these initial experiments, the 10 wt. % CuBTTri/PVA membranes were 
immersed in Millipore water for 3 days and reused in a second set of identical NO release 
experiments. The reused membranes resulted in an NO yield of 103 ± 8%, with a 34% increase in 
the duration of the reaction to 4.7 ± 0.4 h (Figure 5.14).  
Notably, the ability of 10 wt. % CuBTTri/PVA membrane to promote the decomposition of GSNO 
in pH 7.4 PBS at 37 °C was maintained when the buffer solution was sparged with O2 in place of 
N2. This result was determined by conducting the reaction for 3.5 h (the average completion time 
 
Figure 5.13 (a) Representative NO release profiles and (b) cumulative NO release profiles 
for CuBTTri particles and 10 wt. % CuBTTri/PVA membranes, depicting their comparative 
performance. Experimental conditions: pH 7.4 PBS at 37 °C, with a 10 µM initial GSNO 
concentration (n ≥ 3). Cumulative NO release plot depicts both the mean and standard 
deviation. Reproduced by permission of the American Chemical Society. 
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under typical measurement conditions) with constant O2 sparging. Any remaining GSNO was 
subsequently decomposed by injection of an aqueous solution of copper(II) chloride, and the 
resulting NO release was quantified under standard analytical conditions. This test resulted in the 
recovery of only 53 ± 12% of theoretical NO, and provides the first experimental confirmation that 
the reaction proceeds under aerobic conditions, albeit at a lower yield. A similar outcome for the 
thermal decomposition of RSNOs was observed by Grossi et al., where bubbling with O2 was 
found to noticeably decrease the rate of decomposition.53 Since the combination of NO and O2 is 
known to form products such as nitrous acid (HNO2) under aqueous conditions, it may be the case 
that the change in chemical environment is solely responsible for the increased reaction time.54 
 
Figure 5.14 (a) Representative NO release profiles and (b) cumulative NO release profiles 
for the initial use of 10 wt. % CuBTTri/PVA membranes and subsequent reuse after 
immersion in Millipore water for 72 h. Experimental conditions: pH 7.4 PBS at 37 °C, with 




Alternatively, O2 may oxidize a putative copper(I) active site to an inactive copper(II) form, a 
process that has previously been observed in multiple copper-based MOFs.55 The potential 
involvement of copper(I) sites has been invoked in computational studies that specifically 
investigated the interaction of RSNOs with copper-based MOFs, where reduction of framework 
copper(II) to copper(I) was included as a crucial step in the mechanistic process.56,57 However, it 
remains unclear if this type of mechanism is operative in the case of CuBTTri and whether 
framework copper actively participates in the observed NO-forming activity of the MOF. 
5.4.2 Effect of varying copper(II) benzene-1,3,5-tris(1H-1,2,3-triazole-5-yl) concentration.  
The influence of CuBTTri concentration on the performance of the CuBTTri/PVA 
membrane was determined by evaluating the ability of 1 and 5 wt. % CuBTTri/PVA membranes 
 
Figure 5.15 (a) Representative NO release profiles depicting enhanced NO generation in 
the presence of the CuBTTri/PVA membranes at concentrations of 1, 5, and 10 wt. % 
CuBTTri. (b) Cumulative NO release plots for 1, 5 and 10 wt. % CuBTTri/PVA 
membranes. Experimental conditions: pH 7.4 PBS at 37 °C, with a 10 µM initial GSNO 
concentration (n ≥ 3). Reproduced by permission of the American Chemical Society. 
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to induce NO release from GSNO in pH 7.4 PBS at 37 °C. At 5 wt. % CuBTTri, the total NO 
recovery of 97 ± 6% was obtained after 5.0 ± 0.7 h, representing a statistically significant 43% 
increase in reaction time compared to the 10 wt. % CuBTTri/PVA membranes (Figure 5.15). At 
1 wt. % CuBTTri, total NO recovery (102 ± 3%) required 13 ± 1 h, corresponding to a 270% 
increase in completion time (Figure 5.15). The maximum NO fluxes observed for 5 and 1 wt. % 
CuBTTri membranes were 0.16 ± 0.06 and 0.051 ± 0.008 nmol·cm-2·min-1, respectively (Figure 
5.12). These results indicate that lowering the concentration of CuBTTri from 10 to 1 wt. % 
predictably results in a significant lengthening of the reaction time but does not affect overall NO 
recovery. The observed reduction in maximum NO flux and extension in overall reaction time that 
accompanies the decrease in CuBTTri concentration may permit application-specific tuning of 
CuBTTri/polymer blends based on the amount of incorporated MOF. This behavior is directly 
attributable to the reduced availability of active species at lower MOF concentration as a similar 
relationship was observed by Major et al. in the case of copper nanoparticles blended into a 
hydrophilic polyurethane at various concentrations.25  
5.4.3 Effect of polymer water permeability. 
 The water permeability and uptake of CuBTTri/polymer blends influences the rate at which 
dissolved RSNOs interact with the MOF. To investigate the water uptake properties of 10 wt. % 
CuBTTri/PVA membrane, dry samples were weighed and subsequently immersed in water for 24 
h. The 10 wt. % CuBTTri/PVA membrane exhibited a swelling ratio of 203 ± 3% (Table 5.1). For 
comparison, additional 10 wt. % CuBTTri films were prepared using Tecoflex SG-80A, a 
comparatively hydrophobic polyurethane often used for medical device fabrication. The swelling 
ratio of 10 wt. % CuBTTri/Tecoflex SG-80A films was determined gravimetrically to be 2.0 ± 
0.3%, indicating an approximate 100-fold difference in water uptake relative to hydrophilic PVA-
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based membranes. The NO release profiles for GSNO in the presence of 10 wt. % 
CuBTTri/Tecoflex SG-80A films were subsequently acquired in pH 7.4 PBS at 37 °C over a 
duration corresponding to the completion time of experiments performed using 10 wt. % 
CuBTTri/PVA membranes. Over this period, only 1.5 ± 0.4% of theoretical NO was recovered, 
compared to 97 ± 6% for the 10% CuBTTri/PVA membranes (Figure 5.16). These results support 
prior observations that hydrophobic polymers with decreased water permeability/uptake inhibit 
 
Figure 5.16 (a) Representative NO release profiles depicting enhanced NO generation in 
the presence of 10 wt. % CuBTTri/PVA and the absence of this effect in the case of 10 wt. 
% CuBTTri/Tecoflex SG-80A. This outcome is primarily attributable to differences in 
water uptake between hydrophilic PVA and hydrophobic Tecoflex SG-80A. (b) Cumulative 
NO release plots for 10 wt. % CuBTTri/PVA membrane and 10 wt. % CuBTTri/Tecoflex 
SG-80A films. Experimental conditions: pH 7.4 PBS at 37 °C, with a 10 µM initial GSNO 
concentration (n ≥ 3). Reproduced by permission of the American Chemical Society. 
 
Table 5.1 Tabulated water uptake data 
Sample Water Uptake (%) 
10 wt. % CuBTTri/PVA 203 ± 3 
10 wt. % CuBTTri/Tecoflex SG-80A 2.0 ± 0.3 
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the NO-forming interaction of RSNOs with CuBTTri. In general, it is clear that only hydrophilic 
polymers such as PVA permit sufficiently rapid transport of GSNO to exploit the NO-forming 
capability of the MOF. The broader implication of this outcome is that medical devices fabricated 
from or coated with CuBTTri/polymer formulations are likely obligated to use hydrophilic 
polymers that facilitate diffusion of water and endogenous RSNOs into the polymer matrix. This 
observation is in agreement with a literature example using copper nanoparticles blended into 
polyurethane to produce NO from RSNOs.25 In this case, contact between RSNOs and the active 
copper species was dependent upon the hydrophilicity of the polymer since the reaction was 
hypothesized to occur within the polymer itself and must therefore be preceded by RSNO transport 
into the material. 
5.4.4 Effect of lower temperature.  
Additionally, the impact of lower temperature on the ability of 10 wt. % CuBTTri/PVA 
membranes to promote NO release from GSNO was evaluated in pH 7.4 PBS. This assessment is 
of particular importance for topical blood-contacting applications (e.g., wound dressings) since 
skin temperature can be anticipated to range from near ambient temperature to a normal 
physiological value of approximately 37 °C.58  For 10 wt. % CuBTTri/PVA membranes, lowering 
the temperature of the reaction from  37 °C to 20 °C resulted in an 84% decrease in NO recovery 
over 3.5 h (the duration of the reaction at 37 °C) from 97 ± 6% (essentially quantitative) to 16 ± 
1% (Figure 5.17[a, b], Figure 5.18 ). When a suspension of CuBTTri powder was used, a similar, 
statistically significant decrease of 77% was observed (90 ± 1 to 21 ± 1% NO recovery) (Figure 
5.17[c, d]). These results indicate that the reaction of GSNO with CuBTTri is accelerated at 
physiological temperature, as expected. To further elucidate the role of temperature on the 
interaction of GSNO with CuBTTri, a 10 wt. % CuBTTri/PVA membrane was used to promote 
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NO release from GSNO at 37 °C then subsequently reused at 20 °C in an otherwise identical 
experiment. The rate of NO release remained largely consistent with previous experiments 
conducted at 20 °C, suggesting that elevation to 37 °C in the presence of GSNO does not activate 
the MOF in an irreversible manner. 
5.4.5 Effect of varying pH conditions. 
It has been previously observed that the stability of the S-nitrosothiol functional group is 
influenced by pH.59 However, the influence of pH on the homogeneous copper-catalyzed 
decomposition of RSNOs or the ability of copper-based MOFs such as CuBTTri to promote NO 
 
Figure 5.17 (a) Representative NO release profiles and (b) cumulative NO release of 10 wt. 
% CuBTTri/PVA membranes at 37 oC and 20 oC. (c) Representative NO release profiles 
and (d) cumulative NO release plots for suspended CuBTTri powder at 37 oC and 20 oC. 
Experimental conditions: pH 7.4 PBS, with a 10 µM initial GSNO concentration (n ≥ 3). 
Reproduced by permission of the American Chemical Society. 
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release from RSNOs has not been clearly established. For this reason, the ability of 10 wt. % 
CuBTTri/PVA membranes to decompose GSNO was evaluated in pH 6.0 and 8.0 PBS at 37 °C, 
supplementing existing data collected at pH 7.4. To avoid the possibility that alternative buffer 
systems might independently influence the behavior of the reaction, the pH 7.4 PBS used for other 
experiments was adjusted to the appropriate pH. At pH values of 6.0 and 8.0, the respective NO 
yields were 96 ± 1% and 103 ± 4% (Figure 5.19). Compared to the mean reaction time of 3.5 ± 
0.4 h for 10 wt. % CuBTTri/PVA at pH 7.4, depression to pH 6.0 resulted in a statistically 
significant 22% decrease to 2.7 ± 0.2 h (Figure 5.19). Elevation of the pH to 8.0 increased the 
required reaction time by 17% to 4.1 ± 0.2 h (Figure 5.19[a, b]). To explore the influence of pH 
specifically on CuBTTri, GSNO was exposed to an aqueous suspension of MOF powder in pH 6.0 
and 8.0 PBS at 37 °C (Figure 5.19[c, d]). At pH 6.0, the total NO recovery was 92 ± 1% after 
 2.1 ± 0.1 h, corresponding to a statistically significant 36% decrease in reaction time (Figure 
5.19[c, d]). At pH 8.0, a total of 91 ± 3% of theoretical NO was recovered after 3.2 ± 0.3 h at pH 
8.0 (Figure 5.19[c, d]). Lower pH appears to consistently promote acceleration of the NO-forming 
 
Figure 5.18 (a) Representative NO release profiles and (b) cumulative NO release profiles 
for CuBTTri particles and 10 wt. % CuBTTri/PVA membranes, depicting their comparative 
performance at reduced temperature. Experimental conditions: pH 7.4 PBS at 20 °C, with 
a 10 µM initial GSNO concentration (n ≥ 3). Cumulative NO release plot depicts both the 
mean and standard deviation. Reproduced by permission of the American Chemical 
Society. 
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reaction with CuBTTri, regardless of whether CuBTTri is evaluated as a suspension or 
incorporated within a PVA matrix. In contrast, slight elevation in pH from 7.4 to 8.0 increases the 
duration of the reaction with 10 wt. % CuBTTri/PVA membrane but has no significant impact on 
the performance of the suspended MOF powder (Figure 5.19[c, d], Figure 5.20). In the case of 
10 wt. % CuBTTri/PVA membranes, the 17% increase in reaction time at pH 8.0 may be 
attributable to impaired GSNO diffusion through the PVA matrix. This hypothesis is supported by  
the observation that no difference in the overall reaction time between pH 7.4 and 8.0 is observed 
for suspended CuBTTri powder. At elevated pH, it may be predicted from the pKa values of 
glutathione that an increasing fraction of acidic groups may exist in the negatively-charged 
 
Figure 5.19 (a) Representative NO release profiles and (b) cumulative NO release for 10 
wt. % CuBTTri/PVA membranes at pH 6.0, 7.4 and 8.0. (c) Representative NO release 
profiles and (d) Cumulative NO release profiles for suspended CuBTTri powder at pH 6.0, 
7.4 and 8.0. Experimental conditions: PBS at 37 °C, with a 10 µM initial GSNO 
concentration (n ≥ 3). Reproduced by permission of the American Chemical Society.  
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carboxylate form. This phenomenon may reduce the propensity of GSNO to diffuse through the 
PVA matrix. At pH 6.0, both the 10 wt. % CuBTTri/PVA membranes and the suspension of 
CuBTTri powder exhibit accelerated reactions with GSNO (Figure 5.21). The magnitude of this 
acceleration is slightly greater in the case of the CuBTTri powder suspension, which may indicate 
a diffusion-related delay as shown in Figure 8.  
As a comparative study, aqueous copper(II) chloride was used to decompose 10 µM GSNO 
in PBS at 37 °C. As anticipated from the use of a homogeneous catalyst, the reaction between 
solution-phase copper ions and GSNO was significantly faster (<30 min completion time) than the 
rates observed for CuBTTri. In addition, the behavior of the reaction as the pH was reduced from 
7.4 to 6.0 was reversed. Unlike the acceleration observed in the case of CuBTTri (whether in the 
 
Figure 5.20 (a) Representative NO release profiles and (b) cumulative NO release profiles 
for CuBTTri particles and 10 wt. % CuBTTri/PVA membranes, depicting their comparative 
performance at increased pH. Experimental conditions: pH 8.0 PBS at 37 °C, with a 10 µM 
initial GSNO concentration (n ≥ 3). Cumulative NO release plot depicts both the mean and 
standard deviation. Reproduced by permission of the American Chemical Society.  
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form of a suspended powder or blended PVA membrane), the time required for copper(II) chloride 
to decompose GSNO in PBS at 37 °C was significantly lengthened by 74% as the pH was 
decreased from 7.4 to 6.0. No statistically significant difference manifested at a slight pH elevation 
to 8.0 in accordance with the performance of suspended CuBTTri. These observations with 
copper(II) chloride and GSNO may support the prevailing understanding of both RSNO stability 
and the mechanism for homogeneous copper-catalyzed decomposition of RSNOs. The rapid and 
complete NO-forming decomposition of RSNOs is typically effected by the addition of catalytic 
quantities of copper(II) salts.31,60,61 Although copper(II) itself was initially implicated as the active 
species in this reaction,  McAninly et al. proposed a mechanism based on the reduction of 
copper(II) to copper(I) by thiolate anions.61 The crucial role of copper(I) in the catalytic 
 
Figure 5.21 (a) Representative NO release profiles and (b) cumulative NO release profiles 
for CuBTTri particles and 10 wt. % CuBTTri/PVA membranes, depicting their comparative 
performance at decreased pH. Experimental conditions: pH 6.0 PBS at 37 °C, with a 10 µM 
initial GSNO concentration (n ≥ 3). Cumulative NO release plot depicts both the mean and 
standard deviation. Reproduced by permission of the American Chemical Society.  
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decomposition of RSNOs was later supported by the ability of neocuproine (a copper(I)-specific 
chelator) to arrest the reaction.62 
The rate-determining, thiol-mediated reduction of copper(II) may result from trace thiol 
remaining in RSNO samples or the regeneration of thiol from RSNOs in aqueous media.63 It may 
therefore be reasoned, a priori, that a decrease in pH (and corresponding decrease in the ratio of 
thiolate to thiol) could potentially impair the rate at which the active copper(I) species is generated, 
increasing the completion time of the NO-forming reaction. This hypothesis aligns with the NO-
generating performance of copper(II) chloride as a function of pH. For example, it has been 
theorized that the decomposition of dissolved RSNOs is arrested under acidic conditions due to 
reduced thiolate concentration, which inhibits reduction of copper(II) to copper(I).64 In contrast, 
the significant acceleration of the reaction between CuBTTri and GSNO as pH is decreased may 
imply that an alternative process is operative, which is sufficiently distinct in mechanism to 
produce an inversion of pH sensitivity. While the distinction in behavior between CuBTTri and 
solution-phase copper ions may arise from the comparative role of thiol in each reaction, it must 
be noted that the ability of copper ions to form sparingly soluble copper phosphate species may 
influence the kinetics of the latter reaction in PBS. Following the reactions with 10 wt. % 
CuBTTri/PVA membrane, the copper concentrations of the pH 6.0 and pH 7.4 buffer solutions 
were found to correspond to 0.31 ± 0.03 and 0.34 ± 0.08% of theoretical copper in the membranes, 
respectively. In the case of suspended CuBTTri powder, these values were 0.32 ± 0.01 (pH 6.0) 
and 0.20 ± 0.03% (pH 7.4). The absence of a statistically significant difference between the 
apparent level of copper leaching as a function of the pH decline from 7.4 to 6.0 indicates that pH-
related decomposition of the MOF (and potential copper ion leaching) is not a clear factor in the 
acceleration of the reaction.  
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5.4.6 Effect of thiol blocking with N-ethylmaleimide.  
The ability of thiol to affect the structural characteristics of copper-based MOFs has been 
previously described. In the specific case of the carboxylate-derived MOF Cu-BTC, exposure to 
high concentrations of thiophenol or 1,3-propanedithiol in acetonitrile at 70 °C results in the 
decomposition of the MOF to copper(0) nanoparticles.65  Ke et al. showed that Cu-BTC could be 
post-synthetically modified by exposure to dithioglycol (1,2-ethanedithiol), which resulted in 
grafting of the thiol to coordinatively unsaturated copper centers.66 As previously discussed, it has 
also been suggested that the NO-forming behavior of Cu-BTC proceeds through the reduction of 
copper centers, a process that may be induced by thiol.56,57 To explore the potential role of 
thiol/thiolate in the CuBTTri-promoted decomposition of GSNO, NO release experiments were 
performed using GSNO that had been incubated with a 10-fold excess of N-ethylmaleimide 
(NEM). This maleimide-based alkylating reagent reacts with thiol groups to form an effectively 
irreversible thioether linkage, and it is commonly used to modify cysteine residues in proteins.67 
In the case of 10 wt. % CuBTTri/PVA membranes, an 84% decrease in NO yield (over 3.5 h) was 
observed using GSNO that had been treated with NEM (from 97 ± 6% to 16 ± 1%) (Figure 5.22[a, 
b], Figure 5.23). A smaller 39% decrease (90 ± 1% to 55 ± 2%) was observed when a suspension 
of CuBTTri powder was evaluated under identical conditions (Figure 5.22[c, d], Figure 5.23). 
While it was previously hypothesized that the function of CuBTTri may have little dependency on 
reduction by thiolate (as supported by acceleration of the reaction under acidic conditions), the 
reduction in NO production observed after GSNO was treated with NEM may indicate that residual 
thiol does have an influence on the activity of the MOF.  
However, the fact that this effect is most pronounced when diffusion into the PVA matrix 
must occur prior to the reaction may support alternative hypotheses. The presence of a 10-fold 
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excess of NEM may simply inhibit the ability of GSNO to reach active sites within the MOF, 
whether through modification of the primary amine to form a bulkier derivative or through 
competitive interactions with the MOF itself.68  The direct exposure of CuBTTri powder to neat 
ethanethiol results in regeneration of the triazole ligand and loss of the diffraction pattern 
associated with the MOF. Exposure to 3 mM glutathione (the thiol precursor to GSNO) in pH 7.4 
PBS for 24 h at ambient temperature resulted in the release of 16 ± 1% of theoretical copper into 
solution. These findings suggest that high concentrations of thiol are capable of degrading 
CuBTTri. However, previous observations that physiological (10 µM) and elevated (10 mM) 
concentrations of RSNO do not produce substantial copper leaching or loss of MOF structure 
 
Figure 5.22 (a) Representative NO release profiles and (b) cumulative NO release of 10 wt. 
% CuBTTri/PVA membranes with and without NEM (c) Representative NO release 
profiles and (d) cumulative NO release profiles for CuBTTri particles with and without 
NEM. Experimental conditions: pH 7.4 PBS at 37 °C, with a 10 µM initial GSNO and 100 




suggest that this type of degradation is unlikely to contribute to the NO-forming activity of 
CuBTTri. As further support for this hypothesis, the addition of NEM does not significantly reduce 
the trace amount of copper recovered subsequent to the reaction, with 0.28 ± 0.03% of theoretical 
copper determined in the buffer solution by ICP-AES. This outcome suggests that, at physiological 
RSNO concentrations, the role of thiol/thiolate (if any) is unlikely to include the formation of labile 
copper species that are subsequently released into solution.  
5.5 Summary and conclusions 
Membranes were prepared from hydrophilic PVA and the triazolate-bridged MOF CuBTTri 
and subsequently evaluated for their ability to induce NO release from GSNO, a biomolecule 
 
Figure 5.23 (a) Representative NO release profiles and (b) cumulative NO release profiles 
for CuBTTri particles and 10 wt. % CuBTTri/PVA membranes in the presence of GSNO, 
with and without a 10-fold excess of NEM to illustrate the effect of adding a thiol-blocking 
agent. Experimental conditions: pH 7.4 PBS at 37 °C, with a 10 µM initial GSNO 
concentration and a 100 µM NEM concentration (n ≥ 3). Cumulative NO release plot 
depicts both the mean and standard deviation. Reproduced by permission of the American 
Chemical Society.  
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identified in blood. All results are summarized below (Table 5.2). In pH 7.4 PBS at 37 °C, it was 
demonstrated that 1, 5, and 10 wt. % CuBTTri/PVA membranes were able to effectively induce 
NO production from GSNO at levels that may be associated with antithrombotic effects. In the 
case of 10 wt. % CuBTTri/PVA membrane, a 36-fold increase in the rate of NO production was 
observed relative to the thermal decomposition of GSNO over an identical duration. While 
incorporation of 10 wt. % CuBTTri within PVA results in delayed NO production kinetics relative 
to a suspension of MOF particles, the overall completion time of the reaction was statistically 
unchanged. The maximum NO flux ranged from 0.051 ± 0.008 (1 wt. % CuBTTri) to 0.20 ± 0.02 
nmol·cm-2·min-1 (10 wt. % CuBTTri) compared to an estimated endothelial flux of 0.05 to 0.4 
nmol·cm-2·min-1. This performance suggests that CuBTTri/PVA membranes may be suitable for 
the production of a physiologically-relevant NO flux from endogenous sources. The level of NO 
production and the time required to consume available GSNO are directly related to the weight 
percentage of CuBTTri blended into the membrane, which indicates the potential for controllable 
NO generation. This NO-generating activity is apparently unaccompanied by detectable 
degradation of the MOF itself (pXRD), and only trace quantities of copper (<1% of theoretical) 
are present in the buffer following the reaction. The ability of CuBTTri/PVA materials to initiate 
NO release from GSNO relies upon the substantial water uptake of the PVA membrane and 
hypothesized transport of GSNO to the active MOF species. Without this level of water uptake, as 
in the case of 10 wt. % CuBTTri films prepared from hydrophobic Tecoflex SG-80A, no short-
term increase in NO production is observed. The NO-forming reaction between GSNO and 
CuBTTri exhibits temperature dependence and dramatically decreases in rate at 20 °C, with an NO 
yield of only 16 ± 1% over 3.5 h, compared to 97 ± 6% at 37 °C. This finding leads to the 
conclusion that therapeutically useful activity is most probable at or near physiological 
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temperature, as in the case of flowing blood. This result may also suggest that a significant 
thermodynamic barrier exists for the rate-determining step of the reaction, in contrast to the rapid 
and complete reaction of GSNO with homogeneous copper ion catalysts at ambient temperature. 
The reaction is also pH-dependent, with a substantial increase in the rate of NO production 
observed as pH declines from 7.4 to 6.0, contrasting with the opposite behavior in aqueous 
copper(II) chloride. This effect is present regardless of whether the MOF is incorporated within a 
PVA matrix, and is not accompanied by an increase in the quantity of trace copper in the buffer 
solution. The lack of soluble copper ion formation indicates that pH-related decomposition of 
either the MOF itself or secondary active species is not a clear factor in the acceleration of the 
reaction under mildly acidic conditions. When a 10-fold excess of the thiol-blocking reagent NEM 
is present during the reaction (pH 7.4 PBS, 37 °C), NO generation is reduced by 84% in the case 
of 10 wt. % CuBTTri/PVA membrane. A significantly less dramatic 39% decrease in the rate of 
the reaction is observed for a suspension of CuBTTri powder when exposed to NEM-treated 
GSNO. These findings reveal that trace thiol may influence the reaction, potentially through the 
reduction of copper sites as described elsewhere for Cu-BTC. The observed properties of 
CuBTTri/PVA blends indicate that the materials are capable of generating NO from the 
endogenous compound GSNO, and that therapeutically useful levels can be produced at 
physiological temperature and pH. These findings support the notion that CuBTTri/PVA has the 
potential to produce NO directly from blood, a phenomenon that would be advantageous given the 
large number of blood-contacting applications for PVA. Taken together, these studies have 
identified the characteristics (e.g., hydrophilicity) that CuBTTri/polymer blends must exhibit for 
optimized therapeutic use, and also provide a greater understanding of factors that influence 




Table 5.2  Tabulated nitric oxide release data 
Reaction Conditions NO Yield (%)b 
Completion 
Time (h)c 
GSNO (pH 7.4, 37 °C)a 2.7 ± 0.3 n/a 
GSNO + PVA (pH 7.4, 37 °C)a 2.5 ± 0.1 n/a 
GSNO + 10 wt. % CuBTTri/Tecoflex SG-80A 
(pH 7.4, 37 °C) 
1.5 ± 0.4 n/a 
GSNO + 10 wt. % CuBTTri/PVA (pH 7.4, 37 °C) 97 ± 6 3.5 ± 0.4 
GSNO + 10 wt. % CuBTTri/PVA (pH 6.0, 37 °C) 96 ± 1 2.7 ± 0.2 
GSNO + 10 wt. % CuBTTri/PVA (pH 8.0, 37  
°C) 
103 ± 4 4.1 ± 0.2 
GSNO + 10 wt. % CuBTTri/PVA (pH 7.4, 20 °C) 16 ± 1 n/a 
GSNO + 1 wt. % CuBTTri/PVA (pH 7.4, 37 °C) 102 ± 3 13 ± 1 
GSNO + 5 wt. % CuBTTri/PVA (pH 7.4, 37 °C) 97 ± 6 5.0 ± 0.7 
GSNO + 10 wt. % CuBTTri/PVA (reuse, pH 7.4, 
37 °C) 
103 ± 8 4.7 ± 0.4 
GSNO + NEM + 10 wt. % CuBTTri/PVA (pH 
7.4, 37 °C) 
16 ± 1 n/a 
GSNO + CuBTTri (pH 7.4, 37 °C)a 90 ± 1 3.3 ± 0.2 
GSNO + CuBTTri (pH 6.0, 37 °C)a 92 ± 1 2.1 ± 0.1 
GSNO + CuBTTri (pH 8.0, 37 °C)a 91 ± 3 3.2 ± 0.3 
GSNO + CuBTTri (pH 7.4, 20 °C)a 21 ± 1 n/a 
GSNO + NEM + CuBTTri (pH 7.4, 37 °C)a 55 ± 2 n/a 
 
aReactions consist of the NO-forming decomposition of 10 µM S-nitrosoglutathione 
(GSNO) at varying temperature, concentration, and pH, or in the presence of N-
ethylmaleimide (NEM).  aCuBTTri powder added in a quantity corresponding to the amount 
present in experiments conducted with 10 wt. % CuBTTri/PVA. bNO yield refers to 
measured NO/theoretical GSNO × 100. cCompletion time refers to the mean time required 
for NO measurements to reach baseline levels, which is inferred to represent depletion of 
available GSNO. Experiments with incomplete NO recovery were performed for fixed 
intervals corresponding to the mean duration of the parent experiment. All values reported 
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6.1 Project Summary 
While the principle of generating NO from endogenous substrates has been the subject of 
research for over a decade, the conscription of MOFs for this purpose is a relatively recent 
development. In the original 2012 report from Harding et al., the commercial carboxylate-based 
MOF CuBTC was used to produce NO from S-nitrosocysteine in reagent alcohol. This seminal 
work demonstrated the feasibility of utilizing a copper-based MOF to catalyze the release of NO 
from RSNOs, albeit under conditions that were far from physiological relevance. S-nitrosocysteine 
is not known to occur endogenously except in the form of residues in macromolecular peptides, 
while the use of reagent alcohol was necessitated by the instability of CuBTC in water. Moreover, 
cysteine was added in a stoichiometric quantity relative to theoretical MOF copper sites to promote 
the reduction of Cu2+ to Cu+, a process that may lead to the formation of structural defects and 
secondary catalysts. Additionally, measurement of NO generation was performed under anaerobic 
conditions, thus the ability of the MOF to generate NO under truly physiological conditions 
(aerobic) had not been demonstrated. In 2014, a subsequent publication established the concept of 
embedding CuBTC particles within a polymer matrix to model the fabrication of implantable 
devices. It was observed that the reaction rate may be influenced by the need for the RSNO 
substrate to diffuse through the polymer matrix before interacting with the MOF. This principle 
contributed to the notion of localizing the MOF to the surface of a polymeric substrate to minimize 
the influence of this type of diffusion.  
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Because the effective translation of copper-based MOFs to commercial blood-contacting 
applications requires their immobilization within a polymeric support, the work presented in this 
dissertation focused on identifying and optimizing the parameters needed to produce MOF-based 
materials that retain the therapeutic activity of the MOF itself. In Chapter 2, the concept of 
localizing the MOF to the surface of a polymer substrate was explored through the direct growth 
of CuBTC on carboxymethylated cotton fabric using a layer-by-layer (LBL) methodology. This 
LBL methodology was modified from a previous report by Pinto et al. who observed that the order 
of reagent addition impacted the degree of CuBTC deposition.1 The CuBTC-coated fabric 
produced from this modified method exhibited significantly enhanced surface coverage, 
demonstrating how CuBTC deposition could be further optimized. Evaluation of the coated fabric 
indicated that the material was able to induce NO formation from S-nitrosocysteamine at rates 
comparable to unsupported CuBTC particles. Overall, this work demonstrated deposition of 
CuBTC onto a flexible polymeric material with excellent coverage, as well as promotion of NO 
release from S-nitrosocysteamine at therapeutically-relevant levels. However, this model system 
remained confined to alcohol and a non-physiological RSNO substrate, preventing its use in blood-
contacting applications. The 2014 observation that water-stable CuBTTri could promote NO 
release from RSNOs in a manner analogous to the reactivity of CuBTC permitted progress toward 
MOF-based materials for practical biomedical use. Chapter 3 described the incorporation of 
CuBTTri within films made from PVC, a polymer used to fabricate the tubing used to transport 
blood in extracorporeal circuits (ECCs). This work was the first to assess the toxicological impact 
of CuBTTri-based materials, and used 3T3-J2 murine embryonic fibroblasts and primary human 
hepatocytes (PHHs) to model liver function. No significant toxicity was observed over 16 days of 
exposure, providing key support for the potential implementation of CuBTTri in medical 
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applications. Additionally, the ability of CuBTTri to enhance the rate of NO generation from 
RSNOs was retained following incorporation within PVC. Following exposure to SNAP at 
ambient temperature and physiological pH, it was observed that CuBTTri/PVC films were able to 
generate NO at a level frequently associated with antithrombogenic surfaces. However, SNAP 
does not occur endogenously, and the concentration of the compound used in NO release 
experiments was above the physiological values that are generally reported for RSNOs in blood. 
The absence of definitive evidence that either CuBTC or CuBTTri could initiate the decomposition 
of the physiological RSNO reservoir (which is largely composed of S-nitrosoalbumin and GSNO) 
remained a significant obstacle to further development. While the ability of CuBTTri/PVC to 
produce NO from GSNO was assessed in unpublished experiments, no enhancement in the rate of 
NO release was detected. In contrast, preliminary experiments had suggested that it was indeed 
possible for unbound CuBTTri particles to generate NO from GSNO, indicating that the 
hydrophobic polymer may inhibit diffusion of the substrate.  
Based on these results, polymer formulations with increased hydrophilic character were 
evaluated in Chapters 4 and 5. Chapter 4 discussed the inclusion of CuBTTri within the naturally-
derived polysaccharide chitosan to form membranes that were evaluated for their ability to enhance 
NO generation from GSNO. This was the first report which evaluated MOF-induced NO release 
from GSNO, the most abundant small-molecule RSNO in the blood. As previously mentioned, the 
RSNO concentrations used in prior accounts were non-physiological. In Chapter 4, a lower, near 
physiological concentration of GSNO is used (20 µM). Furthermore, incorporation of CuBTTri 
within hydrophilic chitosan did not impair the activity of the MOF, unlike earlier efforts using 
PVC. In an effort to provide insight into the mechanism of action, the major organic product of 
CuBTTri-promoted GSNO decomposition was identified as oxidized glutathione via mass 
212 
spectrometry. This result confirmed the hypothesis that the RSNOs are decomposed by the MOF 
to generate NO and the corresponding disulfide, similar to the decomposition products formed in 
the presence of copper ions. However, the mechanism of RSNO decomposition in the presence of 
CuBTTri remains unknown. While this project expanded the activity of CuBTTri to include a 
physiological RSNO substrate, chitosan exhibits pronounced hemostatic effects (properties which 
are used to stem blood loss from hemorrhagic injuries) that render it less than ideal for blood-
contacting applications aimed at preventing thrombus formation.  
The subsequent work from Chapter 5 resulted in the incorporation of CuBTTri within 
hydrophilic membranes prepared from PVA, a polymer that has been examined for numerous 
biomedical applications. These CuBTTri/PVA membranes promoted NO release from GSNO at 
physiological temperature and pH. It is particularly noteworthy that this NO release occurred at a 
surface flux within the range associated with the natural endothelium and was achieved from a 
GSNO concentration of 10 µM, a concentration that is within the upper end of the reported 
physiological RSNO concentrations. Furthermore, a technique was developed in order to 
demonstrate for the first time that CuBTTri is capable of inducing NO production from GSNO 
under aerobic conditions. Moreover, in an effort to permit optimization for potential medical 
applications, a more comprehensive analysis of the parameters that could influence CuBTTri 
efficacy were investigated, including pH, temperature, and polymer material. These findings 
suggest that CuBTTri/PVA membrane holds promise for therapeutic utility through its ability to 
generate NO from endogenous substrates.  
As mentioned in the introduction, these MOF-based materials must demonstrate several 
basic characteristics to be feasible for translation to clinical use. In general, the MOF must retain 
its structure and function upon incorporation into the polymeric material and at physiological 
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temperature and pH with minimal to no leaching of the organic ligand or copper. Additionally, 
interaction of the MOF with endogenously available RSNOs should result in the generation of NO 
flux ranges associated with the nonthrombogenic endothelium (Figure 6.1).  
Prior to this research, there was no direct evidence that MOF-polymer materials were 
capable of enhancing NO generation from RSNOs under truly physiologically relevant conditions. 
This dissertation demonstrated that materials based on CuBTTri have met these requirements, 
advancing their translation to clinical use. Moving forward, there are several concepts that must 
be taken into consideration when further developing NO-producing MOF-based materials. 
6.2 Device fabrication 
The therapeutic potential of CuBTTri is supported by clear evidence that the MOF retains 
its ability to induce the NO-forming decomposition of RSNOs after inclusion within several 
different polymer matrices. However, translation of this technology to clinical use requires the 
fabrication of devices that exploit the unique chemistry of copper-based MOFs. High similarity to 
 
Figure 6.1 Minimum characteristics MOF-based materials should demonstrate for clinical 
application. All requirements have been met.  
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existing medical devices facilitates the clinical implementation of this chemistry, therefore the 
direct blending of CuBTTri within common medical polymers is desirable as a fabrication 
technique. While materials of this type remain in a developmental stage, a significant body of 
preliminary work has been carried out to examine the practicality of creating CuBTTri-based 
devices. Towards this end, MOF/polymer coatings have been applied to catheters, ECCs, and 
thromboelastography (TEG) cups. As depicted in both SEM and optical microscope images, 
CuBTTri is clearly dispersed throughout the entire surface of both Tygon and polyurethane blood 
flow loops (Figure 6.2). Additionally, cross-sectional analysis with EDS overlay shows the 
presence of CuBTTri within 20 µm of the polymer layer deposited on the parent device. As 
characterized by EDS, copper (derived from the MOF) is dispersed over the entire inner surface 
of the device, with the greatest concentration occurring at sites where the presence of crystalline 
MOF is apparent.  
 
Figure 6.2. Fabrication of Cu-BTTri/polymer coated catheters (a) SEM imaging with EDS 
overlay showing the inside surface of the coated catheters and a cross section showing the 
thickness of the Cu-BTTri/polymer coating on the catheter. (b) Microscope imaging of the 
surface of the inner lumen of the Cu-BTTri/polymer coating. 
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However, this dispersion is far from uniform, with certain regions of the tubing displaying 
little to no coverage and areas with a higher degree of particle agglomeration. Indeed, this lack of 
uniformity represents one of the chief complications when fabricating MOF/polymer composite 
materials. The MOF and the polymer host material exhibit distinct physical and chemical 
properties that can induce the agglomeration of MOF particles. This complication has been 
observed elsewhere and can be partially addressed by priming of the MOF particles. This priming 
technique involves the suspension of the MOF particles in the selected solvent, followed by the 
addition of a small amount of the dissolved polymer solution. The MOF particles are then coated 
in a small amount of the polymer before being dispersed into the main polymer solution, thus 
decreasing the affinity of the particles for each other and creating a more homogenous dispersion.2 
While use of this approach has decreased the degree of particle agglomeration in coatings prepared 
using CuBTTri, the aggregation of MOF remains a substantial concern. For this reason, the 
utilization of extrusion would be advantageous to the development of MOF/polymer composites. 
During the process of extrusion, the raw materials (MOF and polymer) are mixed and melted, then 
the molten polymer mixture is forced through a die which shapes the material as it is cooled. This 
processing technique allows for the formation of a highly homogeneous material. The feasibility 
of this approach was demonstrated in 2014 by Harding et al. who blended CuBTC into a 
polyurethane using industrial extrusion processing methods to form both pellets and segments of 
tubing (Figure 6.3).3  
Another important factor to consider when developing these MOF/polymer composite 
materials is the nature of the polymer (i.e., hydrophobic or hydrophilic) and its potential impact on 
the ability of the RSNOs to interact with the MOF. As demonstrated in Chapter 5, the use of a 
hydrophobic polyurethane compared to a hydrophilic crosslinked PVA significantly hindered NO 
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generation. In the case of the CuBTTri/Tecoflex SG-80A films, only 1.5 ± 0.4% of theoretical NO 
was released, whereas 97 ± 6% was recovered in the presence of the CuBTTri/PVA membranes. 
These materials had respective water uptake values of 2.0 ± 0.3 and 203 ± 3%, demonstrating the 
importance of the hydrophilic character of the polymer in facilitating NO generation. This 
phenomenon affects the clinical utility of the material, since its potential antithrombotic properties 
are dependent upon the NO-forming interaction of the MOF with endogenous RSNOs. However, 
the transport of GSNO through polymer matrices remains a poorly understood process. It is 
therefore obvious that the study of GSNO diffusion through polymers would provide valuable 
insight into the interaction of polymer-bound CuBTTri with RSNOs. In general, the nature of a 
polymeric material has been found to significantly influence the transport behavior for a given 
molecule. Factors such as degree of crosslinking, polarity, molecular weight, and extent of 
 
Figure 6.3 Images of the CuBTC/polymer materials produced through industrial extrusion 
processes. (a) CuBTC/polymer pellets (b) CuBTC/polymer tubing.  
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unsaturation will all affect molecular transport.a In addition, the size and shape of the molecule 
will influence transport within a polymeric matrix.  
As the nature of the polymeric material seems of vital importance in facilitating the 
interaction of CuBTTri with GSNO, a further understanding of these transport properties is 
necessary for their development. Once understood, these properties can aid in device fabrication 
aimed at optimizing NO generation from the endogenous RSNOs. An understanding of the 
polymer transport properties in combination with a reliable methodology for improving MOF 
dispersion throughout the polymer will ultimately aid in designing these MOF/polymer composite 
materials for biomedical applications.  
6.3 Assessment of blood compatibility 
Biomaterials that include CuBTTri possess significant clinical potential due to the ability of 
the MOF to modulate biological processes such as clotting, infection, and wound healing. 
However, these materials are presently confined to the laboratory as a result of an unclear 
understanding of their behavior in a biological environment, Nevertheless, preliminary studies 
have revealed that CuBTTri may produce detectable effects in the presence of blood. For example, 
a collaboration with the U.S. Army Institute of Surgical Research assessed the impact of CuBTTri 
on real-time clot formation in human blood using TEG analysis.4 TEG is an instrumental technique 
which uses viscoelastic methods to provide real-time kinetics of clot initiation, formation, strength, 
and breakdown. Typically, this technique has been used in clinical settings to assess a patient’s 
bleeding and thrombotic risks. However, TEG is now utilized as an experimental technique to 
assess the influence of various biomaterials on blood at the blood-material interface under ex vivo 
conditions.5-6 In this technique, whole blood is placed into a plastic cup which is capped with a lid 
containing a pin that is submerged in the blood. The pin is slowly oscillated at an angle of 4ᵒ45’. 
218 
As clot formation occurs, the impeded rotation of the pin and the corresponding change in torque 
is detected by the pin. The measurement is graphically represented as a trace profile over time 
which can be used to extrapolate the clotting time, clot formation, maximum clot strength, and 
fibrinolysis.7  
In the collaborative manuscript currently under consideration by the Journal of Trauma and 
Acute Care Surgery, TEG was used to examine the efficacy of CuBTTri in preventing thrombus 
formation by detecting changes in the stages of clot formation in real-time. These experiments 
were performed by dispersing the MOF powder in a small amount of PBS followed by addition to 
a sample of whole blood. When compared to the control (whole blood + PBS), the MOF powder 
produced a notable reduction in clot strength (MOF=53.67 ± 1.35 mm, C= 56.22 ± 1.42 mm) and 
an accelerated rate of clot lysis after 30 (MOF = 3.22 ± 0.99%, C = 0.82 ± 0.26%) and 60 min 
(MOF = 8.75 ± 1.64%, C = 2.33 ± 0.77 %) (Figure 6.4). This observation of reduced clot strength 
and accelerated clot lysis was hypothesized to result from NO through inhibition of platelet 
aggregation and promotion of clot dissolution. However, it should be noted that no experiments 
were performed to further confirm this hypothesis. These initial experiments suggest that CuBTTri 




Figure 6.4 (a) TEG trace of the MOF powder in blood (green) compared to the control 
(blood + PBS) (black). (b) Graphical representation of the mean ± standard error for reaction 
time, clot formation time, alpha angle, clot strength, clot lysis at 30 minutes, and clot lysis 
at 60 minutes as determined by TEG of human blood. (n=10) 
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these MOFs in biomedical applications is dependent on their performance following inclusion in 
polymeric devices, as the character of the polymeric material can influence the MOFs ability to 
facilitate NO generation. Notably, when the same experiments were performed on samples in 
which the inside cup and peg had been coated with a hydrophobic MOF/polymer layer, no change 
in clotting kinetics was observed compared to the control (polymer coating). 
Because it is critical that these materials generate NO in blood-contacting applications, a 
crucial area of refinement involves the continued investigation of polymer formulations that permit 
interaction of RSNOs with the encapsulated MOF. Based on existing evidence, it is reasonable to 
hypothesize that hydrophilic polymers which allow for increased water uptake may display a 
greater level of NO generation. Commercial hydrophilic polymer formulations that are potential 
candidates include HydrothaneTM, HydromedTM (D-7), and TecophilicTM (SP-80A-150, SP-60D-
60). HydroThaneTM is a hydrophilic polyurethane exhibiting water absorption of up to 25% (by 
weight) and HydroMedTM is a hydrophilic polyurethane specifically designed for use as a coating 
on devices including catheters and heart valves with water absorption up to 30%. Notably, 
HydroMedTM has been used as a coating to decrease the adsorption of proteins and cellular material 
to devices. TecophillicTM formulations are hydrophilic polyurethanes with water uptake of 60 and 
150%. With the exception of HydroMedTM, these polymer formulations can all be processed by 
extrusion. In addition to these hydrophilic formulations, hydrophobic materials such as Tygon and 
TecoflexTM should be evaluated for the degree of platelet adhesion and activation on the surface 
as a point of comparison.  
Despite the demonstrated ability of CuBTTri/polymer materials to generate NO from a 
biologically-available RSNO (Chapter 4 and 5) within the range of the endothelial flux, no in vitro 
or in vivo biological studies have been performed to investigate their performance. Because this 
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type of evaluation is a necessary step toward clinical use, it is sensible to pursue in vitro blood 
studies to assess the effect of the CuBTTri/polymer materials on key blood clotting components 
such as platelets. This type of evaluation would provide insight into the impact of the polymer on 
the degree of platelet adhesion. If accompanied by parallel NO generation measurements, it may 
be possible to establish a relationship between the observed NO flux and the degree of platelet 
adhesion on the material. In principle, this would permit identification of optimal MOF/polymer 
formulations for the fabrication of blood-contacting materials that produce predictable levels of 
NO from blood. However, the design of such experiments requires acknowledgement of one of 
the most challenging aspects of NO generation from endogenous substrates: the unknown, and 
potentially highly variable RSNO content of human blood.  
As the therapeutic properties of the MOF are based on its ability to generate NO by 
harvesting LMW RSNOs in the blood, the basal RSNO blood concentration must be sufficient to 
produce an NO flux capable of preventing thrombus formation. The concentration of RSNO in 
blood is a highly debated topic with existing reports ranging from sub-nM to µM. Additionally, 
questions arise related to the variability in available RSNO from person to person. To date, none 
of these questions have been satisfactorily addressed, and reports that utilize copper species 
(complexes or MOFs) rely on exogenous RSNO to demonstrate their function. A large majority of 
the publications that utilize copper complexes test their NO-forming properties using SNAP due 
to its high stability, yet this compound is not produced physiologically. Variability in blood RSNO 
concentration and its impact on the efficacy of the MOF should be assessed in part by performing 
blood studies on blood taken from multiple donors.  
In reality, the potential lack of sufficient blood RSNO to produce antithrombotic effects is a 
significant limiting factor in the translation of MOF-based materials to clinical use. For this reason, 
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in vitro blood studies should be performed which assess the MOF/polymer both with and without 
the addition of exogenous GSNO. If the formulation is unable to prevent platelet adhesion without 
exogenous GSNO, it is likely that the materials will be unsuitable for internal blood-contacting 
applications. Nevertheless, such materials could potentially be utilized for external blood-
contacting devices (e.g., ECC tubing) if the addition of exogenous RSNO results in an 
antithrombotic flux, since such compounds can be supplied in a relatively straightforward manner.  
It should be noted that these CuBTTri/polymer composites are not isolated to blood-
contacting applications. It was recently reported by Neufeld et al. that CuBTTri/chitosan films 
demonstrated a 75-79% reduction in the bacterial attachment of Pseudomonas aeruginosa 
compared to a chitosan control.8 The observed decrease in attachment was related to the presence 
of CuBTTri in the films. Because no exogenous source of NO was present in the system, this may 
suggest that CuBTTri can independently function as an antibacterial agent. Extensive control 
experiments were performed in order to ensure that the observed antibacterial activity was not an 
artifact from the presence of copper ions. While the mechanism of action of CuBTTri against 
bacteria is currently unknown, these initial findings demonstrate the material’s versatility in 
medical applications.  
6.4 Final Thoughts 
Since the basic observation that the suspension of blood in a solution of paraffin oil 
prolonged blood clotting in the early 19th century, research related to blood-material interactions 
has grown exponentially. The research discussed in this dissertation represents one aspect of an 
interdisciplinary approach needed for enhancing the integration between the human body and 
medical devices. The successful design of blood-contacting materials involves not only the 
materials and their surfaces, but also an understanding of human biology and the adequate 
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assessment of blood-material interactions. Each of these parameters plays a vital role in the 
development of enhanced blood-material interfaces. A promising approach involves mimicking 
biological mechanisms for internal regulation of the cardiovascular system. The use of MOFs for 
therapeutic NO generation from endogenous molecules offers a unique approach for enhancing 
blood-material interactions. Currently, the development of MOFs for biomedical applications 
remains in an adolescent stage, with no current use in patient care. For instance, an understanding 
of the biodegradability, stability, and toxicity of MOFs is an undeveloped field with information 
regarding these critical factors limited to only a handful of publications. In regards to the use of 
MOFs for biomedical applications, the majority of reports have focused their attention specifically 
on MOF particles. However, potential applications will remain limited unless the materials are 
incorporated within a polymeric support. When developing materials specifically for blood-
contacting applications, NO release function is a well-established, promising approach to 
preventing thrombus formation. As polymeric encapsulation can significantly influence NO 
generation using MOFs, part of the challenge involves identification of polymers that optimize the 
productive, NO-forming interaction between aqueous-phase RSNOs and CuBTTri. Taken 
together, this work has expanded on the initial reports and has identified ideal characteristics that 
MOF/polymer composites should exhibit in order to optimize them for therapeutic use. This work 
serves as a starting point for developing MOF-based materials to their fullest capability for their 
intended use. The future investigation and assessment of their in vivo activity will aid in the 
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